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INTRODUCTION: 
Myelodysplastic syndromes (MDS) are a very heterogeneous group of clonal hematopoietic 
stem cell disorders that represents a spectrum of diseases characterized by; ineffective 
erythropoiesis and marrow failure limited by acute leukemias, chronic leukemias and 
myeloproliferative disorders at one end of the spectrum, in which hypercellular marrow is typical, 
to aplastic anemia at the other end (1–3). 
Hypoplastic Myelodysplastic syndromes (hMDS) refers to a morphological entity in which 
the bone marrow cellularity is low for the age (<30% cellularity if  age is <60 years or <20% 
cellularity if age is >60 years) (2). It represents approximately 10-15% of all MDS cases (2,4–9). 
Hypoplastic MDS however, does not represent a defined MDS category according to the WHO 
classification, but it rather denotes the morphologic status of other MDS categories (2). It is difficult 
to distinguish hMDS from acquired aplastic anemia (AA), because of considerable clinical, 
histologic, and cytologic similarities between the two disorders (10).  
Patients with hMDS tend to be younger, have more profound thrombocytopenia and 
neutropenia, lower percentage of blasts, lower probability to evolve to leukemia, and they are less 
likely to display abnormal karyotype, compared to patients with normocellular or hypercellular 
MDS (1,2,6,11). Compared to AA, hMDS have a poorer prognosis and have frequent karyotypic 
and FISH abnormalities and are prone to conversion to acute myeloid leukemia (12). The prognosis 
for hMDS falls between that of severe and very severe AA patients (12).  
The pathophysiology of hMDS is not very well known. Evidence suggests that immune 
mediated mechanisms may play a role (5). This subtype is most likely to respond to treatment with  
immunosuppressive agents (13).  
Other than a few case reports and small case series, there are no published data on the 
clinical profile and response to treatment in patients with hypoplastic MDS from India.   
2 
 
REVIEW OF LITERATURE 
DEFINITION:  
MYELODYSPLASTIC SYNDROMES: The myelodysplastic syndromes (MDS) are a group of  
clonal haematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more of 
the myeloid cell lines, ineffective haematopoiesis, and increased risk of development of acute 
myeloid leukemia (AML) (14). The enhanced degree of apoptosis in these disorders contribute to 
the cytopenia(s) (14). The thresholds for cytopenias recommended in the IPSS (International 
Prognostic Scoring System) for risk stratification in MDSs  are as follows (14); 
- Hemoglobin < 10g% 
- Absolute neutrophil count < 1800/mm
3
, and  
- Platelets <100,000/mm
3
. 
If definite morphologic and / or cytogenetic findings are present, values above the thresholds are 
not exclusionary for a diagnosis of MDS (14). There may be increase in myeloblasts in the 
peripheral blood or bone marrow accompanying the dysplasia, but the number is <20% (7,14).   
 
HYPOPLASTIC MYELODYSPLASTIC SYNDROMES:  Usually, patients with MDS have a 
hypercellular bone marrow (5,14) . In a minority of the cases (~10 - 15% of cases), the cytopenia is 
associated with a hypoplastic bone marrow (2,4–9,14).  Hypoplastic Myelodysplastic syndromes 
(hMDS) refers to a morphological enitity in which the bone marrow cellularity is low for the age 
(<30% cellularity if  age is <60 years or <20% cellularity if age is >60 years) (2,5,14).  In these 
cases distinguishing between  hMDS and aplastic anemia may be difficult; the presence of a 
hypocellular marrow with features of dysplasia in one or more cell lines, increase in reticulin 
content on bone marrow trephine, increase in number of blasts/CD 34+ cells on bone marrow 
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trephine, or abnormal karyotype showing malignant clonal cells, all favor the diagnosis of  hMDS 
(2,3,5,6,9,14–16).   
EPIDEMIOLOGY:  
According to the WHO classification, hMDS does not represent a defined MDS category, 
but rather denotes the morphologic status of other MDS categories.  Patients with hMDS tend to be 
younger (2) than those with normo/hypercellular MDS. The median age of patients with hMDS 
have been reported between 39 and 58 years (1,12), where as in normo/hypercellular MDS the age 
ranges from 60 and 75 years (1,5,9,14). Maschek H et al reported a  higher median age (72.6 years; 
range;33-88 years) in patients with hMDS (9). The non-age adjusted annual incidence of MDS 
(including hMDS)  reported is 3-5/100,000 persons, rising to over 15-50 /100,000 in those over 70 
years of age (5,9,14) in the US population. The reports suggest that the sex distribution is balanced, 
although there are studies reporting a male preponderance in the hMDS group (1,5,9,14).  There is 
no published data on the exact prevalence or incidence of hMDS among Indian population.  In a 
study of 30 cases of MDS (April 1998 to May 2006 ) reported from India by Shah NM et al, the 
mean age at presentation was 55 years (range 8-73 years) with a male preponderance (1,17).  A 
recent initiative is the ‘Indian MDS registry’ aimed at analyzing the different aspects 
(epidemiology, clinico-pathology, diagnosis, therapeutic protocols and outcome) of MDSs among 
the Indian population.  
 
ETIOLOGY AND PATHOGENESIS: 
The exact pathophysiology of  hMDS is not known; there are multiple, complex and poorly 
understood mechanisms involving abnormalities in the regulation of cellular proliferation, 
maturation, and survival (2,5,18).  Association of  hMDS with increasing age suggests a genetic 
damage caused by hazardous exposure or inherited susceptibility (14,18).  
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In hypoplastic MDS, marrow failure results not only from ineffective erythropoiesis of 
abnormal clones, but also due to the inhibition of normal progenitors (2). There is increasing 
experimental and clinical indication of an immune-mediated damage to the hematopoietic 
precursors and changes in the hematopoiesis-supporting microenvironment contributing to the 
development of the disease (2). Immunosuppressive therapy with anti-thymocyte globulin, 
cyclosporine, or alemtuzumab may alleviate cytopenias and induce cytogenetic remission in some 
instances (2). However, all patients do not respond to immunosuppression. Identification of relevant 
biomarkers for an immune mechanism may help in identifying those patients who may benefit from 
immunosuppressive therapy (5,18). 
 
IMMUNOLOGICAL CHANGES IN hMDS (2) 
As observed in aplastic anaemia, abnormalities indicative of an active immune process mediated 
by a Th1-cell response are observed in MDS, including hMDS. These include;  
1. Abnormal Cytokine Profile (2):  
a. High levels of tumor necrosis factor-α (TNF-α).   
b. Over-expression of TNF-related apoptosis-inducing ligand (TRAIL) - preferentially 
targets abnormal clonal cells with aberrant chromosomes, inducing apoptosis.  
c. Lower levels of FLIP, a cytoplasmic inhibitor of apoptosis; this explains the higher 
sensitivity to TRAIL in cytogenetically abnormal clones.  
d. Over-expression of Interferon-γ (INF-γ) by bone marrow mononuclear cells in MDS. 
Both IFN-γ and TNF-α activate the expression of iNOS (induced nitric oxide synthase), which 
potentially mediate the dysregulation of haematopoiesis in MDS through Fas-mediated apoptosis. 
The cytokine expression profile may also have prognostic significance. In a recent study, 
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interleukin-4 (IL-4) and C-C motif chemokine 3 (CCL3) serum levels were consistently under-
expressed in MDS and independently associated with survival (2) . 
2. T-Cell Mediated Attack (2): 
 There are strong laboratory evidence suggesting that the marrow failure is the result of an 
antigen-driven lymphocyte destruction of the haemopoietic tissue. An expansion of cytotoxic T 
cells expressing defined T-cell-receptor (TCR) Vβ chain, indicating the oligoclonality of the T-cell 
repertoire is observed in these patients as well as in MDS. These skewed T-cell populations are 
observed to reduce or disappear after response to immunosuppressive therapy. Conversely, the 
dominant T-cell clone persists after treatment in those who fail treatment. The antigens triggering 
the immune response in MDS are not known. Patients with trisomy 8 often respond to 
immunosuppression, indicating a strong immunological mechanism for the underlying marrow 
failure. In patients with trisomy 8, the CD8+ T cells are able to recognize WT1 peptides and engage 
INFγ expression in vitro, suggesting that this antigen may contribute to elicit an immune response. 
Whether WT1 antigenicity may be used therapeutically is still unknown (2). 
3. Genetic factors:  
      As observed in several auto-immune disorders, HLA-DR15 antigen is overrepresented in 
patients with acquired AA, MDS with refractory anaemia, and  in patients with MDS bearing a 
PNH clone These observations taken together further suggest that some MDS cases are immune-
mediated (2).  
Aplastic anaemia and hMDS also may share genetic defects. Gene mutations encoding the 
telomerase complex (responsible for maintaining the length of telomeres), resulting in excessive 
telomere shortening in hematopoietic progenitors, are found in some cases of apparently acquired 
aplastic anaemia (2,9). The observation that a small subset of patients with hMDS respond to 
androgenic steroids, support this theory. These patients also often evolve to hMDS and acute 
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myeloid leukemia. Acquired aplastic anaemia patients with shorter telomeres (lowest quartile for 
telomere length) are those with higher risk to evolve to MDS, especially monosomy 7 (2). 
 
CLINICAL FEATURES:  
Majority of patients (i.e.50%), are asymptomatic at the time of  initial diagnosis (5,14), with 
the median age of presentation in the fourth to sixth decade (1,17). These patients present with signs 
and symptoms secondary to the cytopenia(s), while some are diagnosed on a routine blood count. 
The dominant findings in hMDS include anemia, thrombocytopenia, and leukopenia, either alone or 
in any combination, resulting from progressive hematopoietic failure (5,14). At the time of  
diagnosis, anemia is an almost universal characteristic finding, with > 80% of patients presenting 
with a hemoglobin level <10 g/dl and a reduced reticulocyte count (5,14). In 25-30% of patients, 
the blood leukocyte count is low, and the granulocytes may exhibit features of dysplasia (5,14). One 
third of the individuals have recurrent infections, due to granulocytopenia as well as the result of 
defects of neutrophil function (i.e. impaired chemotaxis & reduced phagocytic activity) (5,14). 
Thrombocytopenia and the concomitant platelet function defect results in bleeding manifestations 
which may include mainly petechiae, gum bleeding, or hematoma following trivial injuries; with 
<10% of patients presenting with serious bleeding (i.e. gastrointestinal bleed, macro hematuria, 
menorrhagia, or retinal or central nervous system hemorrhage) (5,14). 
 
DIAGNOSTIC WORK-UP 
Patients with hMDS have more profound thrombocytopenia and neutropenia, lower blast 
percentage, and one less likely to display an abnormal karyotype in comparison to patients with 
normo / hypercellular MDS. Diagnosis of low grade MDS is not always straight forward despite the 
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well-established diagnostic criteria and ever-expanding battery of molecular and cytogenetic 
diagnostic assays. The reasons for such difficulty are multiple, i.e. inter-observer disparity in 
documenting extent of dysplasia, (especially when dysplasia is mild to moderate) and the frequent 
lack of detectable chromosomal abnormalities (19). The most difficult part in the diagnosis of 
hMDS is differentiating it from acquired aplastic anemia. 
The diagnostic work-up of  hMDS includes morphologic evaluation of  peripheral blood,  
bone marrow aspirate, and bone marrow biopsy specimens, interpreted in the context of an adequate 
clinical information and CBC results (18).  Correlation with marrow cytogenetics is essential. A 
normal karyotype however does not exclude a diagnosis of an MDS (18).  Recently multiparameter 
flow cytometry has proven to be an important diagnostic tool, especially when added to 
cytomorphology (CM) and cytogenetics (CG) in patients with suspected MDS (19,20). 
 
Blood and bone marrow morphology and immunohistochemistry: 
Although MDS can be suspected from the clinical history and the peripheral blood counts, 
the diagnosis is often made by morphologic inspection of the peripheral blood, bone marrow 
aspirate, and bone marrow biopsy specimen (18).  
The current World Health Organization (WHO; 2008) system approach is a more 
comprehensive one, which stresses the importance of integrating other techniques; ie bone marrow 
biopsy histologic examination,  molecular genetics,  and cytogenetics in the light of relevant clinical 
information (18). Morphologic dysplasia is not necessarily synonymous with an MDS. To address 
the issue of “false-positive” myelodysplasia, the current WHO classification system recommends 
that,  to declare a dysplasia of a particular lineage, at least 10% of cells in the lineage has to be 
morphologically dysplastic (14,18). Specific criteria for dysplasia in the three different cell lineages 
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are detailed in the table in Appendix 1 (Table: 1 in Appendix 1) below (14,21). The presence of 
dysgranulopoiesis and dysmegakaryopoiesis favor the diagnosis of hMDS over AA.  
 
Blasts:   
The percentage of blasts in the bone marrow is important for the diagnosis, classification 
and prognostication of MDS. It is also an integral component of the currently used prognostic 
scoring systems; ie International Prognostic Scoring System (IPSS), WHO classification–based 
prognostic scoring system  and the more recent revised International Prognostic Scoring System  
(IPSS-R) (18).  Immature cells to be included in the blast count include myeloblasts (with and 
without a few fine azurophilic granules), megakaryoblasts and monoblasts, promonocytes are 
considered as “blast equivalents” in the WHO classification scheme (14,18).  It may be hard to 
appreciate blast in marrow biopsy specimen, particularly if there is marrow fibrosis (14,18). 
Immunohistochemical (IHC) stain for CD34 antigen may be very helpful in such a situation 
(14,18). Additional markers used to facilitate visibility of CD34– blasts include; CD117, lysozyme, 
and CD68 (14,18).  The blasts seen in MDS, are often myeloperoxidase negative or only weak 
positive (18).   
Flow cytometry may help in confirming the immunophenotype and assessing the frequency 
of blasts. In addition, side scatter abnormalities (due to granulocyte hypogranularity) and aberrant 
antigen expression have also been shown to correlate with the severity of the MDS (18).  Aplastic 
anemia can be distinguished from hMDS by the presence of a decreased number of CD34+ cells 
and reduced expression of proliferating cell nuclear antigen (PCNA) in bone marrow (10). The 
presence of increased reticulin content on silver staining on trephine biopsy favors the diagnosis of 
hMDS over AA. 
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CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES:   
To classify MDSs, a number of morphological classifications are in place; the most recent 
one being the WHO classification  (2008 Revision, 4th ed) (22). The current WHO classification of  
MDS is principally based on the blast percentage in the peripheral blood and bone marrow, and the 
type and degree of dysplasia (14,18). In particular, the extent of dysplasia, multilineage  vs 
unilineage, and the presence of ring sideroblasts (assessed by iron staining) have important roles in 
the WHO sub-classification (14,18). The absence of monocytosis (monocytes <1,000/μL in the 
blood and <5% in bone marrow) is important to distinguish between CMML (chronic 
myelomonocytic leukemia), and MDS (18).  
The WHO Classification of Myelodysplastic Syndromes (table below), recently published, 
distinguishes the following MDS subtypes (14,18):  
(1)  Refractory cytopenia with unilineage dysplasia (RCUD); subcategories- Refractory 
anemia (RA), Refractory neutropenia (RN), & Refractory thrombocytopenia (RT);  
(2)  Refractory anemia with ring sideroblasts (RARS);  
(3)  Refractory cytopenia with multilineage dysplasia (RCMD);  
(4) Refractory anemia with excess blasts (RAEB), with subcategories RAEB-1 & 2.  
(5) MDS, unclassifiable (MDS-U); and  
(6) MDS with isolated del (5q) chromosomal abnormality.  
The WHO 2008 classification of MDS is detailed in Appendix 1 (Table:2 in Appendix 1).  
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Hypoplastic MDS: In about 10-15 % of patients with myelodysplastic syndromes, the bone 
marrow is hypocellular, referred to as ‘hypoplastic MDS’ (5,14,18). This group do not have 
independent prognostic significance per se (14,18). The major problem is in the differential 
diagnosis with aplastic anemia. Toxic myelopathies and auto-immune disorders should be excluded 
when a diagnosis of hypoplastic MDS is considered (5,14,18). According to the WHO 
classification, Hypoplastic MDS however, does not represent a defined MDS category, but it rather 
denotes the morphologic status of other MDS categories (2,14,18).   
MDS with fibrosis: In a small subset of patients (~10%) with MDS, significant degrees of 
myelofibrosis are observed (14). These are referred to as MDS with fibrosis. Most of these cases 
have excess blasts and an aggressive clinical course (14). In the fibrotic group, due to inadequate 
aspirate, most often blast determination requires immunohistochemical studies (for CD34 on the 
trephine biopsy) (14).  
Multiparameter Flow Cytometry (MFC) in MDS:  The current World Health Organization 
classification of MDSs is based on morphological evaluation of bone marrow dysplasia. The 
reproducibility of the recognition of dysplasia is poor in clinical practice, especially in cases where 
specific markers such as ring sideroblasts and clonal cytogenetic abnormalities are lacking (23,24). 
In patients with MDS, a recent complementary DNA microarray analyses on CD34+ hematopoietic 
progenitor cells have found that MDS, including the early-stage/low-grade MDS, is characterized 
by a B-cell progenitor defect (19). Many genes involved in B-lymphocyte development are down-
regulated (19).  This observation was validated by the flow cytometric finding that  in a small 
number of MDS patients, the maturing B-lineage precursors (hematogones)  are reduced (19,23).   
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Recently a multiparameter flow cytometric scoring system has been validated for the 
diagnosis of myelodysplastic syndrome. This encompass four reproducible parameters  i.e. CD34+ 
myeloblast-related and B-progenitor- related cluster size (defined by CD45 expression and side 
scatter characteristics on CD34+marrow cells), myeloblast CD45 expression and granulocyte side 
scatter value (23). A flow cytometric score may help to establish the diagnosis of myelodysplastic 
syndrome, especially when morphology and cytogenetics are indeterminate (i.e. early-stage/low-
grade MDS). The calculations of flow cytometric score for the diagnosis of low-risk MDS is 
detailed in Appendix 1 (Table: 3 in Appendix 1). 
Cytogenetic and molecular studies: Molecular and cytogenetic studies have a major role in the 
evaluation of patients with myelodysplastic syndrome with regard to prognosis, determination of 
clonality and recognition of morphologic, cytogenetic and clinical correlates (5,14). Clonal 
cytogenetic abnormalities are usually observed in ~ 50% of cases of MDS (and upto 80% of cases 
with mutagen-related MDS) (5,14). A study by Vundinti BR et al (25) reported 54.48% 
chromosome abnormalities including novel chromosome aberrations in patients with and that these 
chromosome aberrations increased with advancing age. Cytogenetic changes observed in MDS are 
not unique to the disease; both numerical and structural cytogenetic changes may occur. Most 
frequent chromosomal abnormalities observed involve, deletions of chromosomes 5, 7, 11, 12, and 
20 and/or trisomy 8 (5,14). The chromosomal aberrations and its frequencies are described in detail 
in table in Appendix 1 (Table:4 in Appendix 1) 
Detection of certain chromosomal abnormalities, either by routine cytogenetic analysis or 
FISH, aids in the classification of MDS and determination of the prognostic risk group (5,14). With 
occasional exceptions (i.e. 5q- syndrome/MDS with isolated del(5q)), chromosomal abnormalities 
in MDS have not correlated with specific clinical or morphological subsets using the WHO 
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classification system (5,14).  Deletion of the long arm of chromosome 5 (5q) is the most common 
chromosomal abnormality seen in MDS (in 15% of cases). Cytogenetic and molecular analysis has 
led to the identification of two small commonly deleted regions; i.e. del (5q33.1) which is most 
commonly associated with the 5q minus syndrome with a relatively good prognosis, and del (5q31), 
which is more commonly seen with therapy-related MDS and is associated with more aggressive 
disease. MDS with 5q minus syndrome occur primarily in women, and is characterized by 
refractory macrocytic anemia, normal or increased platelet count, megakaryocytes with non-lobated 
or  hypolobated nuclei, a favorable clinical course & good response to lenalidomide treatment (14).  
Cytogenetics as a predictor of prognosis: Cytogenetic abnormalities have an impact on outcomes 
in patients with MDS. The abnormalities are risk categorized into 3 different cytogenetic categories 
in the international prognostic scoring system (IPSS) and WHO prognostic scoring system,  and 
into 5 groups in the recent revised IPSS (IPSS-R) (26) . The risk categories, their risk for 
progression to AML and median survival for the different groups are as follows; 
 
Cytogenetic subgroups in the IPSS & WPSS for adults with MDS. 
 
Prognostic subgroups Cytogenetic 
abnormality 
25 % AML 
progression 
Median 
survival 
Good risk Normal karyotype, 
isolated del(5q), 
del(20q), or –Y 
5.6 years 3.8 years 
Intermediate risk Other abnormalities 1.6 years 2.4 years 
Poor risk -7/del(7q), or complex 
karyotypes(≥3 abn) 
0.9 years 0.8 years 
 
 
The 5 cytogenetic risk categories and their median OS in the revised IPSS (IPSS-R) are as follows; 
 Cytogenetic subgroups in the IPSS-R for adults with MDS 
Prognostic  Subgroups Cytogenetic abnormality Median OS 
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Very Good del(11q),-Y          60.8 months 
Good  Normal, del(20q), del(5q) alone and 
double, del(12p) 
48.5 months 
Intermediate  +8, 7q-, i(17q), +19, +21, any other 
single or double, independent clones 
25.0 months 
Poor  der(3)q21/q26-7, double including 7q-, 
complex (3 abnormalities 
15.0 months 
Very poor Complex (>3 abnormalities) 5.7 months 
 
GENE MUTATIONS: 
 Abnormalities in certain genes have been identified in patients with MDS and acute 
myeloid leukemia with or without the presence of chromosomal abnormalities. These include 
mutations in TET2, ASXL1, TP53 tumor suppressor gene, RUNX1 transcriptional core-binding 
factor gene(CBF), IDH gene, FLT3 gene  and SF3B1 genes. These  gene mutations also confer 
prognostic significance in adult patients with MDS, for instance, it has been reported that patients 
with TET2 mutations may have higher response rates to azacitidine than those without the 
mutations (26).   
 
PROGNOSIS & RISK STRATIFICATION:  
Myelodysplastic syndromes, in view of the progressive impairment in the ability of the 
myelodysplastic stem cells to differentiate, are clinically characterized by  an increased risk of 
evolution into acute myeloid leukemia (AML) (27). The natural history of MDS ranges from 
indolent conditions spanning years to rapid progression to leukemia. The probability of leukemic 
evolution is lower in hMDS (1,6) than the normo-/hypercellular MDS (NH-MDS) (1,2,6), but 
compared to AA, hMDS have poorer prognosis with frequent karyotypic and FISH abnormalities 
and a higher probability of  leukemic evolution.  
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As the prognosis of patients with MDS is very heterogeneous, development of a prognostic 
system that allow risk stratification and help in the timing and choice of therapy is essential (26). A 
number of prognostic scores are currently in use, and these include;  
a.  IPSS (International Prognostics Scoring System): This is the most commonly used score 
and has been in use since 1997 (26). Prognostic score includes, the number of cytopenias, 
percentage of blasts, and the type of cytogenetic abnormality (26). Based on this scoring 
system there are 4 prognostic risk categories; i.e. ‘Low’ (score:0), ‘Intermediate-1’ (score 
:0.5-1), ‘Intermediate-2’ (score:1.5-2) and ‘High risk’ (score:≥2.5). IPSS is highly 
reproducible and very simple to use, but has several limitations; i.e. it is not a very precise 
predictor of prognosis in those with lower risk disease and it attributes relatively little 
weight to cytogenetics (26).  The IPSS scores, prognostic risk categories and their clinical 
outcomes (in terms of survival and risk of transformation to AML) are detailed in Appendix 
1 (Table:5 in Appendix 1). 
b. Revised international score (IPSS-R) : This score presented at the 2011 MDS Meeting in 
Edinburgh, incorporates a new cytogenetic score and includes different cut off for 
cytopenias (26). Prognostic score includes, the type of cytogenetic abnormality, percentage 
of blasts, hemoglobin level, platelet count and ANC (absolute neutrophil count) (26). Based 
on this systems, there are 5 prognostic risk categories i.e. ‘Very low’ (score:≤1.5), ‘Low’ 
(score:.1.5-3), ‘Intermediate’ (score:>3-4.5), ‘High’ (score: >4.5-6) and ‘Very high’ 
(score:>6) risk groups. The IPSS-R scores, prognostic risk categories along with their 
clinical outcomes (i.e. survival and risk of AML transformation) are outlined in Appendix 1 
(Table: 6 in Appendix 1). 
c. WPSS (WHO prognostic scoring system): This is another commonly used system that 
incorporates the transfusion dependency in addition to cytogenetics and WHO diagnostic 
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category (26). The main limitations of this system is that it requires, prior information of 
transfusion needs and WHO classification (26). A recent modification of  the WPSS score 
included hemoglobin levels instead of transfusion needs(26). Prognostic score includes, the 
WHO MDS category, the type of cytogenetic abnormality and the transfusion requirement 
(26). Based on this system patients are categorized into 5 prognostic risk groups; i.e. ‘Very 
low’ (score=0), ‘Low’ (score=1), ‘Intermediate’ (score=2), ‘High’ (score=3-4) and ‘Very 
high’ (score=5-6).  WHO prognostic scoring system with its clinical outcomes is detailed in 
Appendix 1 (Table:7 in Appendix 1). 
d. Global MDACC (MD Anderson Cancer Center) model: A more recent one is the global 
MDACC model that allows evaluation of all patients considered to have MDS at any time 
during the course of their disease without needed WHO evaluation(26). The Global 
MDACC and MDACC MDS lower risk Prognostic Models are tabulated in Appendix 1 
(Tables:8a & 8b in Appendix 1). 
e. Recently, based on the study on a cohort of 253 patients with hypocellular MDS (diagnosed 
at The University of Texas MD Anderson Cancer Center between 1993 and 2007) and a 
cohort of 1725 patients with hyper-/normocellular MDS (diagnosed during the same time 
period), a new prognostic model was built that segregated patients into 3 distinct risk 
categories independent of International Prognostic Scoring System (IPSS) score (26). This 
model is independent from the IPSS, and further refines IPSS-based prognostication. It  may 
be used to develop of risk-adapted therapeutic approaches for patients with hypocellular 
MDS (26,28). The details of the prognostic model of hypoplastic MDS is tabulated in 
Appendix 1 (Table: 9 in Appendix 1) 
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HYPOPLASTIC MDS AND APLASTIC ANAEMIA: Because of considerable clinical, 
histologic and cytologic similarities between these two disorders, it is sometimes difficult to 
distinguish Hypoplastic myelodysplasia from acquired aplastic anemia (10). The presence of 
dysmegakaryopoiesis, dysgranulopoiesis, increased percentage of blasts, increased bone marrow 
reticulin content and abnormal karyotype, favour the diagnosis of hMDS. In addition, an abnormal 
antigen expression pattern in marrow CD34+ cells indicating an aberrant clone, and the presence of 
elevated haemoglobin F-containing erythroblast production suggest the diagnosis of hMDS. 
However, findings compatible with an immune process (oligoclonal T-cell expansion, relative 
lymphocytosis in the marrow and  increased cytokine levels) do not contribute to differential 
diagnosis, as these elements are present in both (2).  
The distinction between hMDS and AA is of great prognostic and therapeutic importance. 
With modern therapies; ie bone marrow transplantation and immunosuppressive therapy, severe AA 
patients have long term survival (80% at 14 years), and those with moderate AA have a median 
survival of >174 months with androgen and supportive therapy; while for patients with hMDS, the 
median survival is not significantly different from hypercellular MDS (22 to 33 months). Some 
cases of hMDS may show a transient response to androgens and/or immunosuppressive therapy 
thus adding further diagnostic difficulty. Further, there is a higher risk of progression to acute 
leukemia in patients with hMDS compared with AA (29). Recent studies have suggested that in 
AA, bone marrow (BM) is characterized by a decreased number of CD34+ cells and reduced 
expression of proliferating cell nuclear antigen (PCNA), which is not a feature associated with 
MDS (10). A role for tumor necrosis factor-alpha (TNF-alpha) in the development of AA has been 
suggested by recent studies(29). Careful examination of peripheral blood, may also provide 
sufficient information to allow for the distinction between hMDS and AA early in the course of the 
disease (30). Certain morphologic findings i.e. hypochromic red cells, circulating blasts, left shift, 
17 
 
hypersegmentation with long filaments, Dohle bodies hypogranular, ring, and pelgeroid neutrophils, 
circulating micromegakaryocytes and megakaryocytic fragments are seen only in hMDS but not in 
AA (30). The table below summarizes the major differences between hMDS and AA. 
(3,6,15,16,31,32). 
 
 
 
 
Distinction between hypoplastic MDS and Aplastic anemia 
 
Characteristics  Hypoplastic  MDS AA  
Dyserythropoiesis  Yes Sometimes  
Abnormal neutrophil  Yes No  
Dysplastic megakaryocytes  Yes No  
Fibrosis   Occasional No 
Increased blasts   Sometimes (ALIPS) No 
CD34+ cells in BM  Sometimes increased < 1.0% 
Clonality   Sometimes Possible 
Splenomegaly   Occasional Absent 
 
It is fortunate that the distinction is not critical since both aplastic anaemia and hypoplastic 
MDS respond to similar forms of treatment. Indeed there is close similarity between the two 
conditions and they are sometimes called ‘overlap syndromes’. 
 
DIFFERENTIAL DIAGNOSES: 
Acquired aplastic anemia is the most important and difficult differential diagnosis of hMDS 
(discussed above). Other conditions that can present with cytopenia(s) and dysplastic changes 
include; Vitamin B12 & folic acid deficiencies, Copper deficiency & arsenic poisoning, medications 
& drugs, liver failure or hypothyroidism causing macrocytic anemia with a  low reticulocyte count, 
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auto-immune and other hematopoietic neoplasms, e.g. lymphomas, and non-hematopoietic 
malignancies causing para-neoplastic myelodysplasia, Viral infections (e.g. HIV infection,, chronic 
parvovirus, Epstein-Barr virus, and cytomegalovirus infections) and rarely, hemophagocytosis can 
produce marrow changes that resemble MDS (18).  
TREATMENT OF hMDS:  
The treatment of hMDS is similar to aplastic anemia in view of similarity in its 
pathophysiology. The options include; 
A. Options for newly diagnosed patients: In newly diagnosed lower risk group patients, 
therapy is based on the transfusion needs of the patients (26). Transfusion independent 
patients are usually observed until they become transfusion dependent (26). A new and  
important concept in the treatment of lower risk MDS is early intervention in patients with 
‘‘poor prognosis’’ lower risk MDS (26). To improve on the natural history of the disease, 
the identification of these patients is going to be fundamental (26). The upcoming new 
prognostic scoring systems and development of new molecular informations for these 
patients will help in early identification and intervention (26). The list of agents currently 
available for treatment of patients with hMDS is as follows; 
 
1. Immune therapy: Hypoplastic MDS is characterized by dysregulation of immunity, and it 
has been observed that patients with hMDS benefit from immunosuppressive therapy (26). 
The agents studied include cyclosporine-A (CSA), corticosteroids and antithymocyte 
globulin (ATG) (26,33). Standard IST is the combination of ATG & CSA (horse or rabbit 
ATG) with a short course steroid. The dose of ATG used is 40 mg/kg over 4 hours, daily for 
4 days after premedication along with prednisolone (1 mg/kg from day 1 for 2 weeks) for 
serum sickness prophylaxis, and CSA (dose: 10 mg/kg/day from day 1 to target trough 
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level- 200 and 400 ng/ml. Cyclosporine monotherapy (6mg/Kg) is an easily available, and is 
a safe and cheap IST. The group at the NHLBI (National Heart, Lung and Blood Institute)  
has developed an algorithm to predict response to these agents, i.e. younger age, shorter 
duration of transfusion dependency and HLA-DR15 (34). Bone marrow hypocellularity is 
the most important predictor for response (35). Recently alemtuzumab (humanized 
monoclonal antibody that speciﬁcally kills CD52-bearing cells via both antibody-dependent 
cellular cytotoxicity  & complement-mediated lysis; dose is 10 mg Alemtuzumab s/c daily x 
5 days along with CSA (2 mg/kg Q12H) x 3 months, has also been reported to have 
significant activity in those patients with MDS predicted to respond to immune suppressive 
therapy (26,34).  The most important predictor for response has been the presence of 
marrow hypocellularity (26,34).  In younger patients with severe hypoplastic MDS, 
allogeneic stem cell transplantation (Allo SCT) should be considered as soon as possible. 
For those that are not candidates, a combination with equine ATG is recommended. 
Response to immune therapy (IST) reported in literature is a haematologic recovery 
of 75- 90% after one or two courses of IST (36). A response rate of 68% is reported for 
ATG/CSA in AA, while following alemtuzumab therapy upto 57% response has been 
reported by some studies (26,33,36,37). 
 
2. Allogeneic Peripheral blood stem cell transplant: Allogeneic hematopoietic stem cell 
transplantation is the treatment of choice in young patients with severe aplastic anemia or 
hypoplastic MDS. The main causes of failure after this procedure are graft versus host 
disease, infections and graft failure, often exacerbated by large numbers of transfusions and 
prolonged disease duration before transplant (38). A less toxic regimen comprising reduced 
cyclophosphamide (Cy), fludarabine, and anti-thymocyte globulin (ATG) (Cy-Flu-ATG) 
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was used to condition high-risk patients scheduled for allogeneic hematopoietic cell 
transplantation (allo HSCT) instead of standard Cy-ATG in patients with severe aplastic 
anemia (AA) and hMDS (39). Preconditioning with Cy-Flu-ATG was superior to that 
afforded by Cy-ATG in terms of reducing RRT levels without increasing engraftment 
failure (39). Recent study by Szczylik C. et al showed that transplantation of hematopoietic 
stem cell using alemtuzumab, fludarabine and melphalan as a conditioning therapy is safe, 
inexpensive and effective treatment for patients with severe aplastic anemia, including 
multi-transfused adults having their disease for a long time (38). Five year OS following 
matched related and unrelated Allogeneic PBSCT reported are 73% and 60% respectively 
(36,39).  
3. Androgenic steroids: Androgenic steroids i.e. Danazol (derivative of synthetic steroid 
ethisterone-17 α ethinyl testosterone; 300mg daily), Oxymetholone, and Stanazolol 
(synthetic anabolic steroid derived from testosterone; 1mg/Kg/day) have been proved to be 
of benefit in hMDS as seen in Aplastic anemia (40). Androgens are enzymatically converted 
into estradiol (E2) via aromatase.  E2 passively diffuses into cells and binds the α isoform of 
the estrogen receptor (ERα), which acts as a transcriptional activator by binding to estrogen 
response elements (ERE) in genomic DNA. The telomerase reverse transcriptase (TERT) 
promoter contains 2 putative EREs. Therefore, both androgens and estrogens increase TERT 
expression, ultimately resulting in increased telomerase activity in hematopoietic cells. 
Androgens also inhibit both interleukin-1 and TNF-a production. In patients unresponsive to 
IST, a response rate of 30-35% has been reported to androgens in some studies (41). 
 
4. Haematopoietic growth factor support:  Currently a number of erythroid stimulating 
agents (ESA) are available. Reported rates of response to these agents range from 30 to 60% 
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(26,42). In a retrospective observational study by Jadersten M et al (26,43), it was observed 
that addition of  G-CSF to erythropoietin increased the response rates, and early introduction 
of this combination in patients with minimally transfusion-dependent and low risk disease 
may have an impact on survival. In patients with significant anemia and with no other 
cytopenias, a course of  ESA with or without G-CSF is not contraindicated (26). Early 
incorporation of these agents has been found to be more effective than in patients with 
heavy transfusion burdens. Due to complications related to disease transformation and 
marrow fibrosis, the use of  Romiplostin in lower risk MDS is questionable (26).  
5. Supportive care measures: The supportive care measures in hMDS include; use of 
prophylactic antibiotics and iron chelation. No randomized data exists to make formal 
recommendation for any of these interventions (26). 
B. Options for patients with higher risk MDS:  
Treatment options for patients with higher risk MDS have significantly evolved over 
the last decade. Earlier most patients were treated with cytarabine based therapy as for 
AML. Recently the use of azanucleosides (Decitabine & 5-Azacytidine) has modified this 
practice (44,45). Two candidate biomarkers and a clinical model have been proposed 
recently. mutations on TET2  and levels of miR29b and have been reported to be associated 
with response to azacitidine and decitabine respectively (26,46). 
AML-like chemotherapy: In higher risk MDS, AML-like protocols have generally 
used classical anthracycline-araC combinations, similar to that used in de novo AML. 
AML-like therapy results in lower CR rates (40–60%), and shorter CR duration         
(10–12 months) when used in MDS or AML post-MDS. They tend to be associated with 
more prolonged periods of aplasia, and in addition, due to the advanced median age of 
the patients, the feasibility of AML-like therapy is also reduced (26). 
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Allogeneic Stem cell transplant: Allogeneic SCT is the only curative treatment of 
higher-risk MDS.  Selected studies report prolonged DFS in about 30% to 50% of the 
patients. However its use is restricted mainly to younger patients with an appropriate 
donor (26,47). 
RESPONSE CRITERIA: 
Definition of IWG response criteria in MDS: The IWG (International working group ) criteria 
define 4 aspects of responses based on treatment goals: (1) altering the natural history of the 
disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4) QOL (Quality of life) 
(48). The responses assessed include CR (complete remission), PR (Partial remission), Stable 
disease, Failure, Relapse after CR or PR, Cytogenetic response and disease progression. The details 
of the proposed modified International working group response criteria are described in Appendix 1 
(Tables:10a & 10b in Appendix 1). 
SUMMARY:   
Hypoplastic MDS is a distinct clinic-pathologic entity characterized by bone marrow 
hypoplasia, severe leucopenia and thrombocytopenia, macrocytosis, low incidence of progression to 
acute leukemia, and unresponsiveness to conventional therapy (6,8). It represents approximately 10 
- 15% of all MDS cases (2,4–9,14). It is difficult to distinguish hMDS from acquired aplastic 
anemia (AA), because of considerable clinical, histologic, and cytologic similarities between the 
two disorders (1,6,10,14). However, compared to AA, hMDS have poorer prognosis and frequent 
karyotypic and FISH abnormalities (prone to leukemic conversion) (12). The Pathophysiology of 
hMDS is not very well known; auto-reactive and clonal-involved T-cells are believed to suppress 
the normal hematopoietic cells by secretion of inhibitory cytokines (5). This subtype is most likely 
to respond to treatment with immunosuppressive agents; therapy with antithymocyte globulin 
(ATG), cyclosporine (CSA) or both has been shown good response in patients with  hMDS (13).  
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Aims and objectives:  
1. To analyze the clinical profile of adult patients with Hypoplastic Myelodysplastic syndrome 
(hMDS). 
2. To assess the response to different drug therapies in patients with hMDS. 
3. To identify the demographic, clinical, and laboratory parameters that can predict prognosis 
in hMDS. 
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Patients and Methods 
This study protocol was approved by our Institutional Review Board (IRB). This is a retrospective 
analysis of patients diagnosed to have hMDS from January 1998 to June 2012. 
Duration of the study: October 2012 to December 2012.  
Settings of the study: Department of Clinical Haematology.  
Diagnostic criteria: Hypoplastic MDS was diagnosed in patients presenting with cytopenia(s) 
(defined as per the recommendation in the IPSS for risk stratification in MDSs (i.e. Hemoglobin     
<10g%, Absolute neutrophil count <1800/mm
3
, and   Platelets <100,000/mm
3
) associated with a 
hypoplastic bone marrow for the age (2,5,14), and with features of dysplasia in one or more cell 
lines, with or without increase in number of blasts/CD 34+ cells on bone marrow, or increase in 
reticulin content on bone marrow trephine, or abnormal karyotype showing malignant clonal cells 
(all favoring diagnosis of hMDS)  (2,3,5,6,9,14–16).   
 
Patients: 
Inclusion Criteria: 
1.  All adult patients (age≥18yrs) diagnosed to have hypoplastic myelodysplastic syndrome 
from January 1998  to June 2012 
Exclusion Criteria:  
1. Patients with other types of Myelodysplastic syndromes. 
2. Patients with hMDS whose data are not retrievable. 
3. Patients on drugs that can cause dysplasia (e.g. post renal transplant patients) 
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4. Patients with hypoplastic cytopenia(s) and positive test for PNH, or positive stress 
cytogenetic test (clastogenic stress-induced chromosomal breakage). 
Methods: 
Collection of data: After approval by the IRB, the patient data base at our institution was  reviewed 
to identify all patients diagnosed to have hypoplastic MDS at our institute between January 1998 to 
June 2012. Medical information regarding the clinical/laboratory details at diagnosis, post treatment 
response and adverse events were obtained from the hospital records (laboratory reports/ physician 
documentation in hospital charts/hospital discharge summaries). Attempts were made to contact all 
patients by post or e-mail to collect details on any missing data as well as the recent clinical status.  
Only patients who had at least 8 weeks follow up (including those who died within 8 weeks) after 
initiating therapy were categorized as ‘evaluable‘ for assessment of response and survival.  
Treatment: Various treatment modalities that the patients received were reviewed. This included; 
Cyclosporine, anti-thymocyte globulin + CSA, androgenic steroids, corticosteroids, supportive 
measures, and allogeneic peripheral blood stem cell transplant, and a few had received 
haematopoietic growth factors or lenalidomide. Data was collected with regard to type of treatment, 
duration of treatment, side effects and overall outcome with respect to the treatment given. 
Data analysis: Results are analyzed in terms of the clinical characteristics and laboratory 
parameters at diagnosis, response to the different treatment regimens [drug(s)], the survival patterns 
and the prognostic effects of patient characteristics on overall survival. The response to treatment is 
assessed in terms of Complete Remission (CR), Stable disease, Relapse, Progression of disease, No 
response, and failure/death. CR was defined as the absence of any clinical sign of disease and 
attainment of the following haematological parameters i.e. pperipheral blood Hb ≥ 11 g/dL, 
Platelets ≥100 x109/L, Neutrophils ≥1.0 x109/L, Blasts - 0%.  Patients with failure to achieve at 
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least CR, but with no evidence of progression for >8 weeks were considered to have ‘Stable 
disease’.  Relapse after CR was defined as reduction  of values by ≥50% from maximum 
remission/response levels in granulocytes or platelets, and or reduction in Hb concentration by ≥1.5 
g/dL or transfusion dependence. Progression of disease was defined as any one of the following i.e. 
(1) At least 50% decrement from maximum remission/response in granulocytes or platelets, (2) 
Reduction in Hb by ≥ 2 g/dL, (3) Transfusion dependence (Tables:10a & 10b in Appendix 1).   
All patients started on treatment and with a minimum follow up of 8 weeks were considered 
evaluable for response and outcome. Overall survival (OS) was measured from the start of therapy 
until death (from any cause) or last follow-up (49–51). Event-free survival (EFS) was calculated 
from the start of therapy until the first adverse event, i.e. relapse or progression, secondary 
malignancy, death from any cause, or last follow- up (49–51). Progression-free survival (PFS) for 
all patients was taken from the start of therapy until disease progression or death  from hypoplastic 
myelodysplastic syndrome (49–51). Disease-free survival (DFS) for patients in CR was measured 
from the first recording of  response (CR or Stable disease)  to the date of progression or relapse 
(49–51). The closing date for analysis was December 31, 2012.  
Statistics:  Descriptive statistics were calculated for all variables. Differences in proportions were 
assessed using the chi-square statistic or Fisher exact test. Differences in means were tested using a 
t-test or Mann-Whitney-U test as appropriate. Survival curves were drawn by the Kaplan-Meier 
method and compared by the log-rank test. The relationships of clinical features to the outcome of 
the procedure were analyzed by univariate Cox proportional Hazard model. For all tests, a 2-sided 
P-value of 0.05 or less was considered statistically significant. SPSS 16.0 software was used for the 
analysis.  
 
 
27 
 
RESULTS: 
 Between January 1998 and June, 30, 2012, a total of 54413 out patients were seen in the 
Haematology department, of which 1225 (2.3%) were diagnosed to have primary MDS. Of this, 
173 (14.1% of MDS; 0.32% of total patients) were diagnosed to have hypoplastic MDS. The year 
wise distribution of total MDS and hMDS is depicted in Figure:1. 
 All patients (n=173) were included for the analysis of baseline characteristics. Out of the 
total 173 patients, only 111 (64.2%) who had a follow up of >8 weeks after initiation of treatment 
were considered ‘evaluable’ for assessment of response to treatment and for survival analysis.  
 Certain data are available on all patients, while certain data are available only on a portion 
of the patients. For each result category, the numbers of patients involved are mentioned. 
DEMOGRAPHY & CLINICAL FEATURES AT DIAGNOSIS:  (Table:1) 
The median age of the 173 patients was 41 years (range: 18-64).  Seventy two (41.6%) 
patients belonged to the age group of 18-40 years, 51 (29.5%) to 41-55years and 50 (28.9%) were 
above 55 years of age. Males were predominantly represented in the study group i.e. 112 (64.7%) 
males and 61 (35.3%) females. The male female ratio was 1.8:1. 
Pallor and bleeding manifestations were the common presenting symptoms; i.e. in 94.2% 
(n=163) and 40.5% (n=70) respectively. Sixty six (38.2%) patients had history of infections (mainly 
recurrent febrile episodes; a few had lower respiratory tract and skin infections). The median 
duration of symptoms was 3 months (range: 1-120). Clinical examination showed mild (<2cms) 
splenomegaly in 6 patients (3.5%) and mild hepatomegaly (<2cms) in 2 (1.2%) patients.   
Forty eight patients (27.7%) had received previous treatment. This included,. CSA (n=8), 
Azathioprine (n=2), Anabolic steroids (n=8), Prednisolone (n=11), EPO (n=2), GCSF (n=1) or 
Lenalidomide (n=1) for a median duration of 60 days (range: 7-720).  Among the 173 patients, 139 
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had received transfusions (packed red cells and or platelet rich concentrates) before presenting to 
our Institution. The median number of transfusions per month was 2 (range;1-20) units.  
Fourteen patients (8.1%) had past history of treatment for cytopenias; 11 patients were 
diagnosed and treated for Aplastic anemia before the diagnosis of hMDS was made. The median 
time from diagnosis of AA to diagnosis of hMDS was 38 months [range:4-149].  Among them, 2 
each had attained CR or PR and were off therapy for a mean period of 53 months (range: 28-91). 
The remaining 7 remained symptomatic and were diagnosed to have hMDS on re-evaluation. The 
twelfth patient was diagnosed to have B12 deficiency with bicytopenia 6 years back and had been 
lost to follow up while on B12 & folate supplementation; a second patient (male; 23yrs) was 
diagnosed to have Chloramphenicol induced pancytopenia 12 years back which had resolved. The 
last patient (female; 61yrs) was diagnosed to have MDS with fibrosis 3 years back (hypercellular 
marrow with fibrosis, normal cytogenetics), was treated with thalidomide & prednisolone for one 
year followed by danazol for 2 years before she was diagnosed to have hMDS (with cytogenetics-
del5q & WHO group RAEB-1). She was subsequently treated with Lenalidomide with no response 
and expired within 3 months of diagnosis of hMDS. 
 
LABORATORY PARAMETERS AT DIAGNOSIS:  (Table: 2) 
At presentation, majority of the patients (65.3%; n=113) were pancytopenic, while bicytopenia was 
seen in 53 (30.6%) and only 7 (4.1%) had cytopenia involving a single lineage.  The median 
hemoglobin for the entire cohort was 5.8g% (range:1.2-13.2); most of these patients (54.4%; n=94) 
had hemoglobin level <6g% while in 41% (n=71) the level was between 6.1-10g% and only 4.6% 
(n=8) had hemoglobin >10g% at presentation. Neutropenia (an absolute neutrophil count 
<1800/mm
3
) was observed in 135 (78%) patients at presentation, while 38 (22%) had normal 
neutrophil count. ANC below 200/mm
3 
was observed in 8.7% (n=15) while ANC between 201-
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500/mm
3
, 501-1000/mm
3
, 1000-1500/mm
3
, and 1501-1800mm
3 
was found in 16.2% (n=28), 22.5% 
(n=39), 20.8% (n=36) and 9.8% (n=17) respectively. Thrombocytopenia (platelet <100 x10
9
/L) was 
documented in 161 (93%) patients; 61.3% (n=106) had a count < 20 x10
9
/L, while a count of 21-50 
and 51-100 x10
9
/L was observed in 39 (22.5%) and 16 (9.2%) patients respectively.  
 The median reticulocyte percentage at diagnosis (documented in 152 patients) was 1.8% 
(range: 0.05-7.06). Out of the 99 patients in whom the absolute reticulocyte count was available, the 
median absolute reticulocyte count was 37200/mm
3
, with 18 (18.2%) patients having an absolute 
reticulocyte count <20 x10
9 
/L). None of the patients had monocytosis or eosinophilia. The median 
absolute eosinophil (AEC), monocyte (AMC) and lymphocyte (ALC) counts were 0/mm
3
       
(range: 0-966), 36/mm
3
 (range: 0-690) and 1656/mm
3
 (range: 175-8800) respectively.  
Data on auto-immune markers i.e. direct coomb’s and antinuclear antibody tests were 
available only in 39 and 23 patients respectively, with 14 (35.9%) being coomb’s positive and 8 
(34.8%) positive for ANA.  Serum LDH was documented in 160 patients, and majority (81.9%; 
n=131) had level <600 mg/dl. Serum ferritin was available in 24 patients; the median level was 
825ng/ml (range: 138-46775).  Report on serum B12 level was available in only 10 patients and the 
median value was 970pg/ml (range: 248-2000). Out of the 137 patients in whom blood borne virus 
screen was done at diagnosis, 3 patients were positive for HBV, while 1 each positive for HIV and 
HCV respectively.  
BONE MARROW FEATURES & WHO CLASSIFICATION AT DIAGNOSIS: (Table:3 & 
Figures:2a-2h] 
The bone marrow was aplastic, uniformly hypocellular or varyingly hypocellular in 5.2% 
(n=9), 83.2% (n=144) and 11.6% (n=20) of patients respectively (Fig: 2f). The data on BM blast 
count was available in 171 patients, out of which majority (46.8%; n=80) had no blasts on the 
aspirate and no increase in CD 34+ cells on the trephine biopsy.  In 77 (45%) patients, the blast 
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percentage was 1-2%, while 10 (5.8%) had 3-4% blasts and 4 (2.4%) had ≥ 5% blasts on the 
marrow (Fig: 2h). Scattered ring sideroblasts (Fig: 2e) were documented in 47 (39.2% of the 120 
cases where data was available) patients and one had >15% ring sideroblasts.  
Trilineage dysplasia (Figs: 2a-d, 2f) was observed in 57 (33%) patients, while 36 (20.8%) 
patients had unilineage and 80 (46.2%) had bilineage dysplasia respectively. Data on bone marrow 
reticulin was available in 169 patients. Out of this 135 (79.9%) patients showed increased reticulin 
content (Fig: 2g) on silver stain. Most of these patients (47.3%; n=80) showed mild increase in 
reticulin, while 49 (29%) and 6 (3.6%) patients showed moderate and marked increase in reticulin 
respectively. 
 On categorizing the patients according to the WHO classification, majority (77.5%; n=134) 
belonged to the RCMD group, with 4 (2.3%; n=4) belonging to RAEB-1 and 35 (20.2%) belonging 
to the MDS unclassified (MDS-U) group. 
CYTOGENETIC ABNORMALITIES AT DIAGNOSIS: (Table: 4) 
Cytogenetic data was available on 116 (67%) patients. Majority (66.4%; n=77) had normal 
karyotype. Five patients had polyploidy out of which only 2 had associated structural chromosomal 
anomalies while 3 had no anomalies. Among those with chromosomal aberrations, 11.2% (n=13) 
had a sinlge abnormality, while 8 (6.9%) patients had 2 abnormalities, 3 (2.6%) had three 
abnormalities and 15 (12.9%) had more than 3abnormalities/associated monosomy 7.   
   Among the 39 patients with chromosomal abnormalities, 55 numerical abnormalities were 
observed. Most of the numerical anomalies were monosomies (n=37), while 18 were trisomies. 
There were 13 patients (11.2%) with monosomy 7, 7 patients (6%) with trisomy 8, and 8 patients 
(6.9%) with trisomy 21. Other abnormalities noted included translocations (n=5), deletions (n=15), 
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and other rare anomalies i.e. additions (n=5), derivatives (n=4) and duplications (n=1).  Deletion 5q 
was observed in 7 (6%) cases. The details of each anomaly are detailed in table 4. 
CYTOGNETIC & PROGNOSTIC RISK GROUPS AT DIAGNOSIS: (Tables: 5 & 6) 
 Cytogenetic risk groups:  (Table 5) 
One hundred and sixteen  patients in whom the cytogenetic reports were available,  were 
risk categorized into three cytogenetic risk groups (good, intermediate and poor) as per the ‘IPSS & 
WPSS’, and into 5 risk groups (very good, good, intermediate, poor and very poor) according to the 
revised IPSS (IPSS-R ) systems. Majority of the patients belonged to the ‘good’ cytogenetic risk 
group, in either systems (69% [n=80] each in both), while 16.4% (n=19) and 14.6% (n=17) 
belonged to the intermediate and poor risk cytogenetic groups respectively in the ‘IPSS&WPSS’ 
group. Whereas in the IPSS-R group, 3 patients (2.6%) each belonged to ‘very good’ & ‘very poor’ 
risk groups, while 15 (12.9%) each belonged to the ‘intermediate’ & ‘poor risk’ groups 
respectively.   
Prognostic risk groups: (Table: 6) 
The 116 patients were categorized into different prognostic risk groups using three different 
prognostic scoring systems ie; IPSS, IPSS-R and WPSS scoring systems. Using the IPSS system, 
majority (82.7%; n=96) belonged to the ‘intermediate-1’ group, while 17 (14.7%) and 3 (2.6%) 
belonged to the ‘intermediate-2’ and ‘low’ risk groups respectively. There were no patients in the 
high risk group. Using the WHO classification based prognostic scoring system (WPSS), one 
patient (0.9%) was categorized into the ‘very low’ risk group, 68.1% (n=79) into ‘low’ risk group, 
16.4% (n=19) into ‘intermediate’ risk and 14.6% (n=17) into high risk groups respectively. In the 
IPSS-R category, 2 (1.7%) patients were in the ‘very low’ risk group, 22 (19%) in the ‘low’ risk, 68 
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(58.6%) in the ‘intermediate’ risk, 18 (15.5%) in the ‘high’ risk and 6 (5.2%) were in ‘very high’ 
risk groups respectively.   
 
TREATMENT AND RESPONSE:  (Table: 7) 
Patients who had a minimum of  8 weeks follow up after starting treatment (including those 
who expired within 2 months of treatment) were considered evaluable for assessment of response to 
treatment. Among the total 173 patients; 111 patients (109 with >2 months follow up + 2 who died 
within 2 months of starting treatment) were considered evaluable, and the remaining 62 were 
considered non-evaluable for assessment of response to therapy. Out of the 111 evaluable patients, 
cytogenetic data was available only in 79 patients. 
Of the 111 evaluable patients, 99 received treatment with (a) Cyclosporine (CSA) or  (b) 
Antithymocyte globulin+CSA (ATG+CSA) or (c) Androgenic steroids (Danazol/stanazolol) or (d) 
Prednisolone, or (e)  Allogeneic PBSCT (Allo PBSCT) and 12 patients received ‘Other’ therapies 
(i.e. Lenalidomide or EPO/GCSF or supportive measures).   
(a) CSA  (Table:7):  Overall 81 patients received treatment with CSA; out of these  
only 59 were evaluable for response. Among the 59 evaluable patients, 41 showed a response (6 
[10.2%] achieved CR while 35 [59.3%] achieved ‘stable disease’). Six (102%) patients expired 
without attaining any response and the remaining 12 showed no response to CSA. Among the 6 
patients who expired, one had progressed to AML prior to expiry.  Of the non-responders, 8 were 
started on second line treatment with  Androgenic steroids and 4 patients who had matched sibling 
donors were taken up for allogeneic PBSCT (detailed in the section on Allogeneic PBSCT).  
Among the responders, the 6 patients in CR continued to be in CR at last follow up. In the 35 
patients with ‘stable disease’ 24 (68.6%) continued to be in ‘stable disease’ at last follow up (6 are 
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stable & off  treatment, while 16 patients are stable but remain on treatment, and 2 were lost to 
follow up while on treatment).  Of the 35 patients with ‘stable disease’, 11 progressed while on 
follow up. One patient progressed to PNH and was started on Danazol. Another patient was 
started on danazol followed by ALG+CSA with no response (subsequently succumbed to disease 
progression and treatment failure). Of the remaining 9 patients, one expired following disease 
progression and 8 were restarted on CSA (2 were lost to follow up and 6 continue to be on follow 
up). While on treatment with CSA, 5 out of the total patients developed CSA related 
nephrotoxicity elevated serum creatinine, these were non-responders and was changed to 
Androgens) and 2 had gum hyperplasia. The mortality was 13.6% (n=8) among those treated with 
CSA. .Overall the response rate to CSA was 69% (41 out of 59), with mean time to response of 
5.9months (range: 3-36months), and  median duration of treatment of 19 months (range: 3-126).  
At a mean follow up duration of 103 months (range: 8-110), the 5 year OS of the responders 
(n=41) was 96.9% ± 3.1%.  
(b) Antithymocyte globulin+CSA (ATG+CSA)  (Table:7):  A total of 10 patients 
were treated with ATG+CSA. Of these 7 showed response to treatment (2 CR and 5 ‘stable 
disease’), one patient expired without response and 2 showed no response. The 2 non-responders 
were changed over to Androgens.  Among the responders, 2 patients who achieved CR continued   
to remain in CR (on CSA) at last follow up. At last follow up, 3 out of the 5 patients with’ stable 
disease’ continued to be so (2 were off treatment and one was on CSA) and 2 patients progressed 
(out of which one expired and one was continued on treatment). The mortality was 20% (n=2) 
among those treated with ATG+ CSA. Overall the response rate to ATG+CSA was 70% (7 out of 
10), with mean time to response of 1.8 months (range: 1-3 months), and median duration of 
treatment of 12 months (range: 8-72).   At a mean follow up duration of 58 months (range: 16-73), 
the 5 year OS of the responders (n=7) was 75.0% ± 21.7% .  
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(c) Androgenic steroids (Danazol/stanazolol) (Table:7): Out of the 74 patients who 
received treatment with androgenic steroids (29 received danazol while 45 received stanazolol), 
51 were evaluable. Twenty four patients (47.1%) showed response (2 CR & 22 ‘stable disease’), 
while 25 (49%) showed no response to androgens. Two patients (3.9%) expired without any 
response (out of which one expired following progression to AML). Of the non-responders,          
4 patients were changed over to ATG+ CSA, 17 patients to CSA and 4 were lost to follow up.  
One out of the 2 patients who attained CR continued to be in CR at last follow up, while the other 
patient relapsed and was restarted on treatment. Out of the patients who had stable disease, 17 
continued to be stable, while 5 patients showed evidence of progression of disease. Two of the 
patients with progression of disease were restarted on treatment but were subsequently lost to 
follow up; while 3 patients expired following progression of disease (one patient expired 
following progression to AML, second one following progression of disease along with metastatic 
adenocarcinoma and the third due to disease progression). The mortality was 9.8% (n=5) among 
those treated with Androgenic steroids.  Overall the response rate to Androgenic steroids was 47% 
(24 out of 51), with mean time to response of 5.3months (range: 1-27 months), and median 
duration of treatment of 11 months (range: 2-92).  At a mean follow up duration of 68 months 
(range: 20-92), the 5 year OS of the responders (n=24) was 51.40% ± 23.1%. 
(d) Prednisolone  (Table:7):  Twenty four patients received treatment with steroids, but 
only 17 were evaluable. Only four (23.5%) patients showed response (‘stable disease’) to 
prednisolone. One patient (5.9%) expired, while 12 (70.6%) showed no response.  Among the 12 
non-responders, treatment was changed to CSA in 7, to androgens in 4 and one patient was taken 
up for allogeneic PBSCT. Among the 4 patients who attained response to prednisolone, 3 were 
lost to follow up after a mean follow up of 11 (7-13) months, and the fourth patient relapsed after 
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44 months and was then lost to follow up. The median duration of steroid treatment was 4 months 
(range: 2-36) and the mean time to response was 1.9 months (range: 1.3-2.7).  
(e) Allogeneic PBSCT (Allo PBSCT)  (Table:7):   There were a total of 5 patients who 
underwent allogeneic PBSCT. All were males; with age between 19 to 56 years. One patient was 
diagnosed to have Aplastic anemia and had received treatment for 10 months prior to diagnosing 
hMDS. The treatment prior to allogeneic PBSCT included; Cyclosporine-A (CSA) for 2 months in 
3 patients, CSA for 12 months in one patient and Prednisolone for 2 months in one patient. All 
except one patient had normal cytogenetics; the fifth patient had trisomy21 (+21). Four patients 
belonged to ‘Intermediate-1’ IPSS risk group, ‘Low’ WPSS risk group and ‘Intermediate ‘ IPSS-R 
risk group; and the one patient with +21 belonged to intermediate-1 (IPSS), intermediate (WPSS) 
and intermediate (IPSS-R) risk groups respectively.  The donors were related for all 5 patients 
(brother was the donor in 4 of them and sister in one). The conditioning regimen was 
Fludarabine/Cyclophosphamide in  4 patients and Fludarabine/Melphalan in one patient. One 
patient underwent second PBSCT following relapse and received Fludarabine/Melphalan/TBI for 
the second PBSCT. 
Two patients died before engraftment by day 9 and 10 post PBSCT, due to sepsis with VOD 
and fungal pneumonia, and sepsis with actinomycosis of lung respectively. Three patients engrafted 
(by days 11, 12 & 13 respectively). Of the 3 patients who engrafted, one lost response by day 52 
post Allo PBSCT, and died of grade IV acute liver GVHD on day 77 post PBSCT. The second 
patient who responded (age-19yrs) relapsed by day 70 post PBSCT, and underwent DLI followed 
by a second PBSCT (using the same donor). He engrafted by day 11 of second PBSCT, and 
continued to be in CR for next one year. After a year post second PBSCT, he relapsed with 
progression to AML, and succumbed to his illness during the post chemotherapy 
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(Cytosine/Idarubicin) neutropenic period due to sepsis and massive GI bleed. The third patient (age: 
30 years) who responded is the one who was treated for Aplastic anemia for 10 months prior to 
diagnosing hMDS. Post PBSCT, he developed chronic skin GVHD which responded to treatment. 
Presently he is 7 years post PBSCT, on follow up and continues to be in CR off drugs (except for 
warfarin).  
(f) ‘Others’:  This included 12 patients (not mentioned in table: 7), who had received 
treatment with Lenalidomide (n=3) or EPO/GCSF (n=1), or only supportive measures (n=4), or in 
whom the drug was not known due to unavailable/missing data (n=4). In this group 2 cases 
attained ‘CR’, 6 attained ‘stable disease’, 4 expired without response and          2 expired 
following progression of disease after initial response. Among those who received Lenalidomide, 
2 attained ‘Stable disease’, and one expired without attaining any response. The one patient who 
received EPO/GCSF progressed and expired after a short period of response (stable disease). Two 
out of the 4 patients who opted for supportive measures expired following disease progression and 
the other 2 showed spontaneous recovery of blood counts (CR) within 2 months and were 
subsequently lost to follow up. There were 4 cases where data on the drug were not available. One 
patient expired without response and 3 had shown initial response to treatment (stable disease). Of 
the 3 who showed response, one was lost to follow up, one patient subsequently progressed and 
expired, and the third patient who had been diagnosed and treated in 1998 was found to be stable 
and off drug on last follow up (the information was obtained by mail, documents on previous drug 
treatment could not be retrieved). 
TREATMENT RELATED MORBIDITY: 
Sixty three (36.4%) patients developed morbidities during treatment. Drug induced 
nephropathy was observed in 6 (3.5%) of the patients. Of these, 5 (83.3%) patients had CSA 
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induced and one (16.7%) had analgesic induced nephropathy. Two patients had Cyclosporine 
related gum hyperplasia.  Drug related hepatitis (transaminitis) was documented in 7 (4.0%) 
patients (stanazolol induced in 5 (71%) patients and Danazol induced in 2(29%)). Three (1.7%) 
patients were HBV positive at diagnosis, while an additional one patient (0.6%) was documented to 
be positive for hepatitis B virus during follow up. Three (1.7%) patients developed lower limb Deep 
vein thrombosis; one among them developed pulmonary embolism. Nine (5.2%) developed steroid 
induced diabetes mellitus, of which one had Cushing’s habitus. Two patients (1.2%) developed 
tuberculosis while on treatment for hMDS (one had pulmonary tuberculosis and one had lymph 
node tuberculosis). Fourteen (8%) patients developed infectious complications during treatment (i.e. 
febrile neutropenia with/without sepsis in 10 cases, and Gram negative bacilli sepsis, peri-anal 
abscess, cellulitis and osteomyelitis in one patient each respectively. On follow up, 2 patients were 
found to have vitamin D deficiency while evaluating for back ache, and one of them presented with 
vertebral fracture. In Allo PBSCT patients, one had acute grade IV liver GVHD and the other had 
chronic skin GVHD. 
MORTALITY: Table: 8 
Twenty six (15%) patients expired on follow up. Of these, 16 (61.6%) patients died because 
of poor response to treatment, while 10 patients died following disease progression/relapse after 
attaining response (‘CR’ or ‘stable disease’). Of the former 16 patients, 2 were of post Allo PBSCT 
status, while 2 had progressed to AML without attaining any response, and the remaining 14 
patients died of primary treatment failure. Among the 10 patients who died following disease 
progression after CR or ‘stable disease’, one patient was of post Allo PBSCT status and had 
progressed to AML (following relapse after second Allo PBSCT),  while a second patient was the 
one who had responded to androgens and then progressed to AML, the third patient was an initial 
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responder to androgens who subsequently progressed with associated metastatic adenocarcinoma. 
The remaining 7 patients died of progressive disease. 
Sepsis with multi-organ failure was the immediate cause of death in 10 patients, while          
2 patients died following massive intracranial bleed, 3 following severe pneumonia and one 
following grade IV GVHD. All the remaining 10 patients died of progressive disease related events 
(details of the exact events not available). Among those patients who died of sepsis, one had 
disseminated  mucor ycosis, 4 had fungal pneumonia, one had pulmonary actinomycosis, and 
another one patient had associated massive GI bleed.  
 
SURVIVAL ANALYSIS: (Figs: 4-11; Table: 9) 
Survival analysis was done for the 111 patients who were evaluable for treatment response. 
Among these, only 79 patients had cytogenetic data.  
Overall (OS), Event free (EFS), progression free (PFS) and disease free survivals 
(DFS) (Figs: 4-7): The mean follow up was 110 months (range: 1-178). There were a total of 26 
deaths, all deaths were due to progressive disease and related complications. The 5 year and 10 year 
overall survivals for the whole cohort (n=173) was 61.9% ± 7.2%, and 53.1% ± 10.3% respectively.  
With a mean follow up period of 70 months (range: 1-178), the 5 year EFS for the entire 
cohort was 37.9% ± 7.8%.  The 5 year progression free survival with a mean follow up period of 86 
months (range:1-78) for the entire cohort was 49.5% ± 9.3% and the 5 year disease free survival 
with a median follow up period of 69 months (range:1-166) was 46.6 ± 9.5%. 
OS of the different IPSS risk groups (Table: 9 and Fig:8):  Among the 79 evaluable 
patients with cytogenetic data, with a mean follow up period of 125 months (range:1-178) and 34 
months (range:1-78) respectively,  the 5 year OS in the lower risk groups (Low+Int-1) versus higher 
risk groups (Int-2+high) was  65.9% ± 9.7% versus 38.1% ± 20.4% respectively (P= 0.056). 
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OS of different WPSS risk groups (Table: 9 and Fig: 9): In the WPSS risk groups, the 
mean follow up period was 83 months (range:2-110), 92 months (range:1-178) and 34 months 
(range:1-78) for the lower risk (very low + low risk), intermediate risk and high risk groups 
respectively. The 5 year OS was noted to be significantly higher in the lower risk groups than the 
higher risk groups (Int and high risk groups ); ie Lower versus Int (5yr OS= 66.6% ± 12.1% versus 
50.5%±15.8%; P=0.026), Lower versus High (66.6%±12.1% vs 38.1%±20.4%; P=0.017). 
However there was no significant survival advantage for the intermediate risk group over high risk 
group (P=0.973). 
OS of different IPSS-R risk groups (Table: 9 and Fig: 10): The mean follow up period of the 
IPSS-R risk groups were as follows; 83 months (range: 2-110) for the lower risk group (very low + 
low + Int) and 67 months (1-178) for the higher risk group (high + very high). The 5 year OS of the 
lower risk groups (ie very low + Low + Int) was again significantly better than the higher risk 
groups (High + very high), ie; 68.0% ± 10.8% vs 35.0% ± 15.7% (P=0.002). 
OS of different WHO classification groups (Fig: 11): Using the WHO criteria, the out of the 111 
evaluable patients, 82 belonged to RCMD, 26 to MDS unclassified and 3 to RAEB-1. With a mean 
follow up period of 109 (range:1-82), 61(2-78) and 8.5 (range:3-14) months, the 5 year OS was 
61.2% ± 8.4%, 74.4 % ± 11.8% and 0 % ± 0% for  RCMD, MDS-U and RAEB-1 respectively 
(P=0.000).  
 
UNIVARIATE ANALYSIS OF ADVERSE EFFECTS OF PATIENT CHARACTERISTICS 
ON OVERALL SURVIVAL (Table: 10) 
Univariate Cox proportional hazard model was used to find out significant prognostic 
factors for adverse effects on survival among overall hMDS patients. Variables with significant 
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adverse effects on overall survival included age, gender, blood counts (Haemoglobin, ANC, platelet 
count), number of cytopenias, serum LDH, bone marrow cellularity, bone marrow blast percentage, 
bone marrow dysplasia, bone marrow reticulin, WHO classification groups, chromosome changes 
and prognostic risk categories (IPSS, WPSS & IPSS-R).  Parameters of independent significance 
associated with poor overall survival were;  ANC < 0.2 x10
9
/L at diagnosis (RR=4.2; 95%CI=1.32-
13.5;P= 0.015), Bone marrow blast at diagnosis > 5%  (RR=11.0; 95%CI=2.27-53.77; P= 0.003),  
WHO category RAEB-1, (RR=7.5; 95%CI=1.68-34.12; P= 0.008), Moderate/marked increase in 
BM reticulin,  (RR=4.0; 95%CI=1.13-14.17; P= 0.031),  >3 cytogenetic anomalies,  (RR=3.5; 
95%CI=1.09-11.82; P= 0.035), Monosomy 7,  (RR=5.1; 95%CI=1.54-17.03; P= 0.008), Trisomy 
21, (RR=14.4; 95%CI=2.88-72.7; P= 0.001),WPSS intermediate risk group,  (RR=3.3; 
95%CI=1.11-10.00; P= 0.031), WPSS high risk group , (RR=3.6; 95%CI=1.11-12.00; P= 0.033), 
and IPSS-R very high risk group (RR=13.5; 95%CI=2.64-69.90; P= 0.002). However on 
multivariate analysis, none of the above parameters retained its statistical significance. 
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RESULTS - TABLES: 
Table 1: DEMOGRAPHY & CLINICAL FEATURES AT DIAGNOSIS: 
n =173 
Variables   n (%) / Median(Range)   
Age at diagnosis in years 
   18-40 
   41-55 
   >55 
 
72 
51 
50 
 
(41.6) 
(29.5) 
(28.9) 
Gender  
    Male 
    Female 
 
112 
61 
 
(64.7) 
(35.3) 
Presenting symptoms 
    Pallor 
    Bleeding 
    Infection 
 
163 
70 
66 
 
(94.2) 
(40.5) 
(38.2) 
Duration of symptoms (months) 3 (1-120) 
Organomegaly  
   Splenomegaly 
   Hepatomegaly  
 
6 
2 
 
(3.5) 
(1.2) 
Patients who received prior treatment 48 (27.7) 
Median duration of previous treatment (days) 60 (7-720) 
Past history treatment for cytopenia (s) 14 (8.1) 
Median transfusions per month (n=139)   2.0 (1-20) 
. 
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Table 2: LABORATORY PARAMETERS AT DIAGNOSIS 
n=173 
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables   n (%) / Median (Range)   
Hemoglobin [g%] 
   <6 
   6.1-10 
   >10.0 
 
94 
71 
8 
 
(54.4) 
(41.0) 
(4.6) 
Absolute neutrophil count[x10
9
/L] 
  <0.2 
   0.21-0.5 
   0.51-1.0 
  1.1-1.5 
  1.51-1.8 
  >1.8 
 
15 
28 
39 
36 
17 
38 
 
(8.7) 
(16.2) 
(22.5) 
(20.8) 
(9.8) 
(22.0) 
Platelet count [x10
9
/L] 
  <20 
  21-50 
  51-100 
  >100 
 
106 
39 
16 
12 
 
(61.3) 
(22.5) 
(9.2) 
(7.0) 
Reticulocyte count 
   Median Percentage of reticulocytes  (n=152) 
   Median Absolute reticulocytes [x10
9
/L] (n=99) 
 
1.8 
37200 
 
(0.05-7.06) 
(6175-133472) 
No. of cytopenia(s) 
  Single cytopenia 
  Bicytopenia  
  Pancytopenia 
 
7 
53 
113 
 
(4.1) 
(30.6) 
(65.3) 
Direct coomb’s test  (n=39) 
  Positive  
  Negative 
 
14 
25 
 
(35.9) 
(64.1) 
Antinuclear antibody (n=23) 
   Positive  
   Negative 
 
8 
15 
 
(34.8) 
(65.2) 
Serum LDH [mg/dl] (n=160) 
 <600 
 >600 
 
131 
29 
 
(81.9) 
(18.1) 
Serum ferritin [ng/ml] (n=24) 825 138-46775) 
Serum Vitamin B12 [pg/ml] (n=10) 970 (248-2000) 
Blood borne virus screen (n=137) 
     Positive 
     Negative 
 
5 
132 
 
(3.6) 
(96.4) 
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Table 3: BONE MARROW FEATURES & WHO CALSSIFICATION AT DIAGNOSIS: 
n = 173 
Variables n (%) 
Bone marrow cellularity 
   Aplastic 
   Uniformly hypocellular  
   Varyingly hypocellular 
 
9 
144 
20 
 
(5.2) 
(83.2) 
(11.6) 
BM blasts[%] (n=171) 
   0 
   1-2 
   3-4 
   ≥5 
 
80 
77 
10 
4 
 
(46.8) 
(45.0) 
(5.8) 
(2.4) 
BM ring sideroblasts (n=120) 
   >15% 
   Scattered/occasional 
   Absent    
 
1 
47 
72 
 
(0.8) 
(39.2) 
(60.0) 
BM dysplasia 
  Unilineage  
  Bilineage  
 Trilineage 
 
36 
80 
57 
 
(20.8) 
(46.2) 
(33.0) 
BM Reticulin (n=169) 
  Normal 
  Mild increase 
  Moderate increase 
  Marked increase   
 
34 
80 
49 
6 
 
(20.1) 
(47.3) 
(29.0) 
(3.6) 
WHO classification 
  MDS-Unclassified   
  RCMD 
  RAEB-1 
 
35 
134 
4 
 
(20.2)  
(77.5) 
(2.3) 
Abbreviations: MDS: Myelodysplastic syndrome, RCMD: Refractory  
cytopenia with multilineage dysplasia, RAEB: Refractory anemia with 
 excess blast. 
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Table 4: CYTOGENETIC ABNORMALITIES AT DIAGNOSIS 
        n =116 
Variables n (%) 
Cytogenetic  abnormalities  
  No abnormality 
  One abnormality 
  Two abnormalities 
  Three abnormalities 
  >3 / chromosome 7 abn 
 
77 
13 
8 
3 
15 
 
(66.4) 
(11.2) 
(6.9) 
(2.6) 
(12.9) 
Individual chromosomal aberrations 
Monosomies: 
    -7   
   -5 
   -Y 
   -X 
   Other monosomies
@
 
 
 
13 
2 
3 
2 
17 
 
 
(11.2) 
(1.7) 
(2.6) 
(1.7) 
(14.7) 
Trisomies: 
    +8 
   +21 
   Other trisomies
@
 
 
7 
8 
3 
 
(6.0) 
(6.9) 
(2.6) 
Translocations 
   t(18;21) 
   t(20;21) 
   t(11;14) 
   t(7;13;16) 
   t(7;?) 
 
1 
1 
1 
1 
1 
 
(0.9) 
(0.9) 
(0.9) 
(0.9) 
(0.9) 
Deletions: 
   del 5q 
   del 11q 
   del 12p 
   del 20q 
   Other deletions
@
 
 
7 
2 
1 
1 
4 
 
(6.0) 
(1.7) 
(0.9) 
(0.9) 
(3.4) 
Other rare anomalies
@
 
   Additions  
   Derivatives 
   Duplications  
 
5 
4 
1 
 
(4.3) 
(3.4) 
(0.9) 
@  
Other anomalies included; monosomies (-1, -2,-3,-9,-10,-13,-14,-15,-16, & -19 seen in one 
patient each and  -11, -18, &-20 seen in two patients each), trisomies (+1, +2,+4 seen in one patient 
each), deletions (del 11q in 2 patients and 1p, del 5p, del 6q, del 9q, del 12p, & del 20q seen in one 
patient each), additions (+11p,+11q,+14q,+1p, & +7q seen in one patient each), derivatives [der(7), 
der(12), der(14), & der(16 seen in one patient each) and duplication (dup1), seen in one patient. 
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Table 5: CYTOGNETIC RISK GROUPS AT DIAGNOSIS 
n =116 
 IPSS&WPSS cytogenetic risk group IPSS-R cytogenetic risk group 
n  (%) n  (%) 
Very good - - 3 (2.6) 
Good 80 (69.0) 80 (69.0) 
Intermediate 19 (16.4) 15 (12.9) 
Poor 17 (14.6) 15 (12.9) 
Very  poor - - 3 (2.6) 
Abbreviations: IPSS: International prognostic scoring system, WPSS: WHO prognostic scoring 
system, IPSSS-R: Revised IPSS. 
 
 
          
Table 6: PROGNOSTIC RISK GROUPS AT DIAGNOSIS:     
          n = 116 
Risk group IPSS WPSS IPSS-R 
 n (%) n (%) n (%) 
Very low - - 1 (0.9) 2 (1.7) 
Low 3 (2.6) 79 (68.1) 22 (19.0) 
Intermediate-1/ 
Intermediate 
96 
- 
(82.7) 
- 
- 
19 
- 
(16.4) 
- 
68 
- 
(58.6) 
Intermediate-2 17 (14.7) - - - - 
High 0 (0.0) 17 (14.6) 18 (15.5) 
Very high - - - - 6 (5.2) 
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Table 7: TREATMENT AND RESPONSE: 
                                               DRUG GROUPS  
CSA ATG +CSA Androgens  Prednisolone Allo-PBSCT 
 n (%) n (%) n (%) n (%) n (%) 
 Total patients (n=173) 
   Non-evaluable 
   Evaluable 
81 (46.8) 
22 (27.0) 
59 (73.0) 
10 (5.8) 
0 (0.0) 
10 (100.0) 
74 (42.8) 
23 (31.0) 
51 (69.0) 
24 (13.9) 
7 (29.0) 
17 (71.0) 
5 (2.9) 
0 (0.0) 
5 (100.0) 
Response:  
   CR  
   Stable disease 
   No response (LFU/drug changed) 
   Failure (expired with no response) 
 
6 (10.2) 
35 (59.3) 
12 (20.3) 
6 (10.2) 
 
2 (20.0) 
5 (50.0) 
2 (20.0) 
1 (10.0)  
 
2 (3.9) 
22 (43.2) 
25 (49.0) 
2 (3.9) 
 
0 (0.0) 
4 (23.5) 
12 (70.6) 
1 (5.9) 
 
2 (40.0) 
1 (20.0) 
0 (0.0) 
2 (40.0) 
On follow up: 
CR: 
   Continued in CR 
   Relapse & alive/LFU 
   Relapse & expired 
Stable disease: 
   Continued in Stable  
   Progression & alive/LFU 
   Progression & expired 
 
 
6 (100.0) 
0 (0.0) 
0 (0.0) 
 
24 (68.6) 
9 (25.7) 
2 (5.7) 
 
 
2 (100.0) 
0 (0.0) 
0 (0.0) 
 
3 (60.0) 
1 (20.0) 
1 (20.0) 
 
 
1(50.0) 
1(50.0) 
0(0.0) 
 
17(77.3) 
2 (9.1) 
3(13.6) 
 
 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
3(75.0) 
1(25.0) 
0 (0.0) 
 
 
1(50.0) 
0 (0.0) 
1(50.0) 
 
0 (0.0) 
0 (0.0) 
1(100.0) 
Duration of treatment-months; median(range) 19 (3-126) 12 (8-72) 11 (2-92) 4 (2-36) -- 
Response rate  69% 70% 47% 23.5% 60% 
Time to response - months; mean (range) 5.9 (3-36) 1.8 (1-3) 5.3 (1-27) 1.9 (1.3-2.7) 0.5 (0.4-0.5) 
Follow up duration –months; mean(range) 103 (8-110) 58 (16-73) 68 (20-92) 19 (7-44) 39 (15-81) 
Mortality in each drug group 8 (13.6) 2 (20.0) 5 (9.8) 1 (5.9) 4 (80.0) 
5 year OS of responders  96.9% ± 3.1% 75.0% ± 21.7% 51.4% ± 23.1% 100%** 33.3% ± 27.2% 
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Table 8:  MORTALITY: 
Variables n               (%) 
Total number of death 26 (15.0) 
Disease status at death  (n=26) 
  Failure without any response 
  Progression/Relapse after CR or ‘stable disease’  
 
16 
10 
 
(61.6) 
(38.4) 
Cause of death 
  Disease failure related events (exact event unknown) 
  Sepsis with MODS 
  ICH 
  Liver GVHD 
  Pneumonia 
 
10 
10 
2 
1 
3 
 
(38.5) 
(38.5) 
(7.7) 
(3.8) 
(11.5) 
 
 
 
 
Table 8: OVERALL SURVIVAL OF DIFFERENT PROGNOSTIC RISK GROUPS. 
Risk group IPSS WPSS IPSS-R 
 n (%) 5 yr OS n (%) 5 yr OS n (%) 5 yr OS 
Very low - - 1 (0.9) 0% ± 0% 2 (1.7) 0% ± 0% 
Low 3 (2.6) 0% ± 0% 79 (68.1) 66.6% ±12.1% 22 (19.0) 73%±14% 
Intermediate-1/ 
Intermediate 
96 (82.8) 
- 
68.3%±9.7% 
- 
- 
19 (16.4) 
- 
50.9%±15.8% 
- 
68 (58.6) 
- 
68.4%±12.2 
Intermediate-2 17 (14.6) 39.3%±2% - - - - 
High 0 (0.0) 0 (0) 17 (14.6) 39.3%±20.8% 18 (15.5) 48.8±19.3 
Very high - - - - 6 (5.2) 0% ± 0% 
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TABLE 9: UNIVARIATE ANALYSIS OF ADVERSE EFFECTS OF PATIENT 
CHARACTERISTICS ON OVERALL SURVIVAL. 
      n =111 
Variables Alive 
n (%) 
Dead 
n (%) 
RR 95% CI P-value 
Age at diagnosis in years:  
     18-40 
      41-55 
      >55     
 
38(44.7) 
28(32.9) 
19(22.4) 
 
9(34.6) 
7(26.9) 
10(38.5) 
 
1.0 
1.0 
1.8 
 
- 
0.38-2.80 
0.74-4.50 
 
- 
0.933 
0.189 
Sex   
    Female  
    Male 
 
33(38.8) 
52(61.2) 
 
5(19.2) 
21(80.8) 
 
1.0 
2.3 
 
- 
0.87-6.13 
 
- 
0.092 
Hb at diagnosis  
    >10.1 
    6.1 – 10 
    <6 
 
4(4.7) 
39(45.9) 
42(49.4) 
 
1(3.8) 
9(34.6) 
16(61.5) 
 
1.0 
2.1 
3.4 
 
- 
0.26-17.91 
0.44-27.02 
 
- 
0.466 
0.235 
ANC [x10
9
/L] 
  >1.5 
  1.0-1.5 
  0.5-1.0 
  0.2-0.5 
  <0.2 
 
30(35.3) 
21(24.7) 
21(24.7) 
11(12.9) 
2(2.4) 
 
7(26.9) 
3(11.5) 
8(30.8) 
3(11.5) 
5(19.2) 
 
1.0 
0.5 
1.7 
1.7 
4.2 
 
- 
0.13-2.09 
0.63-4.86 
0.44-6.97 
1.32-13.50 
 
- 
0.372 
0.282 
0.418 
0.015 
Platelet [x10
9
/L] 
 >100  
  51-100 
  21-50  
  <20 
 
7(8.2) 
9(10.6) 
19(22.4) 
50(58.8) 
 
2(7.7) 
4(15.4) 
8(30.8) 
12(46.2) 
 
1.0 
1.3 
1.0 
0.6 
 
- 
0.24-7.30 
0.22-5.19 
0.15-3.14 
 
- 
0.742 
0.922 
0.637 
No. of cytopenia(s) 
  Single cytopenia 
  Bicytopenia 
  Pancytopenia 
 
3 (3.8) 
30(35.3) 
52(61.2) 
 
1(3.8) 
8(30.8) 
17(65.4) 
 
1.0 
0.8 
0.9 
 
- 
1.00-6.48 
0.12-7.30 
 
- 
0.837 
0.974 
Serum LDH (n=101) 
 <600 
 >600 
 
65(83.3) 
13(16.7) 
 
18(78.3) 
5(21.7) 
 
1.0 
1.5 
 
- 
0.55-4.10 
 
- 
0.420 
Bone marrow cellularity 
   Varyingly hypocellular  
   Uniformly hypocellular  
   Aplastic 
 
11(12.9) 
73(85.9) 
1(1.2) 
 
2(7.7) 
23(88.5) 
1(3.8) 
 
1.0 
1.8 
1.2 
 
- 
0.15-20.91 
0.29-5.42 
 
- 
0.631 
0.745 
BM blasts [%; n=109] 
   0 
   1-2 
   3-4 
   ≥5 
 
42(50.0) 
37(44.0) 
4(4.8) 
1(1.2) 
 
9(36.0) 
11(44.0) 
3(12.0) 
2(8.0) 
 
1.0 
1.2 
2.9 
11.0 
 
- 
0.52-3.04 
0.77-10.87 
2.27-53.77 
 
- 
0.610 
0.113 
0.003 
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TABLE 10: UNIVARIATE ANALYSIS OF ADVERSE EFFECTS OF PATIENT 
CHARACTERISTICS ON OVERALL SURVIVAL contd… 
 
Variables Alive 
N (%) 
Dead 
N (%) 
RR 95% CI P- value 
BM dysplasia  
  Unilineage  
  Bilineage  
  Trilineage  
 
22(25.9) 
37(43.5) 
26(30.5) 
 
5(19.2) 
10(38.5) 
11(42.3) 
 
1.0 
1.0 
1.2 
 
- 
0.36-3.18 
0.44-3.69 
 
- 
0.888 
0.652 
BM Reticulin (n=108) 
  Normal 
  Mild increase 
  Moderate/Marked  increase 
 
20(23.8) 
42(50.0) 
22(26.2) 
 
3(12.5) 
8(33.3) 
13(54.2) 
 
1.0 
1.6 
4.0 
 
- 
0.43-6.28 
1.13-14.17 
 
- 
0.456 
0.031 
WHO SUB-CLASS 
  MDS-Unclassified  
  RCMD 
  RAEB1   
 
22(25.9) 
62(72.9) 
1(1.2) 
 
4(15.4) 
20(76.9) 
2(7.7) 
 
1.0 
0.7 
7.5 
 
- 
0.24-2.15 
1.68-34.12 
 
- 
0.569 
0.008 
Cytogenetic anomalies (n=79) 
   No anomaly 
   One anomaly 
   2-3 anomalies 
   >3 anomalies or -7 
 
47(77.0) 
5(8.2) 
4(6.6) 
5(8.2) 
 
9(50.0) 
3(16.7) 
2(11.1) 
4(22.2) 
 
1.0 
2.4 
2.3 
3.5 
 
- 
0.65-9.00 
0.50-10.92 
1.09-11.82 
 
- 
0.182 
0.274 
0.035 
Individual chromosomal abn 
(n=75) 
   Normal 
   del 5q 
   Monosomy 7 
   Trisomy 21 
   Trisomy 8 
   Monosomy Y 
 
47(82.4) 
4(7.0) 
4(7.0) 
0(0.0) 
1(1.8) 
1(1.8) 
 
9(50.0) 
1(5.6) 
4(22.2) 
2(11.0) 
1(5.6) 
1(5.6) 
 
1.0 
1.0 
5.1 
14.4 
3.4 
4.2 
 
- 
0.13-8.55 
1.54-17.03 
2.88-72.7 
0.43-27.78 
0.51-34.24 
 
- 
0.947 
0.008 
0.001 
0.241 
0.178 
IPSS Risk groups:  (n=79)           
  Low 
  Intermediate-1 
  Intermediate-2 
 
2(3.3) 
54(88.5) 
5(8.2) 
 
1(5.6) 
13(72.2) 
4(22.2) 
 
1.0 
0.6 
1.8 
 
- 
0.08-4.88 
0.20-16.84 
 
- 
0.664 
0.583 
WPSS Risk groups (n=79)           
  Very low 
  Low 
  Intermediate 
  High 
 
1(1.6) 
49(80.3) 
6(9.8) 
5(8.2) 
 
- 
9(50.0) 
5(27.8) 
4(22.2) 
 
- 
1.0 
3.3 
3.7 
 
- 
- 
1.11-9.95 
1.13-12.24 
 
- 
- 
0.032 
0.030 
IPSS-R Risk groups (n=79)           
  Very low   
  Low 
  Intermediate 
  High 
  Very high 
 
1(1.6) 
16(26.2) 
36(59.0) 
8(13.1) 
0(0.0) 
 
- 
3(16.7) 
8(44.4) 
4(22.2) 
3(16.7) 
 
- 
1.0 
1.1 
2.9 
14.1 
 
- 
- 
0.30-4.30 
0.65-13.66 
2.75-72.19 
 
- 
- 
0.847 
0.157 
0.001 
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RESULTS - FIGURES: 
Figure 1:  Year wise distribution of total MDS vs hMDS 
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Figure 1: Year wise distribution:  Total MDS versus hypoplastic MDS cases from January 1998 to June 2012. 
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Figure 2: Peripheral blood and Bone marrow findings: 
                                                                                   
 
 
 
                   
                                                
                                                                            
 
                                                                                                    
 
 
 
 
 
 
       
 
2a  2b  
2c 2d 
2e 2f 
 2g 2h 
Figure 2: Peripheral blood and bone marrow findings. Figures 2a & 2b: PB smear 
showing granulocyte dysplasia - pelger heut anomaly and hypogranularity, 2c: BM aspirate 
smear showing dyserythropoiesis, 2d: BM aspirate smear showing micro-megakaryocytes, 
2e: BM aspirate smear showing ring sideroblasts. 2f: BM trephine biopsy showing 
hypocellular marrow & dysplastic megakaryocytes. 2g: BM trephine biopsy silver stain 
showing increased rericulin and 2h: BM trephine biopsy showing CD34+ cells. 
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    Figure 3: Response rate to different drugs 
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SURVIVALS:   
Figure 4: Overall survival of total evaluable patients (n=111) 
         
 
 
P= 0.017 P= 0.185 
CSA vs ATG+CSA (P= 0.974) 
5 year OS = 61.9% ± 7.2% 
Figure 3: On comparing the response rate to different drugs, response rate to CSA 
was found to be significantly (69% vs 47%; P=0.017) superior to Androgenic 
steroids. The number of patients who received other drugs was few to compare 
enough number of patients to compare. 
Figure 4: Kaplan Meier curve for overall survival of the entire cohort of 
evaluable patients (n=111). With a median follow up duration of 110 months 
(Range: 1-178), the 5 year and 10 year OS were 61.9% ± 7.2% & 53.1% ±10.3% 
respectively. 
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Figure 5: Event free survival of total evaluable patients (n=111) 
          
 
 
 
Figure 6: Progression free survival of total evaluable patients (n=111) 
          
 
 
5 year EFS = 37.9% ± 7.8% 
5 year PFS = 49.5% ± 9.3% 
Figure 5: Kaplan Meier curve for Event free survival of the entire cohort of 
evaluable patients (n=111). With a mean follow up duration of 70 months 
(Range: 1-178), the 5 year & 10 year EFS were 37.9% ± 7.8% & 25.3% ±8.0% 
respectively. 
 
Figure 6: Kaplan Meier curve for Progression free survival of the entire cohort 
of evaluable patients (n=111). With a mean follow up duration of  86 months 
(Range: 1-78), the 5 year  & 10 year PFS was 49.5% ± 9.3% & 33.0% ±10.1% 
respectively. 
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Figure 7: Disease free survival of total evaluable patients (n=111) 
                                                               
 
 
SURVIVAL BY PROGNOSTIC RISK GROUPS: 
Figure 8: OS of IPSS risk groups (n=79) 
                                  
 
 
Int-1 + Low  
Int-2 
P-value = 0.062 
5 year DFS = 46.6% ± 9.5% 
Figure 7: Kaplan Meier curve for Disease free survival of the entire cohort of 
evaluable patients (n=111). With a mean follow up duration of  69 months (Range:     
1-166), the 5 year & 10 year DFS was 46.6% ± 9.5% & 18.1%±8.9% respectively. 
 
Figure 8: Kaplan Meier curve for OS IPSS risk groups. Among the 111 evaluable patients, 
cytogenetic data was available only in 79. With a mean follow up period of 125 months (range:1-178) 
and 34 months (range:1-78) the 5 year OS in the lower risk groups (Low+Int-1) versus higher risk 
groups (Int-2+high) was  65.9%  ±  9.7% versus 38.1% ± 20.4% respectively.. The higher survival 
noted in the lower risk group was statistically near significant (p= 0.056). 
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Figure 9: OS of WPSS risk groups (n=79) 
     
 
 
 
 
Figure 10: OS of IPSS-R risk groups (n=79) 
          
 
 
Low + very low 
Int 
High 
P-value = 0.019 
Very low+Low+Int  
High+Very high 
P-value = 0.002 
Figure 9: Kaplan Meier curve for OS of WPSS risk groups. With a mean follow up 
period was 83 (range:2-110), 92 (range:1-178) and 34 months (range:1-78) for the lower 
risk (very low + low risk), intermediate risk and high risk groups respectively, the 5 year OS 
were, Lower versus Int (66.6% ± 12.1% vs 50.5% ± 15.8%; P value=0.026), Lower vs High 
(66.6% ±12.1% vs 38.1%±20.4%; P value=0.017). OS was significantly higher in the lower 
risk groups than the higher risk groups (Int and high risk groups), but there was no 
significant survival advantage for the intermediate risk group over high risk group (P 
value=0.973). 
 
Figure 10: Kaplan Meier curve for OS of  IPSS-R risk groups. With a mean follow up period 
of 83 months (range:2-110) for the lower risk group (very low+low+Int) and 67 months (1-178) for 
the higher risk group (high+very high), the 5 year OS was noted to be significantly higher in lower 
risk group than higher risk groups (High + very high), ie;  68.0% ± 10.8% vs 35.0% ± 15.7% 
(P=0.002). 
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Figure 11: OS by WHO classification for the entire evaluable patients (n=111) 
              
 
 
 
Figure 12: Overall survival of responders to different drugs  
               
 
 
 
MDS Unclassified 
RAEB-1 
RCMD 
P-value = 0.000 
CSA 
ATG+CSA 
Androgens 
P-value =0.213  
Figure 12: Kaplan Meier curve for OS of responders to different drugs. The OS 
of the responders to different drugs showed no significant difference. The 5 yr OS of 
CSA vs Androgens was  96.9% ±3.1 % vs 51.4% ± 23.1% (P=0.090); ATG vs 
Androgens was 75.0  % ±21.7 % vs 51.4% ± 23.1% (P=0.972) and CSA vs 
ATG+CSA was 75.0  % ±21.7 % vs  96.9% ±3.1 % (P=0.180).  
 
Figure 11: Kaplan Meier curve for OS of  WHO classification groups Using the 
WHO criteria, the out of the 111 evaluable patients, 82 belonged to RCMD, 26 to MDS 
unclassified and 3 to RAEB-1. With a mean follow up period of 109 (range:1-82), 61(2-
78) and 8.5 (range:3-14) months, the 5 year OS were 61.2% ± 8.4%, 74.4 % ± 11.8% 
and 0 % ± 0% for  RCMD, MDS-U and RAEB-1 respectively.  MDS-U and RCMD 
showed significantly better survival than RAEB-1 (P=0.000).  
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DISCUSSION:  
Between January 1998 and June 2012, there were a total of 173 adult patients (age ≥18 
years) diagnosed to have hypoplastic myelodysplastic syndrome from January 1998 to June, 30, 
2012. The total number of patients seen in the outpatient department of Clinical Haematology 
during this period was 54413, out of which 1225 (2.3%) adult patients were diagnosed to have 
primary MDS. In this study, hMDS constituted 14.1% of MDS cases diagnosed during this period. 
This is similar to that reported in literature ; i.e. 10-15% of all MDS cases (2,4,7–9,14) [Fig:1]. 
 
In the present study the majority (41.6%; n=72) of the patients belonged to the age group 
18-40 years, with a median age of 41 years (range: 18-64). In a study by Koh Y and colleagues, 
based on a medical record review at Seoul National University Hospital, 51 patients were diagnosed 
to have  hMDS, and the median age reported was 39 years (12), similar to the observation in the 
present study. This is much lower than the median age of patients with normo/hypercellular MDS 
ie; 60–75 years (5). However in a comparative study of hypoplastic myelodysplastic syndrome 
(MDS) with normo-/hypercellular MDS by Huang et al, the median age reported was similar in 
both groups ie; 58  years (range: 26–86) in hMDS and  55 years  in  normo-/hypercellular MDS (1). 
In the present study, 112 were males (64.7%) and 61 females (35.3%), with a male: female ration of 
1.8:1.  A similar observation of male preponderance was reported by Huang et al ( 29:8) (1).  
 
The median duration of symptoms before diagnosing hMDS was 3 months. The duration of  
symptoms before diagnosis is made ranges from 6-12 months as per reports by Hoffman and 
Koeffler (5). Majority of the patients in the present study (94.2%; n=163) were diagnosed following 
evaluation for pallor.  Diagnosis was made following a routine medical check-up in 5.8% (n=10) of 
the patients.  In  MDS as a whole, it is reported that 50% of the patients are asymptomatic and are  
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diagnosed following routine check-up (5). The presence of occasional splenomegaly has been 
reported by some authors (3,16); in the present study 3.5% (n=6) of patients had mild splenomegaly 
[Table:1].  
Haemogram showed that 95.4% (n=165) had a hemoglobin level below 10g%, with a 
median hemoglobin of 5.8g% (range: 1.2- 13.2). In the study by Huang et al (1) the median 
hemoglobin reported was 7.8g% (range: 4.0–14.0), a little higher than that observed in the present 
study.  The median WBC count and ANC at diagnosis were 3.3x10
9
/L (range: 0.2-13.8) and 1.05 
x10
9
/L (0.0-5.32) respectively. This is slightly higher than that reported by Huang et al (1)  i.e. 2.37 
x10
9
/L (range:1.00–15.70)  of  WBC count and 0.98 x109/L  (range: 0.196–10.360) of ANC. In the 
present study, majority of the patients had a severe thrombocytopenia with 61.3% (n=106) of 
patients presenting with platelet count <20 x10
9
/L. The median platelet count was 14 x 10
9
/L 
(range:1-307), much lower than that observed in the study by Huang et al ie; 54 x10
9
/L (range:     
3–433) (1).  However, only 70 patients presented with bleeding manifestations [Table:2].  
The diagnosis of hMDS was based on the presence of a hypocellular marrow with features 
of dysplasia in one or more cell lines, increase in reticulin content, increase in the number of 
blasts/CD34+ cells on the bone marrow trephine, or abnormal karyotype, all favoring the diagnosis 
of hMDS (3,6,15,16).  Out of the 169 cases where data on reticulin content was available, increase 
in reticulin content was seen in 79.9% (n=135) [Table3].  The median bone marrow blast 
percentage was 1 (range: 0-5), as compared to 2.6% (0–26.0) in the Huang et al  study (1). All cases 
with bone marrow blasts greater than 5%, and/or those with a diagnosis of RAEB-2 or acute 
leukemia at presentation, irrespective of the presence of hypocellular marrow were excluded from 
the study. This may be the reason for the lower range of BM blasts observed in this study. Ring 
sideroblasts were observed in 48 cases (27.8%), of which only one (0.6%) had >15% ring 
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sideroblasts (RCMD-RS). This is similar to the study published by Huang et al (1), where only 2 
(5.4%) cases were diagnosed to have RARS. 
 WHO classification of the cases in the present study showed that 77.5% (n=134) befitted the 
RCMD (Refractory cytopenia with multilineage dysplasia) group, while 20.2% (n=35) were     
MDS-U (MDS unclassified) and 4 (2.3%) were RAEB-1 (Refractory anemia with excess blasts-1) 
[Table:3]. In the studies by Nand S et al (8) and Huang et al (1), the FAB classification was 
followed. In these studies the FAB subgroups included RA (n=7), RARS (n=1) and RAEB (n=3) in 
the former and RA (n=21), RARS (n=2), RAEB (n=9) and RAEB-T (n=5) in the latter study 
respectively. 
Cytogenetic data was available in 116 (67%) patients. A normal karyotype was found in 77 
(66.4%). Earlier reports by Toyoma K et al have shown that patients with hMD frequently had 
complex aberrations (chromosome changes at three or more regions) (53).  In the present study 
among the 39 (33.6%) patients with abnormal karyotype, 2.6% (n=3) had three aberrations and 
12.9% (n=15) had more than 3 aberrations / monosomy 7. Among the numerical abnormalities 
observed in 55 (47.4%), majority had monosomies (n= 37). Monosomy 5 (-5)/del 5q (5q-) was 
observed in 9 (7.8%) cases, and monosomy 7 (-7) was found in 13 (11.2%) patients [Table: 4].  The 
reports on  chromosomal aberrations in hypoplastic MDS are limited (1,8,9).  In the report by Nand 
and Gonwinz (1,8), none of the nine h-MDS patients  harboured  monosomy 7/7q-, while only one 
out of 23 hMDS patients reported by Tuzuner et al (1,54)  showed this abnormality.  On the 
contrary, Maschek et al (1,9) demonstrated  monosomy 7 in two out of the six h-MDS patients. The 
karyotype profile in the Huang et al (1) study showed that 57.6% (n=19) had normal karyotype, and 
among those with abnormal karyotype, 3% (n=1) had -5/5q-, none had chromosome7 abnormalities, 
12.1% (n=4) had trisomy 8, 24.2% (n=8) had single aberration, 9.1% (n=3) had double aberrations 
and 9.1% (n=3)  had complex aberrations. This observation is similar to the observation in the 
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present study except that chromosome7 abnormalities were observed in 11.2% of patients in this 
study. Further studies on more patients may be needed to clarify whether the variations in the 
frequency of cytogenetic abnormalities, especially involving chromosome7, in h-MDS observed 
among these reports may represent the difference of the pathogenesis of h-MDS in different 
geographical areas. 
 As per the IPSS/WPSS and IPSS-R cytogenetic risk categorization, in the present study, 
majority belonged to the Intermediate cytogenetic risk group (69% each in either category) 
[Table:5]. While applying various MDS prognostic scoring systems, majority fell into the 
intermediate -1 (82.8%; n=96) by IPSS, intermediate category (58.6%; n= 68) by IPSS-R, and low 
risk (68.1% (n= 79) by WPSS [Table: 6]. A similar observation was noted in the comparative study 
by Huang et al (1), where 57.6% (n=19) of patients were scored into the intermediate -1 risk 
category of IPSS. In our study none of the  cases belonged to the IPSS high  risk group, while 9.1% 
(n=3) cases belonged to high risk group in the study by Huang et al (1). This may be due to the fact 
that patients with RAEB-2 and Acute leukemia were excluded in the present study. 
One hundred and eleven (64.2%) patients who had atleast 8 weeks follow up after initiation 
of therapy were evaluated for response. Eighty seven (78.4%) showed response, either ‘Complete 
remission‘[CR] (12.6%; n=14) or ‘Stable disease” (65.8%; n=73) [Table:7]. On comparing the 
response rate to different drugs, the response rate to cyclosporine was found to be significantly 
higher than Androgens (69.5% vs 47.1%; P=0.017) . Although a 70% response rate was seen to 
ATG+CSA, this was not found to be significantly superior over other drugs [Fig:3]. The 5 year 
overall survival among the responders to the different drugs however showed no statistically 
significant difference [Fig;12]. The mean time to response were 5.9 months (range: 3-36) in CSA 
group, 1.8 months (range: 1-3) in ATG+CSA group and 5.3 months (1-27) in androgen group 
[Table:7]. In a prospective randomized multicenter phase III trial (where 9 out of total 45 cases 
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were hMDS) comparing Antithymocyte globulin + cyclosporine with best supportive care by 
Passweg JR et al (33), 29% of the total 45 patients showed response to ATG+CSA by 6 months. In 
a study on Cyclosporine therapy in hMDS by Jonasova A  et al (55), out of the  9 patients of  hMDS 
(of total 17 MDS cases),  8 showed response, and the time to response was observed to be between 
3 to 9 months, similar to the observation in our study. However in another study by  Catalano Let al 
(56), out of  9 patients with hypoplastic refractory anemia who were treated with cyclosporine, 3 
showed response in a mean duration of  22 months (median 14.5 months); longer than that observed 
in this study. 
 Literature review shows reports suggesting better response to immunosuppressive therapies 
(CSA, ATG) in patients with hMDS by several authors (2,13,33,57,58). However data comparing 
the response to different drug groups in hMDS could not be found.  In our study, the number of 
patients in other drug groups are very few (eg; ATG+CSA [n=10], Lenalidomide [n=3], Allogeneic 
PBSCT [n=5], Haematopoietic growth factors [n=1], and supportive treatment [n=4]), limiting 
significant correlative study between these groups. 
  For the entire cohort, with a median follow up duration of 110 months, the 5 year OS, EFS, 
PFS and DFS are 61.9%+7.2%, 37.9%+7.8%, 49.5%+9.3% and 46.6% ± 9.5% respectively [Figs: 
4-7].  Bartl and colleagues, in a retrospective and prospective follow-up study of 495 patients with 
MDS between 1975 to 1991, reported a median survival of  29 months (n=95) in patients with 
hMDS (7).  In the study by Huang et al (1),  the OS was less than the present study (5b year OS: 
<60%; median survival = 58 months).  
To identify different survival groups in h-MDS patients, we took advantage of the different 
risk scoring systems (IPSS, WPSS & IPSS-R). Obviously, in this study, h-MDS patients of lower 
risk groups had a significantly higher 5 year OS than those of higher risks groups in the WPSS 
(P=0.018) and IPSS-R (P=0.002) systems [Figs:9,10]. Risk categorization by the IPSS showed 
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only near significant survival benefit in the lower over the higher groups [Fig:8]. Our study 
demonstrate that in hypoplastic MDS, WPSS and IPSS-R prognostic scoring systems are better than 
the IPSS systems in predicting survival advantage. However in the comparative study by Huang et 
al (1), a significant survival difference was  observed between these two groups in h-MDS patients 
(median survival 112 vs 16 months, P=0.002).  The OS of  IPSS lower risk groups reported by 
Huang et al  (1), however is much lower than that observed in our study (5 year OS:  <40%)  versus 
66.0% ± 9.7%) .   
The overall mortality was 26 patients (15% of the total 173 cases and 23.4% of the 111 
evaluable patients). Of these 4 had shown progression to Acute myeloid leukemia, whereas one 
patient developed metastatic adenocarcinoma along with progression of disease. With a mean 
follow up duration of 110 months in 111 evaluable patients, the cumulated incidence of  
transformation to acute leukemia at 5 years was 3.6 % (n=4) [Table:8]. In the study by Huang et al 
(1), with a median follow-up duration of  98 months in 187 evaluable patients, the cumulated 
incidence of acute leukemic transformation at 7 years was 8.1% for h-MDS. This is higher than the 
observation in our study. This may be due to the fact that hypocellular RAEB 2 was excluded from 
our study. 
Univariate Cox proportional hazard model was used to find out significant prognostic 
factors for survival among overall hMDS patients [Tables:10-12]. Parameters of independent 
significance for adverse effects on overall survival were ANC < 0.2 x10
9
/L at diagnosis, bone 
marrow blast at diagnosis >5%, WHO category RAEB-1, moderate/marked increase in BM 
reticulin, >3 cytogenetic anomalies,  monosomy7,  trisomy 21, WPSS intermediate risk group,  
WPSS high risk group , and IPSS-R very high risk group. In the multivariate model by Huang et al 
(1), parameters of independent significance for overall survival were age, marrow hypocellularity, 
RA with excess of blast, RA with excess of blast-T, monosomy 5 or 5q deletion and monosomy 7 
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or 7q deletion. However on multivariate analysis, none of the above parameters retained its 
statistical significance. 
 
 
LIMITATIONS OF THE STUDY: 
1. Retrospective study: limited available data due to non-retrievable records, intractability of 
patients due to wrongly recorded/changed/non-availability of address. 
2. Not all hypocellular MDS were recruited in this study; RAEB-2 and AML with hypocellular 
marrow were excluded. In the reported studies on hMDS; all categories of hypocellular 
MDS are included into the group hypoplastic MDS. This limits the comparison with these 
studies. 
3. Karyotyping is not available for all patients- limited by the nature of the study. 
4. Lesser number of patients in drug groups limiting comparison between drug groups. 
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CONCLUSION: 
Hypoplastic MDS is a distinct subgroup of MDS of unknown etiology which needs to be 
distinguished from aplastic anemia. It is a disease associated with a relatively good prognosis, with 
significant response to immunosuppressive therapy and reasonable response to treatment with 
androgens, and a lower probability for leukemic transformation.  Cytogenetic analysis at diagnosis 
is crucial in prognostic risk categorization of the patient. WHO classification based prognostic 
scoring system and revised IPSS appear to be better than IPSS in predicting survival.  
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APPENDIX-1 
(Table: 1) Criteria for dysplasia in the three different cell lineages 
Granulocytic dysplasia  Erythroid dysplasia  Megakaryocytic dysplasia 
Hypogranularity Anisopoikilocytosis Small/large  
megakaryocytes 
Abnormal nuclear 
segmentation 
Nuclear lobulation, 
budding, karyorrhexis 
Abnormal nuclear 
lobulation 
Hypo- or hyperlobulated 
Hyposegmentation (most 
common) 
Megaloblastoid changes 
 
Large, hypogranular 
platelets 
Hypersegmentation 
 
Abnormal iron incorporation 
- 
Ring sideroblasts 
Megakaryocytic clustering 
in core biopsy 
Hypercondensed nuclear 
chromatin 
Increased coarse iron 
granules 
Platelet dysfunction 
Megaloblastoid changes 
 
Loss of colony formation 
in core biopsy 
 
Abnormal localization of 
immature precursors 
(ALIP) in core biopsy 
Defective hemoglobinization  
Neutrophil dysfunction   
(Table:2) WHO Classification of Myelodysplastic Syndromes 
Disease  Blood findings  Bone marrow findings 
RCUD            
(RA,RN,RT) 
Unicytopenia or 
bicytopenia; blasts 
(<1%) 
Dysplasia (≥10%) in 1 lineage only;   <5% blasts;  
<15% ring sideroblasts 
RARS Anemia; no blasts Erythroid dysplasia only;<5% blasts; ≥15% ring 
sideroblasts 
RCMD Cytopenia(s);  
blasts (<1%) 
Dysplasia in >10% of the cells of ≥2 myeloid 
lineages, <5% blasts; ±15% ring sideroblasts; no 
Auer rods 
RAEB-1 Cytopenias; <5% blasts, 
no Auer rods 
Unilineage or multilineage dysplasia; 5%-9% 
blasts, no Auer rods 
RAEB-2 Cytopenias; 5%-19% 
blasts; Auer rods +/– 
Unilineage or multilineage dysplasia; 10%-19% 
blasts, Auer rods +/– 
MDS- U Cytopenia(s); <1% blasts Uneqivocal dysplasia in <10% of the cells in one/ 
more myeloid cell lines when accompanied by a 
cytogenetic abnormality considered as presumptive 
evidence for a diagnosis of MDS; <5% blasts 
MDS with 
isolated del(5q) 
Anemia; usually normal 
or slightly increased 
platelets; <5% blasts; no 
Auer rods 
Normal to increased megakaryocytes with 
hypolobated nuclei; Unilineage erythroid 
dysplasia; <5% blasts; del (5q) is sole cytogenetic 
abnormality; no Auer rods 
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(Table: 3) Calculation of flow cytometric score (FCM-score) for diagnosis of low-risk MDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
*In all nucleated cells; **in all CD34+ cells; # a diagnosis of MDS is formulated in the presence 
 of a FCM-score value ≥2. 
 
 
 
 
 
 
 
 
 
 
(Table:4)  Most frequent chromosomal aberrations in MDS patients 
 
Symbols: –, loss of chromosome; +, additional chromosome; inv, inversion; t, translocation; del, 
deletion. *In the absence of morphologic criteria, the presence of these abnormalities as the sole cytogenetic 
abnormality is not considered as a definitive evidence for MDS.  The other abnormalities if present in the 
setting of persistent cytopenia of undetermined origin, in the absence of definitive morphologic features, are 
considered as presumptive evidence of MDS. 
 
 
 
Cytometric Parameter Cut-off 
values 
Regression 
coefficient 
Variable 
weighted Score
#
 
Myeloblast-related cluster size (%)* ≥ 2 2.59 1 
B-progenitor-related cluster size (%)** ≤ 5 1.87 1 
Lymphocyte to myeloblast CD45 ratio ≤ 4 or≥7.5 1.76 1 
Granulocyte to lymphocyte SSC ratio ≤ 6 2.31 1 
Numerical (%) Translocations (%) Deletions (%) 
+8* (19%) inv 3 (7%) del 5q (27%) 
–7 (15%) t(1;7) (2%) del 11q (7%) 
+21 (7%) t(1;3) (1%) del 12q (5%) 
–5 (7%) t(3;3) (1%) del 20q (5%) 
-Y* (5%) t(6;9) (<1%) del 7q (4%) 
 t(5;12) (<1%) del 13q (2%) 
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     (Table:5) International Prognostic Scoring System (IPSS) 
Prognostic variables  Score value 
0 0.5 1.0 1.5 2.0 
BM blasts (%) <5 5-10 - 11-20 21-
30 
Karyotype Good Intermediate Poor   
Cytopenias 0/1 2/3    
 
IPSS Prognostic Risk Category & Clinical Outcomes 
Risk categories  Low Intermediate-1 Intermediate 
-2 
High 
Score 0 0.5-1.0 1.5-2.0 ≥2.5 
Median survival (yrs) 5.7 3.5 1.2 0.4 
25% AML Evolution(yrs) 9.4 3.3 1.1 0.2 
 
 
 
   (Table: 6)  Revised International Prognostic Scoring System (IPSS-R) 
Variable  Score 
0 0.5 1 1.5 2 3 4 
Cytogenetic 
group 
Very good - Good - Intermediate Poor Very 
poor 
Blasts  ≥2 - >2-<5% - 5-10% >10% - 
Hemoglobin  ≥10 - 8-<10 <8 - - - 
Platelet  ≥100 50-<100 <50 - - - - 
ANC  ≥0.8 <0.8 - - - - - 
IPSS-R Prognostic Risk Category & Clinical Outcomes 
Risk groups Very Low Low Intermediate High Very High 
Score  ≤1.5, >1.5-3 >3 – 4.5 >4.5 – 6 >6 
Survival  8.8 5.3 3.0 1.6 0.8 
AML/25%  NR 10.8 3.2 1.4 0.7 
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   (Table: 7) WHO classification-based prognostic scoring system for MDS (WPSS) 
Variables  Score 
0 1 2 3 
WHO Category RA, RARS, 5q- RCMD RAEB-1 RAEB-2 
Karyotype  Good Intermediate Poor - 
Transfusion requirement*  None Regular - - 
 
WPSS Prognostic Risk Category & Clinical Outcomes 
Risk category  Very low Low Intermediate High Very high 
Score  0 1 2 3 - 4 5 – 6 
Median OS (months) 141 66 48 26 9 
2yr probability of progression to 
AML 
3% 6% 21% 38% 80% 
*Transfusion dependency is defined as at least one red transfusion every 8 weeks over a period of 4 months. 
 
     (Table: 8a) The Global MDACC MDS Prognostic Model 
Prognostic factor  Points 
PS  ≥2 2 
Age :   
      60-64 
          64 
 
1 
2 
Platelets x 109/L 
   30 
30 – 49 
50 – 199 
 
3 
2 
1 
Hemoglobin <12g% 2 
BM blasts  
5-10 
11-19 
 
1 
2 
WBC .20 2 
Alteration of chromosome 7 or ≥3 alterations 3 
Prior transfusion 1 
PS, performance status; BM, bone marrow; WBC- white blood cell count. Patients with 0 to 4 points 
had a median survival of 54 months and a 3 year 63% survival. Patients with 5 and 6 points had a 
median survival of 23 to 30 months and 3-year survival of 30 to 40%. Patients with 7 to 8 points had 
a median survival of 13 months and a 3-year survival rate of 13 to 19%. Patients with 9 or more 
points had a median survival of 5 to 10 months and a 2% 3-year survival. Adapted from Ref. 16. 
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(Table: 8b) MDACC MDS Lower Risk Prognostic Model 
Characteristics Points 
Unfavorable cytogenetics 1 
Age  ≥60 years 2 
Hemoglobin < 10 (g/dL) 1 
Platelets 10
9
/l 
   <50l 
50-200 
 
2 
1 
Bone Marrow Blasts  >4% 1 
Risk group assignments 
Category 1 0-2 
Category 2 3-4 
Category 3 5-7 
 
(Table: 9) A Prognostic Model of Hypoplastic MDS. 
Prognostic factor  P-value 
Hemoglobin <10 g/dl 0.00026 
Performance status  >2 0.00484 
Unfavorable cytogenetics 0.00667 
Bone marrow blast  ≥5% 0.00765 
Serum LDH >600 IU/l 0.00990 
Estimated survival according to independent risk factors in the study group 
Risk group No. of Risk 
factors 
Patient 
n (%) 
Median (months) 2-year/3-year 
survival, % 
Low 0 17 (10) Not reached 71/61 
 1 49 (29) 27 59/38 
Intermediate 2 44 (26) 19.4 43/20 
High 3 39 (23) 9.3 14/7 
 4 17 (10) 4.7 12/6 
 5 3 (2) 2 0/0 
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(Table:10a) Modified International Working Group (IWG)  response criteria for MDS 
Proposed modified IWG response criteria for altering natural history of MDS 
Category  Response criteria (responses must last at least 4 week) 
Complete remission Bone marrow: <5% myeloblasts with normal maturation of all cell lines* 
Persistent dysplasia will be noted*† 
Peripheral blood‡ 
Hgb ≥ 11 g/dL 
Platelets ≥ 100 x109/L 
Neutrophils ≥1.0 x 109/L† 
Blasts - 0% 
Partial remission All CR criteria if abnormal before treatment except: 
Bone marrow blasts decreased by ≥ 50% over pretreatment but still >5% 
Cellularity and morphology not relevant 
Marrow CR† Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment† 
Peripheral blood: if HI responses, they will be noted in addition to marrow 
CR† 
Stable disease Failure to achieve at least PR, but no evidence of progression for > 8 weeks 
Failure Death during treatment or disease progression characterized by worsening of 
cytopenias, increase in percentage of bone 
marrow blasts, or progression to a more advanced MDS FAB subtype than 
pretreatment 
Relapse after CR or PR At least 1 of the following: 
Return to pretreatment bone marrow blast percentage 
Decrement of ≥ 50% from maximum remission/response levels in 
granulocytes or platelets  
Reduction in Hgb concentration by ≥ 1.5 g/dL or transfusion dependence 
Cytogenetic response Complete: Disappearance of the chromosomal abnormality without 
appearance of new ones 
Partial: At least 50% reduction of the chromosomal abnormality 
Disease progression For patients with: 
Less than 5% blasts: ≥ 50% increase in blasts to > 5% blasts 
5%-10% blasts: ≥ 50% increase to > 10% blasts 
10%-20% blasts: ≥ 50% increase to > 20% blasts 
20%-30% blasts: ≥ 50% increase to > 30% blasts 
Any of the following: 
At least 50% decrement from maximum remission/response in       
              granulocytes or platelets 
Reduction in Hgb by ≥ 2 g/dL 
Transfusion dependence 
Survival Endpoints: 
Overall: death from any cause 
Event free: failure or death from any cause 
PFS: disease progression or death from MDS 
DFS: time to relapse 
Cause-specific death: death related to MDS 
Deletions to IWG response criteria are not shown. To convert hemoglobin from grams per deciliter to grams per liter, multiply grams per deciliter by 
10. MDS indicates myelodysplastic syndromes; Hgb, hemoglobin; CR, complete remission; HI, hematologic improvement; PR, partial remission; 
FAB, French-American-British; AML, acute myeloid leukemia; PFS, progression-free survival; DFS, disease-free survival. *Dysplastic changes 
should consider the normal range of dysplastic changes (modification).†Modification to IWG response criteria. ‡In some circumstances, protocol 
therapy may require the initiation of further treatment (eg, consolidation, maintenance) before the 4-week period. Such patients can be included in the 
response category into which they fit at the time the therapy is started. Transient cytopenias during repeated chemotherapy courses should not be 
considered as interrupting durability of response, as long as they recover to the improved counts of the previous course. 
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Table: 10b Modified IWG response criteria for hematologic improvement 
Proposed modified International Working Group response criteria for hematologic 
improvement 
Erythroid response 
(pretreatment, < 11 g/dL) 
Hgb increase by ≥ 1.5 g/dL 
Relevant reduction of units of RBC transfusions by an absolute 
number of at least 4 RBC transfusions/8 wk compared with the 
pretreatment transfusion number in the previous 8 wk. Only 
RBC transfusions given for a Hgb of ≤ 9.0 g/dL 
pretreatment will count in the RBC transfusion response 
evaluation† 
Platelet response 
(pretreatment,<100 x 10
9
/L) 
Absolute increase of  ≥ 30 x 109/L for patients starting with > 20 
x 10
9
/L platelets 
Increase from < 20 x 10
9
/L to > 20 x 10
9
/L and by at least 
100%† 
Neutrophil response 
(pretreatment, < 1.0 x 10
9
/L) 
At least 100% increase and an absolute increase > 0.5 x 10
9
/L 
Progression or relapse after 
HI‡ 
At least 1 of the following: 
At least 50% decrement from maximum response levels in 
granulocytes or platelets 
Reduction in Hgb by ≥ 1.5 g/dL 
Transfusion dependence 
Deletions to the IWG response criteria are not shown. To convert hemoglobin levels from grams per deciliter to grams 
per liter, multiply grams per deciliter by 10. Hgb indicates hemoglobin; RBC: red blood cell; HI: hematologic 
improvement. *Pretreatment counts averages of at least 2 measurements (not influenced by transfusions) > 1 week apart 
(modification). †Modification to IWG response criteria. ‡In the absence of another explanation, such as acute infection, 
repeated courses of chemotherapy (modification), gastrointestinal bleeding, hemolysis, and so forth. It is recommended 
that the 2 kinds of erythroid and platelet responses be reported overall as well as by the individual response pattern. 
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PROFORMA: 
 
 
 
HYPOPLASTIC MDS DATA COLLECTION PROFORMA 
Sl No: ……….. 
 
1. Name:          2. Hospital number:  
3. Age at diagnosis:        4. Sex: 
5. Diagnosis:                       6. Date of diagnosis: 
7. Symptomatic at diagnosis:                           
8. If yes, what symptoms: 
8a. fever    (1. Yes    2. No)    8b. pallor   (1. Yes    2. No)                         
8c. breathlessness       (1. Yes    2. No)       8d. skin bleed       (1. Yes    2. No)               
8e. gum bleed     (1. Yes    2. No)       8f. epistaxis     (1. Yes    2. No)                      
8g. hematuria        (1. Yes    2. No)       8h. systemic infections (1. Yes    2. No)      
8i. skin infections          (1. Yes    2. No)  8j. Others (mention):      
9. Transfusion requirement (1. Yes    2. No)         
10.Duration of symptoms in months:     
11.Previous treatment taken  (1. Yes    2. No  3.NA)   If yes, what treatment?                                 
11a. dexamethasone    (1. Yes    2. No)    11b. prednisolone     (1. Yes    2. No)    
11c  danazol          (1. Yes    2. No)         11d. stanazolol       (1. Yes    2. No)     
11e. cyclosporine     (1. Yes    2. No)         11f. thalidomide      (1. Yes    2. No)     
11g. lenalidomide     (1. Yes    2. No)         11h. ATG              (1. Yes    2. No)                  
11i. EPO              (1. Yes    2. No)         11j. PC transfusion   (1. Yes    2. No)    
11k. if yes PC number:      11L. PRC transfusion:    (1. Yes    2. No)                               
11m. If yes PRC number:   11n. previous treatment duration in months: 
11o. Others (mention): 
12.Associated illness:    (1. Yes    2. No) 
12a. If yes type of disease:     
12b. drug for associated illness: 
12c. treatment duration of associllness in months: 
13.History of malignancy:   (1. Yes    2. No)                                   
13a. if yes type:   
13b. history of chemotherapy drug:  (1.yes    2.No) 
13c. if yes types of drugs:                                                                     
13d. duration of chemotherapy in months:      
13e. last date of chemotherapy: 
14. Clinical examination findings: (1.yes    2.No)          
14a. pallor:         (1.yes    2.No)           14b. skin bleeds:    (1.yes    2.No)     
14c. gum bleeds:     (1.yes    2.No)  14d. haematuria:     (1.yes    2.No)          
14e. LNE:            (1.yes    2.No)                    14f. hepatomegaly:   (1.yes    2.No)         
14g. spleenomegaly:  (1.yes    2.No)     14h. dysmorphic features:                                              
LABORATORY FINDINGS AT DIAGNOSIS: 
15. Peripheral blood  
15a. Hb g%:      15b. TWBC per cumm: 
15c. Platelet per cumm:                     15d. ANC per cumm:  
15e. Blasts %:                          15f. ALC per cumm:         
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15g. AEC per cumm:                        15h. ARC per cumm:   
15i. LDH:                        15j. EPO:                  
15k. Vit B12 (if done):                      15L. folate 9if done):           
15m. Monocytosis:    (1.yes    2.No) 15n. DCT (if done): 
15o. ANA (if done):   15p. PNH IPT (if done):     
16. Bone marrow study:                            
16a.BM blasts%:       16b.BM Asp Celularity:       
16c.BM biopsy Celularity:  16d.Erythroid dysplasia:        
16e.Myeloid dysplasia:            16f.Megakaryocyte dysplasia:     
16g.BM Ring sideroblasts:  16h.BM mast cells:               
16i.BM plasma cells:              16j.BM Eosinophils:              
16k.BM Monocytosis:              16L.BM Erythroids:               
16m.BM Myeloids:   16n.BM Megakaryocytes:                                    
16o.BM Reticulin:   16p.Cytogenetics: 
 
17.IPSS score:     17a.IPSS risk categ:  
18. WPSS score:     18a.WPSS risk categ:  
19. IPSS-R score:          19a.     IPSS-R risk category:     
   
20. First Treatment : 
20a.type of first treatment:       20b. dose of first drug (mg):     
20c .date of starting first treatment:   20d. duration of first treatment in months: 
21.  HI to first treatment:  (1.Yes    2.No    3.NA) 
21a. if yes what HI:   (1. EI    2.NI     3.PI)  21b. date of HI: 
22.  Overall response to first treatment:     (1.Yes    2.No    3.NA)   
22a. if yes what response:     22b. date of response to first treatment:  
 
23. Second Treatment: 
23a.type of second treatment:    23b. dose of second drug (mg):    
23c. date of starting second treatment:  23d. duration of second treatment in months: 
24. HI to second treatment:   (1.Yes    2.No    3.NA) 
24a. if yes what HI:  (1. EI    2.NI     3.PI) 24b.  date of HI : 
25. Overall response to second treatment:     (1.yes    2.No)   
25a.if yes what response:   25b. date of response to second treatment:  
 
26. Third Treatment:           (1.Yes    2.No    3.NA) 
26a. type of third treatment:    26b. dose of third drug (mg):     
26c. date of starting third treatment:   26d. duration of third treatment in months: 
27. HI to third treatment:   (1.Yes    2.No    3.NA) 
27a.if yes what HI;   (1. EI    2.NI     3.PI) 27b. date of HI: 
28. Overall response to third treatment:     (1.yes    2.No)   
28a.if yes what response:      28b.date of response to third treatment:  
 
29.  Relapse of disease:    (1.Yes    2.No    3.NA) 
29a. if yes date of relapse:     
29b. treatment at relapse:  
29c. response to relapse treatment:    (1.Yes    2.No    3.NA) 
29d.type of response:    
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30. CLINICAL STATUS & BLOOD COUNTS AT FOLLOW UP: 
31.    
Chelation:  (1.Yes    2.No    3.NA) 
32a. Date of starting chelation: 
32b. Ferritin level:                                   
32c. Chelation drug:_ 
32d.Duration of chelation in months: 
32.     PBSCT :    (1.yes    2.No) 
33a. Donor; 
33b. HLA match with donor: 
33c. Date of PBSCT: 
33d. disease status of disease at PBSCT: 
33e. Transfusion requirement at PBSCT:   (1.Yes    2.No) 
33f. PC transfusions since diagnosis to PBSCT : 
33g.PRC transfusions since diagnosis to PBSCT: 
33h. serum ferritin at PBSCT: 
33i. Response to PBSCT: 
33j. complications of PBSCT: 
33.     LAST FOLLOW UP DATE:  
34a. Status at LFU:    (1.Alive    2.Dead    3.Not known/lost to FU) 
34b. Symptoms at LFU:   
34c. Hb at LFU:     
34d.Platelets at LFU:  
34e. ANC at LFU:    
34f. Disease status at LFU: 
34g.Drug at LFU:  
34.If dead, date of death:     
35a.Cause of death: 
 
 
 
 
 
 
 
 
 
 
 
 
Date  Symptoms  Transfusions  Hb TWBC ANC Platelet Response  
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MASTER CHART: 
 
sn
o 
Ag
e 
Se
x DOD 
WH
O gr 
Du 
Sym 
Pallo
r 
Blee
d 
InfectIo
n 
Live
r 
Splee
n PC 
PR
C 
h/o 
Cytopeni
a 
Tr
t 
res 
H
b WBC 
Blas
t % 
AN
C PLT 
Reti
c ARC 
LD
H 
FERITI
N 
1 66 2 1-2-2012 1 1 1 1 2 2 2 na na 4 9 5 4300 0 2322 3000 na na 308 na 
2 47 2 2-1-2012 1 3 1 2 2 2 2 6 na 4 9 3 12300 0 1476 11000 2.03 65366 486 na 
3 51 2 2-24-2012 1 7 1 2 2 2 2 12 na 4 9 6 4000 0 1520 11000 2.09 48070 321 na 
4 58 1 3-16-2012 3 12 1 2 1 2 2 2 na 4 9 7 1200 0 144 95000 1.15 39100 409 na 
5 42 1 6-18-2012 1 24 1 2 2 1 2 3 na 4 9 7 3600 0 1368 44000 na na 456 na 
6 19 2 2-16-2012 3 1 1 1 1 2 2 2 2 4 9 5 3700 0 2220 45000 5.74 13489 318 na 
7 20 2 5-25-2012 1 2 1 1 2 2 2 3 3 4 9 6 3900 0 234 16000 0.55 9735 261 na 
8 62 2 5-14-2012 3 10 1 1 1 2 2 5 2 4 9 9 5100 0 1683 8000 1.49 44700 na na 
9 19 1 12.31.2011 1 1 1 2 2 2 2 3 na 4 9 3 2400 0 456 12000 na na 327 na 
10 37 1 2-7-2011 3 1 1 1 1 2 2 na na 4 9 4 1100 0 528 5000 1.26 12222 373 na 
11 41 2 7-8-2011 3 120 1 2 2 2 2 60 na 4 9 6 2700 0 1053 56000 1.5 37200 947 46775 
12 60 1 3-4-2011 1 1 1 2 2 2 2 2 na 4 9 7 7500 0 5175 21000 na na 600 na 
13 31 1 7-22-2011 3 2 1 2 1 2 2 7 na 4 9 5 1400 0 560 14000 2.57 34181 409 na 
14 66 1 6-8-2011 1 3 1 2 1 2 2 10 na 4 9 10 900 0 180 13000 na na na na 
15 56 1 9-12-2011 1 7 1 2 2 2 2 4 na 4 9 5 3100 0 1054 13000 1.85 53095 599 na 
16 26 1 10-5-2011 1 2 1 1 1 2 2 12 na 4 9 2 1800 0 486 8000 0.82 24272 392 na 
17 45 1 8-3-2011 1 3 1 1 1 2 2 6 na 4 9 7 4900 0 1568 2000 1.01 20503 na na 
18 68 1 1-1-2011 1 12 1 2 2 1 2 16 na 4 9 3 2100 0 714 14000 na na na na 
19 33 2 2-14-2011 3 4 2 1 2 2 2 7 na 1 3 7 3300 0 1254 11000 3.31 61897 437 na 
20 63 1 3-4-2011 3 1 1 1 1 2 2 1 na 4 9 6 3600 0 1800 5000 2.4 65750 498 na 
21 57 1 5-17-2010 3 1 1 1 1 2 2 na na 4 9 7 2900 0 116 5000 1.96 39984 319 na 
22 36 1 8-10-2010 3 3 1 2 1 2 2 18 na 4 9 8 2200 0 1100 43000 na na 380 na 
23 37 1 1-4-2010 3 3 1 1 2 2 2 5 na 1 1 6 3300 0 1419 46000 1.83 49842 379 na 
24 30 1 1-19-2010 1 1 1 1 2 2 2 na na 1 3 7 2400 0 480 11000 na na 316 na 
25 58 2 3-1-2010 1 1 1 1 1 2 2 na na 4 9 8 3000 0 1110 31000 1.98 59796 566 na 
26 39 2 3-3-2010 1 7 1 2 1 2 2 14 na 4 9 6 4200 0 546 19000 0.92 21436 415 na 
27 41 1 4-7-2010 1 1 1 1 1 2 2 na na 1 3 5 1600 0 64 12000 2.59 35742 515 2595 
28 61 1 6-29-2010 1 1 1 2 2 2 2 4 na 9 9 6 2300 0 943 247000 0.82 26896 na 883 
29 59 1 7-30-2010 1 4 1 1 1 2 2 7 na 4 9 6 2200 0 660 7000 2.02 14342 288 na 
30 30 2 9-18-2010 1 24 1 2 2 2 2 10 5 4 9 6 2100 0 1428 7000 na na 832 na 
31 31 1 11-19-2010 1 5 1 1 1 2 2 10 7 1 3 7 2500 0 500 5000 3.37 31341 335 na 
32 45 1 10-9-2010 1 1 1 2 1 2 2 2 4 4 9 5 3600 0 972 17000 2.51 41415 385 na 
33 25 1 12-27-2010 1 2 1 2 1 2 2 6 4 4 9 7 3700 0 1332 11000 na na 629 na 
34 35 1 12-2-2010 1 2 1 2 1 2 2 na na 4 9 7 2000 0 680 44000 4 80400 395 na 
35 28 2 11-12-2010 1 1 2 1 2 2 2 na na 1 2 9 1800 0 1224 4000 na na na na 
36 31 1 12-28-2010 1 3 1 1 2 2 2 2 na 1 3 4 3800 0 1216 13000 2.04 51204 523 na 
37 20 2 7-1-2010 3 8 1 2 2 2 2 10 na 4 9 3 3900 0 351 17000 1.44 43920 282 510 
38 46 2 1-9-2009 1 5 1 1 1 2 2 6 na 4 9 4 3200 0 1280 8000 na na 528 697 
39 54 2 1-12-2009 2 1 1 2 1 2 2 3 na 4 9 6 2100 0 252 21000 0.19 6175 395 na 
40 33 1 3-29-2009 1 3 1 1 1 2 2 4 6 4 9 8 4600 0 920 11000 0.44 16192 444 na 
Sl no: serial number, DOD:date of diagnosis, Dur symp:duration of symptoms, Trt res: Treatment response. 
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Sl No 
DC
T 
AN
A 
BBV
S 
BM 
Celllarit
y 
Dysplasi
a 
Blast
% 
R
S 
Meg
s 
My
e 
Er
y 
Reticuli
n 
Cyt-
IPSS/WPS
S 
Cyt 
IPSS
-R 
IPSS 
scor
e 
WPS
S 
score 
IPSS
-R 
score 
CS
A 
CSA
-res ATG 
ATG-
res 
And
r 
Andr
-res 
1 9 9 4 2 3 2 2 4 2 2 1 2 2 0.5 1 3.5 2 4 2 4 1 4 
2 9 9 9 2 4 0 1 2 4 3 2 2 2 0.5 1 3.5 1 2 2 4 2 4 
3 9 9 4 4 2 0 2 2 2 3 3 2 2 0.5 1 3.5 2 4 2 4 1 2 
4 9 9 4 2 1 0 2 2 2 2 2 2 2 0.5 1 3 1 3 2 4 1 3 
5 1 2 4 2 4 3 1 2 2 2 2 9 9 na 9 na 2 4 2 4 1 2 
6 1 1 4 2 1 1 9 2 2 3 2 2 2 0.5 1 3.5 2 4 1 2 2 4 
7 9 9 4 2 3 1 2 2 2 2 1 2 2 0.5 1 4 2 4 2 4 1 2 
8 9 9 4 2 8 1 2 2 2 2 2 2 2 0.5 1 3 1 2 2 4 2 4 
9 9 9 4 4 2 2 2 2 2 2 1 2 2 0.5 1 4 2 4 1 1 2 4 
10 2 9 9 2 1 2 9 2 2 2 2 9 9 na 9 na 2 4 2 4 1 3 
11 1 9 4 2 6 1 9 2 2 3 3 9 9 na 9 na 2 4 2 4 1 2 
12 1 9 4 2 2 0 1 2 2 3 2 9 9 na 9 na 2 4 1 1 2 4 
13 2 9 4 2 1 0 1 2 2 3 2 2 2 0.5 1 4 1 2 2 4 1 2 
14 9 9 4 2 2 2 1 2 2 2 1 9 9 na 9 na 2 4 2 4 1 4 
15 9 9 4 4 4 0 2 2 1 3 2 2 2 0.5 1 3.5 1 2 2 4 1 1 
16 9 9 4 2 4 1 2 2 2 2 2 4 5 1.5 3 7 1 4 2 4 2 4 
17 9 9 9 1 3 0 2 4 2 2 1 9 9 na 9 na 1 3 2 4 2 4 
18 9 9 9 2 7 2 2 2 2 2 2 2 2 0.5 1 4 2 4 2 4 2 4 
19 2 2 4 2 1 2 1 2 2 2 2 2 2 0.5 1 3.5 1 2 2 4 1 2 
20 2 2 4 2 1 0 2 4 2 3 2 9 9 na 9 na 1 4 2 4 2 4 
21 9 9 4 4 1 0 1 2 2 2 3 2 2 0.5 1 4 1 2 2 4 2 4 
22 9 9 9 2 6 0 9 2 2 3 4 9 9 na 9 na 1 2 2 4 2 4 
23 9 9 1 2 6 0 9 2 2 2 3 3 1 1 2 2.5 1 3 2 4 1 1 
24 2 9 4 2 7 1 2 2 2 2 2 2 2 0.5 1 4 2 4 1 2 1 3 
25 1 1 4 2 2 1 2 2 2 2 2 2 2 0.5 1 3.5 2 4 2 4 2 4 
26 9 9 4 2 4 1 2 2 2 2 1 3 3 1 2 5 2 4 2 4 1 2 
27 9 9 4 4 2 1 1 2 2 2 2 2 1 0.5 1 3 2 4 1 2 1 3 
28 9 9 4 2 2 0 1 2 2 3 2 9 9 na 9 na 1 4 2 4 2 4 
29 9 9 9 2 3 1 1 4 2 2 2 9 9 na 9 na 2 4 2 4 1 4 
30 9 9 4 2 7 4 2 1 2 2 3 9 9 na 9 na 2 4 2 4 1 2 
31 9 9 4 2 4 0 2 2 2 2 2 9 9 na 9 na 2 4 1 3 1 2 
32 2 9 9 2 3 0 1 2 2 2 2 9 9 na 9 na 2 4 2 4 1 2 
33 2 2 4 2 4 1 1 2 2 2 2 2 2 0.5 1 3.5 1 1 2 4 2 4 
34 9 9 4 2 2 1 2 2 2 2 2 2 2 0.5 1 4 1 2 2 4 2 4 
35 9 9 4 2 4 0 1 2 2 2 2 2 2 0.5 1 3 2 4 2 4 1 2 
36 9 9 4 2 4 1 1 4 2 2 1 2 2 0.5 1 3.5 1 2 2 4 2 4 
37 1 9 4 2 1 0 1 2 2 2 2 9 9 na 9 na 1 2 2 4 2 4 
38 2 9 4 2 4 0 1 4 2 2 1 2 2 0.5 1 3.5 2 4 2 4 1 2 
39 1 2 4 2 4 5 2 1 2 2 2 2 2 0.5 1 6 2 4 2 4 2 4 
40 9 9 4 4 7 2 2 2 2 2 3 9 9 na 9 na 1 2 2 4 1 4 
DCT: direct coomb’s test, ANA:antinuclear antibody, BBVS: blood borne viral screen, RS: ring sideroblasts, Megs, Megakaryocytes,  Mye: Myeloids, Ery:Erythroids, CSA: cyslosporine Treatment, CSA-res: Reposne to 
CSA, ATG-res: Response to ATG. 
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Sl 
No Pred 
Pred-
res Allo 
Allo-
res Others 
Others-
res Sup 
Sup-
res Response DO res DO relapse 
Trt 
rela Do LFU Alive/Dead 
Drg 
LFU 
Disease 
statusLFU 
Cause 
death 
1 2 4 2 4 1 3 2 4 4 na na 18 1-21-2012 2 3 7 9 
2 2 4 2 4 2 4 2 4 2 5-8-2012 na 18 12-15-2012 2 1 13 9 
3 2 4 2 4 2 4 2 4 2 6-16-2012 na 18 12-1-2012 2 3 17 9 
4 2 4 2 4 2 4 2 4 3 na na 18 12-4-2012 1 15 4 2 
5 2 4 2 4 2 4 2 4 2 10-16-2012 na 18 11-30-2012 2 2 6 9 
6 2 4 2 4 2 4 2 4 2 6-26-2012 na 18 11-23-2012 2 1 12 9 
7 2 4 2 4 2 4 2 4 2 11-5-2012 na 18 11-5-2012 2 3 14 9 
8 2 4 2 4 2 4 2 4 2 8-28-2012 na 18 10-26-2012 2 1 14 9 
9 2 4 2 4 2 4 2 4 1 5-25-2012 na 18 10-23-2012 2 1 1 9 
10 2 4 2 4 2 4 2 4 3 na na 18 3-16-2012 1 2 4 3 
11 2 4 2 4 2 4 2 4 2 11-2-2011 na 18 12-4-2012 2 3 14 9 
12 2 4 2 4 2 4 2 4 1 12-27-2011 na 18 12-27-2011 2 1 1 9 
13 2 4 2 4 2 4 2 4 2 5-31-2012 9-3-2012 6 10-1-2012 2 6 8 9 
14 2 4 2 4 2 4 2 4 4 na na 18 6-16-2011 2 2 7 9 
15 2 4 2 4 2 4 2 4 1 3-23-2012 na 18 9-28-2012 2 2 1 9 
16 2 4 2 4 2 4 2 4 4 na na 18 10-18-2011 2 1 7 9 
17 2 4 2 4 2 4 2 4 3 na na 18 1-5-2012 1 1 4 1 
18 2 4 2 4 1 2 1 4 2 12-1-2011 na 18 12-23-2011 2 6 6 9 
19 2 4 2 4 2 4 2 4 2 7-1-2011 na 18 8-31-2012 2 1 6 9 
20 2 4 2 4 2 4 2 4 4 na na 18 3-6-2011 2 1 7 9 
21 2 4 2 4 2 4 2 4 2 2-1-2011 na 18 4-17-2012 2 15 14 9 
22 1 2 2 4 1 4 2 4 2 3-4-2011 na 18 3-4-2011 2 9 14 9 
23 2 4 2 4 2 4 2 4 1 12-14-2012 na 18 12-14-2012 2 3 1 9 
24 2 4 2 4 2 4 2 4 2 8-24-2010 na 18 11-7-2012 2 15 14 9 
25 2 4 2 4 2 4 1 1 1 3-23-2010 na 18 3-23-2010 2 15 1 9 
26 2 4 2 4 2 4 2 4 2 4-9-2010 na 18 5-11-2010 2 3 18 9 
27 2 4 2 4 2 4 2 4 2 6-24-2010 5-24-2011 6 7-18-2011 1 6 8 2 
28 2 4 2 4 2 4 2 4 2 na na 18 10-11-2010 2 1 7 9 
29 2 4 2 4 2 4 2 4 4 na na 18 8-10-2010 2 2 7 9 
30 2 4 2 4 2 4 2 4 2 3-26-2011 1-19-2012 18 5-19-2012 1 3 8 1 
31 2 4 2 4 2 4 2 4 2 6-21-2011 na 18 9-20-2011 2 2 16 9 
32 2 4 2 4 2 4 2 4 2 2-15-2011 na 18 2-17-2011 2 2 16 9 
33 2 4 2 4 2 4 2 4 1 4-10-2012 na 18 10-1-2012 2 1 1 9 
34 2 4 2 4 2 4 2 4 2 4-29-2011 na 18 4-29-2011 2 1 11 9 
35 2 4 2 4 2 4 2 4 2 11-12-2011 na 18 8-11-2012 2 3 14 9 
36 2 4 2 4 2 4 2 4 2 12-5-2011 na 18 12-13-2012 2 1 12 9 
37 2 4 2 4 2 4 2 4 2 10-13-2011 na 18 9-24-2012 2 1 14 9 
38 2 4 2 4 2 4 2 4 2 5-25-2009 na 18 1-11-2011 2 3 14 9 
39 2 4 2 4 2 4 1 1 1 3-17-2009 na 18 3-17-2009 2 15 1 9 
40 2 4 2 4 2 4 2 4 2 5-3-2010 na 18 5-12-2010 2 2 14 9 
Andr:Androgens, Andr-res: Reposne to androgens, Pred: Prednisoloen, Pred-res: Response to prednisolone, Allo:Allogenic PBSCT, ALLO-res: Response to ALLo PBSCT, Sup:Suppotove treatment,  
Sup-res:Response to supportive treatment, DO res:Date of response, DO Relapse:Date of relapse, Trt relapse: Treatment of relapse, Do LFU:Date of last follow up, Drug LFU:Drug at last follow up,  
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41 49 1 5-19-2009 3 24 1 2 1 2 1 1 na 4 9 7 1700 0 918 46000 1.9 31730 
 
332 
42 41 1 6-11-2009 2 3 1 2 2 2 2 10 na 4 9 5 3100 0 1395 17000 2.73 75348 471 na 
43 56 2 6-9-2009 2 3 1 2 1 2 2 na na 4 9 8 1300 0 260 201000 3.26 65844 1062 na 
44 35 1 6-18-2009 3 1 1 2 2 2 2 na na 4 9 9 2100 0 252 40000 1.14 30096 621 na 
45 59 2 9-14-2009 1 12 1 1 2 2 2 8 na 4 9 6 4100 0 2337 9000 1.44 18000 411 na 
46 42 1 8-31-2009 1 2 1 2 1 2 2 5 4 4 9 4 5400 0 1620 6000 2.21 62543 822 na 
47 61 2 10-26-2009 2 4 1 2 2 2 2 8 na 3 3 5 3800 0 1710 22000 0.1 na 348 5448 
48 38 1 7-15-2008 1 1 1 2 2 2 2 na na 1 2 7 2300 0 115 29000 na na 291 na 
49 63 1 11-21-2008 1 1 1 2 1 2 2 1 7 4 9 9 3100 0 1643 65000 2.16 62208 764 408 
50 43 1 2-29-2008 1 3 1 2 2 2 2 na na 4 9 10 3800 0 1292 26000 1.85 51060 343 138 
51 58 1 7-1-2008 1 1 1 2 2 2 2 5 na 4 9 5 2800 0 1512 136000 0.79 12877 371 na 
52 43 1 1-23-2008 1 3 1 2 2 2 2 3 0 4 9 6 3800 0 1976 307000 na na 412 1910 
53 74 1 2-20-2008 3 1 1 1 2 2 2 2 4 4 9 6 1900 0 304 9000 2.48 36952 355 na 
54 24 1 2-28-2008 1 3 1 2 1 2 2 4 8 4 9 4 1800 0 144 9000 0.94 25662 325 na 
55 24 1 5-17-2008 1 
 
1 1 1 2 2 na na 4 9 9 7300 0 1752 5000 2.48 68200 595 942 
56 49 2 5-12-2008 1 4 1 2 2 2 2 2 na 4 9 5 5700 0 3363 15000 2.09 41862 342 na 
57 35 2 7-25-2008 1 6 1 1 1 2 2 40 na 4 9 7 3100 0 682 5000 1.07 22791 360 na 
58 59 2 7-18-2008 1 1 1 1 2 2 2 20 20 4 9 10 1400 0 476 15000 2.62 80696 533 2000 
59 75 2 5-2-2008 1 3 1 2 1 2 2 8 na 4 9 6 3300 0 792 6000 1.85 34595 441 na 
60 22 1 8-20-2008 1 
 
9 9 9 9 9 na na 9 9 4 2000 0 560 4000 0.94 10246 421 na 
61 24 1 8-25-2008 1 
 
9 9 9 9 9 na na 9 9 4 2900 0 1450 61000 4.78 50190 1206 na 
62 55 2 8-25-2008 1 1 1 1 1 2 2 na na 2 9 6 5800 0 5220 5000 7.06 na 687 na 
63 40 2 10-24-2008 1 5 1 2 1 2 2 5 na 9 9 8 2500 0 325 74000 2.08 60942 465 na 
64 22 1 11-24-2008 3 
 
9 9 9 9 9 na na 9 9 6 1800 0 434 7000 1.03 21527 260 na 
65 35 1 11-19-2008 1 12 1 1 1 2 2 na na 4 9 3 1700 0 884 9000 2.71 26267 276 na 
66 23 1 11-5-2008 3 3 1 1 2 2 2 5 2 4 9 4 3300 0 1089 10000 1.85 27935 409 na 
67 54 2 11-7-2008 1 12 1 1 1 2 2 16 8 4 9 4 1200 0 552 3000 1.07 27941 459 3905 
68 72 1 4-7-2008 1 6 1 2 2 2 2 na na 4 9 7 3100 0 1178 246000 1.47 14259 449 768 
69 19 1 4-28-2008 1 
 
9 9 9 9 9 na na 9 9 7 3500 0 3325 197000 2.3 62677 935 na 
70 65 1 11-22-2008 3 36 1 2 1 2 2 6 na 4 9 8 2300 0 1012 46000 1 na 324 341 
71 62 2 8-13-2008 3 24 1 2 2 2 2 9 na 4 9 4 2100 0 1008 99000 1.86 18972 440 na 
72 56 1 4-28-2007 1 7 1 2 2 2 2 na na 4 9 8 4700 0 1081 30000 1.88 49820 518 na 
73 34 1 1-8-2007 1 3 1 2 1 1 1 na na 4 9 3 1800 0 1260 15000 2.62 17816 380 na 
74 64 2 1-31-2007 1 1 1 1 2 2 2 3 na 4 9 6 3400 0 1564 7000 3.2 78080 400 na 
75 21 1 4-23-2007 1 1 1 1 1 2 2 1 2 4 9 6 600 0 60 17000 0.71 14839 2401 na 
76 42 2 7-24-2007 1 12 1 1 2 2 2 6 na 4 9 10 4800 0 2496 8000 3.01 77658 427 406 
77 20 2 8-4-2007 1 3 1 2 2 2 2 6 na 4 9 8 3600 0 1652 48000 0.51 13719 442 na 
78 55 2 7-31-2007 1 
 
1 2 2 2 2 7 2 4 9 3 6200 0 3410 8000 1.05 36225 616 na 
79 53 1 9-1-2007 1 7 1 1 2 2 2 25 2 4 9 3 1300 0 260 9000 2.73 22113 326 na 
80 52 2 12-22-2007 3 12 1 2 2 2 2 na na 9 9 9 5000 0 2350 13000 2.39 58794 424 na 
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41 9 2 4 2 1 1 1 2 2 2 3 2 2 0.5 1 3.5 2 4 2 4 2 4 
42 9 9 4 1 3 5 1 2 2 2 1 9 9 na 9 na 2 4 2 4 2 4 
43 9 9 4 2 5 5 2 2 2 2 3 3 3 1 2 6 1 3 2 4 2 4 
44 9 9 4 1 6 2 2 2 2 2 3 4 4 1.5 3 5.5 2 4 2 4 1 4 
45 9 9 4 1 2 1 1 2 2 2 2 3 3 1 2 4.5 1 4 2 4 2 4 
46 9 9 9 2 3 0 2 2 2 2 2 2 2 0.5 1 3.5 1 2 2 4 2 4 
47 1 9 4 2 4 5 2 2 2 2 4 3 3 1 2 6.5 2 4 2 4 2 4 
48 9 9 4 2 4 3 1 2 2 2 2 4 4 1.5 3 7 1 3 2 4 1 3 
49 1 1 4 2 2 0 2 2 2 3 1 2 2 0.5 1 2.5 1 2 2 4 2 4 
50 2 9 4 2 3 1 2 2 2 2 1 2 2 0.5 0 3 1 2 2 4 2 4 
51 9 9 4 2 4 0 2 2 2 2 3 2 2 0 1 2.5 1 3 2 4 1 2 
52 2 2 4 2 7 0 2 2 2 2 2 2 2 0 1 2.5 2 4 2 4 1 1 
53 9 9 4 2 1 1 2 4 2 2 1 4 4 1.5 3 6 1 3 2 4 1 4 
54 9 9 4 2 2 0 1 2 2 2 1 9 9 na 9 na 1 1 2 4 2 4 
55 9 9 4 2 3 0 1 2 2 3 1 2 2 0.5 1 3 1 2 2 4 2 4 
56 9 1 4 4 3 0 1 2 2 2 1 3 3 1 2 4.5 1 4 2 4 2 4 
57 2 9 4 2 3 1 2 4 2 2 1 2 2 0.5 1 4 1 2 2 4 1 2 
58 1 9 4 2 4 0 2 2 2 2 2 4 4 1.5 3 5.5 1 4 2 4 2 4 
59 9 9 4 2 3 0 2 2 2 3 2 2 2 0.5 1 4 1 2 2 4 1 4 
60 9 9 4 2 3 2 2 2 2 3 1 2 2 0.5 1 4 2 4 2 4 1 4 
61 9 9 4 2 4 1 2 1 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
62 9 9 4 2 4 0 2 2 2 2 3 9 9 na 9 na 2 4 2 4 1 4 
63 2 9 4 2 4 2 1 2 2 3 3 4 4 1.5 3 5.5 1 2 2 4 1 2 
64 9 9 1 4 5 1 2 2 2 3 2 2 2 0.5 1 4 1 4 2 4 2 4 
65 2 9 4 1 4 0 2 4 2 2 1 9 9 na 9 na 2 4 2 4 1 4 
66 9 9 4 2 1 0 1 2 2 2 1 3 3 1 2 4.5 2 4 2 4 1 4 
67 1 1 4 2 2 2 2 2 2 3 2 2 2 0.5 1 4 1 4 2 4 2 4 
68 2 9 4 2 4 2 2 2 2 2 1 3 3 1 2 3.5 1 2 2 4 2 4 
69 9 9 4 2 4 2 2 2 2 2 2 9 9 na 9 na 2 4 2 4 2 4 
70 9 2 4 2 6 0 1 2 2 2 2 3 3 1 2 4 1 2 2 4 2 4 
71 9 9 4 2 6 0 2 1 2 3 1 2 2 0.5 1 3 2 4 2 4 1 3 
72 9 9 4 2 4 2 1 2 2 3 2 2 2 0.5 1 3.5 1 3 2 4 2 4 
73 9 9 4 2 4 3 2 2 2 3 3 2 2 0.5 1 4.5 2 4 2 4 1 2 
74 2 9 4 2 3 0 2 4 2 2 2 2 2 0.5 1 3.5 2 4 1 2 2 4 
75 2 2 4 2 4 0 2 2 2 2 2 9 9 na 9 na 2 4 2 4 2 4 
76 2 9 2 4 4 0 2 2 2 3 2 9 9 na 9 na 1 4 2 4 2 4 
77 9 9 4 2 7 2 2 2 2 2 2 3 2 1 2 3 2 4 2 4 2 4 
78 9 9 4 2 3 0 1 2 2 2 1 2 2 0.5 1 3.5 1 2 2 4 2 4 
79 9 9 4 1 3 1 1 4 2 2 2 2 2 0.5 1 4 1 4 2 4 2 4 
80 2 9 4 4 1 1 1 2 2 3 2 9 9 na 9 na 1 4 2 4 1 3 
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41 1 2 2 4 2 4 2 4 2 4-5-2010 na 18 6-25-2010 2 15 12 9 
42 2 4 2 4 2 4 2 4 4 na na 18 6-19-2009 2 15 7 9 
43 2 4 2 4 2 4 2 4 3 na na 18 8-12-2010 1 1 4 2 
44 2 4 2 4 2 4 2 4 4 na na 18 6-19-2009 2 2 7 9 
45 2 4 2 4 2 4 2 4 4 na na 18 9-18-2009 2 1 7 9 
46 1 3 2 4 2 4 2 4 2 2-4-2010 na 18 2-4-2010 2 1 18 9 
47 2 4 2 4 1 3 2 4 3 na na 18 1-24-2010 1 5 4 1 
48 2 4 2 4 2 4 2 4 3 na na 18 11-19-2009 1 2 4 9 
49 2 4 2 4 2 4 2 4 2 3-22-2011 na 18 9-4-2012 2 15 12 9 
50 1 3 2 4 2 4 2 4 2 8-15-2008 4-19-2012 4 4-27-2012 2 4 8 9 
51 2 4 2 4 1 3 2 4 2 8-27-2010 12-21-2010 18 1-13-2011 1 15 8 9 
52 1 3 2 4 2 4 2 4 1 4-28-2008 6-4-2009 1 6-5-2009 2 1 10 9 
53 2 4 2 4 2 4 2 4 4 na na 18 3-28-2008 2 3 7 9 
54 2 4 2 4 2 4 2 4 1 9-1-2010 na 18 9-19-2012 2 15 1 9 
55 2 4 2 4 2 4 2 4 2 9-4-2008 na 18 10-4-2011 2 15 14 9 
56 2 4 2 4 2 4 2 4 4 na na 18 5-12-2008 2 1 7 9 
57 2 4 2 4 2 4 2 4 2 9-8-2010 na 18 12-3-2012 2 3 14 9 
58 2 4 2 4 2 4 2 4 4 na na 18 7-18-2008 2 1 7 9 
59 2 4 2 4 2 4 2 4 2 8-25-2008 na 18 10-3-2008 2 3 16 9 
60 2 4 2 4 2 4 2 4 4 na na 18 8-26-2008 2 2 7 9 
61 2 4 2 4 2 4 2 4 4 na na 18 8-25-2008 2 18 7 9 
62 2 4 2 4 2 4 2 4 4 na na 18 9-4-2008 2 3 7 9 
63 1 3 2 4 2 4 2 4 2 1-23-2009 5-11-2009 19 5-12-2009 2 3 8 9 
64 2 4 2 4 2 4 2 4 4 na na 18 11-28-2008 2 1 7 9 
65 2 4 2 4 2 4 2 4 4 na na 18 11-21-2008 2 2 7 9 
66 2 4 2 4 2 4 2 4 4 na na 18 11-14-2008 2 2 7 9 
67 1 3 2 4 2 4 2 4 4 na na 18 12-4-2008 2 1 7 9 
68 2 4 2 4 2 4 2 4 2 7-1-2008 7-8-2009 1 10-4-2010 2 1 8 9 
69 2 4 2 4 2 4 2 4 4 na na 18 4-28-2008 2 15 7 9 
70 2 4 2 4 2 4 2 4 2 1-19-2009 10-7-2010 1 10-7-2010 2 1 8 9 
71 2 4 2 4 1 2 2 4 2 1-22-2009 na 18 9-3-2010 2 15 14 9 
72 2 4 1 2 2 4 2 4 2 6-20-2008 7-7-2008 6 8-1-2008 1 6 8 4 
73 1 3 2 4 2 4 2 4 2 12-24-2007 na 18 5-28-2010 2 2 14 9 
74 2 4 2 4 2 4 2 4 2 4-3-2007 na 18 8-10-2010 2 15 14 9 
75 2 4 2 4 2 4 2 4 4 na na 18 4-25-2007 2 15 7 9 
76 2 4 2 4 2 4 2 4 4 na na 18 8-3-2007 2 1 7 9 
77 1 4 2 4 2 4 2 4 4 na na 18 8-4-2007 2 4 7 9 
78 2 4 2 4 2 4 2 4 2 11-7-2007 na 18 5-20-2011 2 15 14 9 
79 2 4 2 4 2 4 2 4 4 na na 18 10-2-2007 2 1 7 9 
80 2 4 2 4 2 4 2 4 3 na na 18 3-8-2008 2 1 4 9 
86 
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Blast 
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81 19 1 2-25-2006 3 1 1 1 2 2 2 na na 4 9 6 1800 0 360 16000 1.35 28755 272 na 
82 61 1 1-20-2006 1 12 1 1 2 2 2 16 na 4 9 6 2200 0 616 11000 1.55 34100 254 na 
83 46 1 6-23-2006 1 2 1 1 2 2 2 3 3 4 9 7 4200 0 2058 35000 1.99 36019 487 na 
84 50 1 6-26-2006 1 8 1 2 2 2 2 5 na 4 9 5 2900 0 2639 60000 0.98 17150 357 na 
85 32 1 1-12-2006 1 na 9 9 9 9 9 na na 9 9 4 1200 0 96 22000 2.42 36784 301 na 
86 56 1 2-28-2006 1 na 9 9 9 9 9 na na 9 9 5 5000 0 3450 7000 2.79 54784 335 na 
87 49 2 2-8-2006 3 3 1 1 2 2 2 2 na 4 9 7 5500 0 3025 16000 2.14 54998 632 na 
88 45 2 1-4-2006 3 3 1 1 1 2 2 3 na 4 9 2 2600 0 858 6000 na na na na 
89 68 1 3-11-2006 1 6 1 2 2 2 2 na na 4 9 6 1800 0 288 15000 0.39 7644 278 na 
90 45 2 3-7-2006 1 10 1 2 2 2 2 10 na 4 9 5 600 0 60 4000 1.27 23241 252 na 
91 25 1 5-22-2006 1 84 1 1 1 2 2 220 na 4 9 3 1100 0 308 3000 na na 204 na 
92 68 1 7-26-2006 1 2 1 2 2 2 2 na na 4 9 5 4700 0 2256 13000 3.56 42364 237 na 
93 73 1 8-26-2006 1 3 1 1 2 2 2 15 na 4 9 6 3100 0 1364 7000 1.29 24668 296 na 
94 70 1 7-1-2006 3 3 1 2 2 2 2 na na 4 9 4 7900 0 5372 9000 na na 2610 na 
95 63 1 8-11-2006 3 na 9 9 9 9 9 na na 9 9 4 4600 0 1978 15000 3.58 45266 379 na 
96 20 1 9-20-2006 1 1 1 1 1 2 2 3 na 4 9 6 2300 0 184 6000 1.84 36616 235 na 
97 60 2 9-13-2006 3 2 1 2 2 2 2 6 na 4 9 5 3400 0 1020 10000 4.89 61125 517 na 
98 45 2 9-6-2006 1 3 1 1 2 2 2 10 na 4 9 6 3300 0 990 26000 3.28 109224 388 2150 
99 55 2 10-4-2006 1 48 1 1 1 2 2 46 na 1 9 5 4100 0 1353 6000 2.99 65481 429 9350 
100 19 2 10-6-2006 1 3 1 2 2 2 2 3 na 4 9 9 3700 0 703 30100 na na na na 
101 45 2 11.21.2006 1 2 1 2 2 2 2 4 na 4 9 4 3400 0 1564 91000 1.89 51975 340 na 
102 55 1 11.11.2006 1 na 9 9 9 9 9 na na 9 9 12 6500 0 2990 144000 3.06 96696 562 na 
103 47 1 11-4-2006 3 2 1 2 2 2 2 6 na 4 9 4 3800 0 912 17000 1.17 51363 345 na 
104 61 2 5-10-2006 1 6 1 1 1 2 2 25 20 4 9 2 2500 0 1500 3000 1.04 14248 366 na 
105 30 1 11.17.2005 1 4 1 2 2 2 2 3 na 4 9 5 13800 0 4968 64000 3.71 98686 1801 na 
106 46 2 6-14-2005 3 6 1 2 2 2 2 3 na 4 9 8 5700 0 1311 13000 2.41 65311 492 na 
107 40 1 10.28.2005 3 na 1 2 2 2 2 na na 4 9 4 5300 0 742 14000 na na 681 na 
108 38 1 2-25-2005 1 4 1 2 2 2 2 30 na 4 9 9 3200 0 1056 4000 0.99 27225 245 na 
109 48 1 11-1-2004 1 4 1 2 1 2 2 6 na 1 1 11 5300 0 2014 28000 1.61 46690 557 na 
110 38 1 6-21-2005 1 24 1 2 2 2 2 31 na 4 9 5 9000 0 3330 42000 2.14 41088 531 333 
111 40 1 4-1-2005 1 10 1 1 2 2 2 12 na 4 9 5 1300 0 780 7000 1.44 27360 454 na 
112 72 1 5-31-2005 1 1 1 2 2 2 2 2 na 4 9 6 3000 0 1110 13000 1.88 na 345 na 
113 40 2 2-22-2005 1 4 1 2 1 2 2 14 na 4 9 3 1400 0 224 21000 1.01 24543 541 na 
114 23 1 3-22-2005 1 1 1 2 1 2 2 1 na 1 1 5 2300 0 414 7000 2.21 37791 610 na 
115 18 2 5-17-2005 3 24 1 2 2 2 2 12 na 4 9 7 5400 0 2106 30000 3.57 74970 833 428 
116 50 1 8-19-2005 3 1 1 1 1 2 2 5 9 4 9 4 6800 0 2312 14000 3.44 133472 342 na 
117 68 1 1-22-2005 1 3 1 2 2 2 2 5 na 4 9 4 7800 0 1638 225000 0.8 14400 348 na 
118 41 2 11-26-2005 1 7 1 2 2 2 2 5 na 4 9 3 6200 0 2542 73000 3.63 90387 899 270 
119 56 2 7-27-2005 1 3 1 1 2 2 2 2 5 4 9 7 4800 0 4224 11000 2 72200 367 na 
120 30 1 10-26-2005 1 11 1 2 2 2 2 na na 1 3 6 3900 0 858 11000 3.51 56511 478 na 
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81 9 9 4 2 6 2 2 2 2 2 3 2 2 0.5 1 4 1 3 2 4 2 4 
82 9 9 4 2 3 2 2 2 2 2 2 2 2 0.5 1 4 2 4 2 4 1 2 
83 9 9 9 2 3 1 2 2 2 2 2 2 2 0.5 1 3.5 1 4 2 4 2 4 
84 9 9 4 2 4 0 2 2 1 1 3 3 3 1 2 4 2 4 2 4 1 2 
85 9 9 4 2 2 1 1 2 2 3 3 2 2 0.5 1 4 2 4 2 4 1 4 
86 9 9 9 2 4 4 2 2 2 2 2 9 9 na 9 na 2 4 2 4 2 4 
87 9 9 9 2 5 2 2 4 2 2 2 2 2 0.5 1 3.5 1 2 2 4 2 4 
88 9 9 4 2 1 0 1 2 2 2 2 9 9 na 9 na 2 4 2 4 1 4 
89 9 9 9 2 4 1 2 2 2 2 2 4 4 1.5 3 6 1 4 2 4 2 4 
90 9 9 3 2 3 0 1 2 2 2 2 3 3 1 2 5 2 4 2 4 1 4 
91 9 9 4 2 4 0 1 2 2 3 2 4 4 1.5 3 6 1 4 2 4 2 4 
92 2 9 4 2 4 0 1 2 2 3 1 2 2 0.5 1 3.5 2 4 2 4 2 4 
93 9 9 4 1 3 0 1 4 2 2 2 9 9 na 9 na 2 4 2 4 1 4 
94 9 9 9 2 1 0 2 4 3 2 2 2 2 0.5 1 3.5 2 4 2 4 1 4 
95 9 9 4 1 5 0 2 2 2 2 1 9 9 na 9 na 2 4 2 4 1 4 
96 9 9 4 2 4 1 2 2 2 2 2 2 2 0.5 1 4 2 4 2 4 1 4 
97 9 9 4 2 1 0 2 2 2 3 2 9 9 na 9 na 2 4 2 4 1 2 
98 2 1 4 2 4 4 1 2 2 2 1 2 2 0.5 1 4.5 1 2 2 4 2 4 
99 9 2 4 2 7 0 9 2 2 2 2 2 2 0.5 1 3.5 1 4 2 4 2 4 
100 9 9 4 2 4 1 2 1 2 2 2 2 2 0.5 1 2.5 1 1 2 4 2 4 
101 9 9 4 4 7 2 2 2 2 2 3 3 3 1 2 4 2 4 2 4 2 4 
102 9 9 4 4 4 0 2 2 2 2 2 2 2 0.5 1 1 2 4 2 4 2 4 
103 9 9 4 2 1 0 1 4 2 3 3 2 2 0.5 1 3.5 2 4 2 4 2 4 
104 9 9 4 2 3 0 2 4 2 2 1 2 2 0.5 1 3.5 1 4 2 4 2 4 
105 2 9 4 2 3 2 1 2 2 2 1 2 2 0.5 1 3 2 4 2 4 1 2 
106 9 9 4 2 1 1 2 2 2 2 1 4 5 1.5 3 6 1 1 2 4 2 4 
107 9 9 4 2 9 na 9 2 2 2 9 2 2 0.5 1 4 1 3 2 4 2 4 
108 9 9 9 2 2 0 1 2 2 3 2 2 2 0.5 1 3 1 2 2 4 1 2 
109 2 9 4 2 4 1 2 2 2 2 2 9 9 na 9 na 1 2 2 4 2 4 
110 9 9 4 2 4 1 2 2 2 3 3 2 2 0.5 1 3.5 1 2 2 4 2 4 
111 9 9 4 2 3 0 9 2 2 2 2 2 2 0.5 1 4 1 3 2 4 2 4 
112 9 9 4 2 4 2 9 2 2 2 3 2 2 0.5 1 3.5 2 4 2 4 1 4 
113 9 9 4 2 4 1 2 2 2 2 3 4 5 1.5 3 7 2 4 2 4 1 4 
114 9 9 1 2 4 2 2 2 2 2 2 2 2 0.5 1 4 1 4 2 4 2 4 
115 1 2 4 4 1 1 9 2 2 2 2 4 4 1.5 3 5.5 1 2 2 4 2 4 
116 9 9 9 4 1 0 2 2 2 2 2 4 4 1.5 3 5.5 1 1 2 4 2 4 
117 9 9 4 2 4 0 2 2 2 3 1 2 1 0 1 1.5 1 2 2 4 1 3 
118 2 9 4 2 2 0 2 2 1 3 1 2 2 0.5 1 3 1 2 2 4 1 2 
119 9 9 9 4 4 0 1 2 2 3 3 2 2 0.5 1 3.5 2 4 2 4 2 4 
120 9 9 4 2 4 na 9 2 2 2 9 2 2 0.5 1 3.5 1 3 2 4 2 4 
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81 2 4 1 1 2 4 2 4 1 6-22-2006 8-3-2006 22 10-24-2007 1 23 10 2 
82 2 4 2 4 2 4 2 4 2 2-14-2007 na 18 8-13-2008 2 15 14 9 
83 2 4 2 4 2 4 2 4 4 na na 18 6-29-2006 2 1 7 9 
84 1 3 2 4 2 4 2 4 2 4-9-2007 4-26-2010 21 12-15-2011 2 2 14 9 
85 2 4 2 4 2 4 2 4 4 na na 18 1-12-2006 2 2 7 9 
86 2 4 2 4 2 4 1 4 4 na na 18 3-1-2006 2 15 7 9 
87 2 4 2 4 2 4 2 4 2 4-11-2006 8-14-2009 1 3-15-2011 2 1 8 9 
88 1 3 2 4 2 4 2 4 4 na na 18 2-7-2006 2 3 7 9 
89 2 4 2 4 2 4 2 4 4 na na 18 4-20-2006 2 1 7 9 
90 2 4 2 4 2 4 2 4 4 na na 18 3-12-2006 2 3 7 9 
91 2 4 2 4 2 4 2 4 4 na na 18 5-26-2006 2 1 7 9 
92 1 2 2 4 2 4 2 4 2 1-23-2007 10-1-2009 4 3-2-2010 2 4 6 9 
93 2 4 2 4 2 4 2 4 4 na na 18 8-29-2006 2 3 7 9 
94 2 4 2 4 2 4 2 4 4 na na 18 8-25-2006 2 2 7 9 
95 2 4 2 4 2 4 2 4 4 na na 18 9-18-2006 2 2 7 9 
96 2 4 2 4 2 4 2 4 4 na na 18 9-22-2006 2 2 7 9 
97 2 4 2 4 2 4 2 4 2 1-12-2007 na 18 1-12-2007 2 3 6 9 
98 2 4 2 4 2 4 2 4 2 12-7-2006 na 18 1-27-2009 2 1 14 9 
99 2 4 2 4 2 4 2 4 4 na na 18 10-6-2006 2 1 7 9 
100 2 4 2 4 2 4 2 4 1 3-8-2007 na 18 3-8-2007 2 1 1 9 
101 1 4 2 4 2 4 2 4 4 na na 18 12-27-2006 2 4 7 9 
102 2 4 2 4 2 4 1 4 4 na na 18 11-21-2006 2 15 7 9 
103 1 3 2 4 2 4 1 4 4 na na 18 12-5-2006 2 6 7 9 
104 2 4 2 4 2 4 2 4 4 na na 18 6-16-2006 2 1 7 9 
105 2 4 2 4 2 4 2 4 2 2-28-2006 na 18 3-2-2006 2 2 12 9 
106 2 4 2 4 2 4 2 4 1 12-12-2006 na 18 11-8-2011 2 1 1 9 
107 2 4 1 3 2 4 2 4 3 na na 18 12-17-2005 1 8 4 2 
108 1 3 2 4 2 4 2 4 2 11-25-2005 na 18 8-25-2006 2 2 6 9 
109 2 4 2 4 2 4 2 4 2 4-26-2005 10-24-2006 1 10-24-2006 2 1 8 9 
110 2 4 2 4 2 4 2 4 2 9-1-2005 12-6-2011 1 3-5-2012 2 1 6 9 
111 2 4 2 4 2 4 2 4 3 na na 18 6-25-2005 1 1 3 9 
112 2 4 2 4 2 4 2 4 4 na na 18 6-14-2005 2 2 7 9 
113 2 4 2 4 2 4 2 4 4 na na 18 3-10-2005 2 3 7 9 
114 2 4 2 4 2 4 2 4 4 na na 18 4-6-2005 2 1 7 9 
115 1 3 2 4 2 4 2 4 2 10-11-2005 na 18 11-8-2005 2 1 17 9 
116 2 4 2 4 2 4 2 4 1 12-28-2007 na 18 1-17-2012 2 15 1 9 
117 2 4 2 4 2 4 2 4 2 6-1-2005 na 18 2-17-2006 2 1 14 9 
118 2 4 2 4 2 4 2 4 2 10-31-2007 na 18 9-19-2008 2 3 14 9 
119 1 3 2 4 2 4 2 4 3 na na 18 9-6-2005 2 4 3 9 
120 2 4 1 1 2 4 2 4 1 1-20-2006 na 18 7-3-2012 2 15 1 9 
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121 27 1 6-15-2004 1 8 1 1 1 1 2 25 na 9 9 13 4400 0 660 1000 0.3 na 553 na 
122 63 1 6-16-2004 1 4 1 2 2 2 2 12 na 4 9 10 6400 0 3584 21000 0.6 na 757 na 
123 72 1 1-4-2004 1 2 1 2 1 1 2 4 na 4 9 6 1300 0 702 45000 0.4 na 354 na 
124 56 1 7-27-2004 1 6 1 2 1 2 2 2 na 4 9 5 1900 0 912 54000 1.2 na 558 1079 
125 44 2 12-17-2004 1 12 1 2 2 2 2 24 na 4 9 6 2200 0 572 54000 0.69 11520 718 na 
126 18 1 7-10-2004 1 3 1 1 1 2 2 15 na 4 9 3 2400 0 600 6000 0.1 na 254 na 
127 50 2 7-10-2004 1 6 1 1 2 2 2 12 na 9 9 10 4500 0 1485 10000 0.05 na 432 na 
128 24 2 3-9-2004 1 4 1 1 2 2 2 19 na 4 9 10 4600 0 1500 21000 3.5 na 477 na 
129 45 1 8-31-2004 1 4 1 1 1 2 2 10 na 4 9 6 2700 0 540 12000 2 na 275 na 
130 73 2 4-25-2003 1 1 1 2 2 2 2 9 9 4 9 10 3100 0 1085 32000 1 na 349 na 
131 23 1 6-13-2003 1 12 1 1 2 2 2 9 na 4 9 6 3400 0 884 11000 1.5 na 247 na 
132 40 2 6-24-2003 1 6 1 1 2 2 2 28 na 4 9 5 4700 0 1551 11000 1.3 na 427 na 
133 55 1 9-26-2003 1 2 1 2 1 2 2 4 na 4 9 9 3300 0 1352 40000 3 na 580 na 
134 69 1 11-14-2003 1 48 1 2 2 2 2 11 na 4 9 11 6400 0 2048 39000 0.6 na 535 na 
135 26 1 7-1-2003 1 3 1 2 1 2 2 4 na 4 9 7 1400 0 280 140000 2.5 na 788 na 
136 36 2 8-18-2003 1 6 1 2 1 2 2 1 na 4 9 7 200 0 0 69000 2 na 1191 na 
137 46 2 11-5-2003 1 1 1 1 1 2 2 2 2 4 9 6 1500 0 30 11000 0.1 na 680 na 
138 38 1 10-31-2003 1 6 1 2 1 2 2 20 na 4 9 5 3500 0 735 63000 1 na 267 na 
139 43 1 4-25-2003 3 1 1 2 2 2 2 3 na 4 9 7 4700 0 1457 11000 0.4 na 680 na 
140 63 1 11-10-2001 1 6 1 2 2 2 2 5 na 4 9 4 900 0 108 2000 0.3 na 346 na 
141 62 1 8-13-2002 1 6 1 1 1 2 2 9 na 4 9 8 5200 0 3900 8000 0.7 na 534 na 
142 30 1 9-11-2002 1 6 1 1 2 2 2 9 na 4 9 5 6400 0 3456 9000 3.4 na 438 na 
143 58 1 10-26-2002 1 3 1 2 2 2 2 3 na 4 9 6 1300 0 728 20000 1.2 na 306 na 
144 26 2 11-12-2002 1 12 1 1 1 2 2 10 na 4 9 6 2800 0 1344 31000 1.3 34060 332 na 
145 44 2 7-19-2002 3 12 1 2 2 2 2 4 na 4 9 6 4500 0 2925 103000 6 na 298 na 
146 49 1 9-20-2002 1 2 1 1 2 2 2 2 na 4 9 7 8200 0 4018 10000 2 na 326 na 
147 35 1 7-1-2002 1 6 1 1 2 2 2 6 na 4 9 6 3700 0 925 14000 1.2 na 367 na 
148 24 1 10-22-2002 1 7 1 1 2 2 2 3 na 4 9 6 2400 0 1968 50000 1.2 na 284 na 
149 22 1 5-15-2001 1 3 1 1 2 2 2 13 na 4 9 5 3700 0 444 3000 2.3 na 650 na 
150 38 1 6-5-2001 1 4 1 2 2 2 2 3 na 4 9 8 4100 0 738 16000 0.6 na 420 na 
151 21 1 9-10-2001 1 6 1 1 1 2 2 6 na 4 9 2 1500 0 360 5000 0.2 na 280 na 
152 38 1 12-4-2001 1 3 1 2 2 2 2 5 na 9 9 8 1600 0 480 7000 2.41 na 312 259 
153 57 1 3-23-2001 1 1 1 1 1 2 2 4 na 4 9 10 1100 0 240 21000 1.8 na 459 na 
154 44 1 10-17-2001 1 3 1 2 2 2 2 7 na 4 9 9 6100 0 1586 48000 4.4 na 1189 3302 
155 71 2 7-26-2001 1 6 1 2 2 2 2 5 na 4 9 4 4600 0 1702 207000 1.44 na 479 na 
156 41 1 8-24-2001 1 4 1 1 2 2 2 4 na 4 9 3 2000 0 400 13000 3.04 na 518 na 
157 22 1 9-11-2001 1 6 1 2 2 2 2 8 na 4 9 9 6300 0 2898 19000 3.16 na 411 na 
158 58 1 9-30-2000 1 4 1 2 2 2 2 4 na 4 9 6 4000 0 1600 50000 0.2 na 457 na 
159 46 1 4-21-2000 1 18 1 2 2 2 2 6 na 9 9 3 1800 0 468 2000 4 na na Na 
160 52 1 4-25-2000 1 5 1 2 1 1 2 3 na 9 9 6 3700 0 1850 24000 1.74 na na na 
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Sl 
no: DCT ANA BBVS 
BM 
Celllarity Dysplasia Blast% RS Megs Mye Ery Reticulin 
Cyt-
IPSS/WPSS 
Cyt 
IPSS-
R 
IPSS 
score 
WPSS 
score 
IPSS-
R 
score CSA 
CSA-
res ATG 
ATG-
res Andr 
Andr-
res 
121 1 9 4 2 7 2 2 2 2 2 2 9 9 na 9 na 1 2 2 4 1 4 
122 9 9 4 2 4 3 9 2 2 2 3 9 9 na 9 na 1 4 2 4 2 4 
123 9 9 4 2 7 2 9 2 2 2 3 3 3 1 2 5 2 4 2 4 2 4 
124 9 9 4 2 4 1 9 2 2 2 2 3 3 1 2 4 2 4 2 4 2 4 
125 9 9 4 2 2 1 9 2 2 2 3 9 9 na 9 na 1 3 2 4 2 4 
126 9 9 9 2 2 3 9 2 2 3 3 4 4 1.5 3 7 1 4 2 4 2 4 
127 9 9 9 1 4 1 9 2 2 2 1 9 9 na 9 na 1 2 2 4 2 4 
128 9 9 4 2 2 1 1 2 2 2 2 2 2 0.5 1 3.5 1 4 2 4 2 4 
129 9 9 4 2 2 0 9 2 2 2 2 9 9 na 9 na 1 2 2 4 1 2 
130 9 9 4 2 3 1 1 2 2 2 3 2 2 0.5 1 3 1 4 2 4 2 4 
131 9 9 9 2 2 0 9 4 2 2 3 9 9 na 9 na 2 4 2 4 1 4 
132 9 9 9 2 2 1 9 2 2 2 2 2 2 0.5 1 3.5 1 3 2 4 1 2 
133 9 9 4 2 2 1 9 2 2 2 2 2 2 0.5 1 3 1 2 2 4 2 4 
134 9 9 4 2 2 1 1 2 2 2 3 2 2 0.5 1 2 1 2 2 4 2 4 
135 2 2 4 2 4 0 9 2 2 2 2 2 2 0.5 1 3 1 4 2 4 1 3 
136 1 2 4 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
137 9 9 4 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 1 4 
138 2 2 4 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 1 2 
139 9 9 9 2 6 0 9 2 2 2 2 2 2 0.5 1 3.5 1 4 2 4 2 4 
140 9 9 4 2 4 0 9 2 2 2 3 4 4 1.5 3 6 2 4 1 4 2 4 
141 9 2 4 2 4 0 2 2 2 3 2 2 2 0.5 1 3.5 2 4 1 2 1 3 
142 9 9 4 2 2 2 1 2 2 3 9 9 9 na 9 na 2 4 2 4 1 4 
143 9 9 4 2 4 0 1 2 2 2 3 4 4 1.5 3 6 1 2 1 3 1 3 
144 9 9 4 2 4 0 9 2 2 3 2 2 2 0.5 1 3.5 2 4 2 4 1 2 
145 9 9 9 2 6 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
146 9 9 9 2 2 1 2 2 2 2 2 9 9 na 9 na 1 4 2 4 2 4 
147 9 9 4 4 2 2 9 2 2 3 2 9 9 na 9 na 2 4 2 4 1 4 
148 9 1 4 2 2 1 2 2 2 3 3 2 2 0.5 1 3.5 2 4 2 4 1 3 
149 9 9 4 2 2 1 9 2 2 2 2 9 9 na 9 na 2 4 2 4 1 2 
150 9 9 4 2 2 2 9 1 2 2 3 4 4 1.5 3 6 2 4 2 4 1 2 
151 9 9 4 2 4 0 9 2 2 2 2 9 9 na 9 na 2 4 2 4 1 4 
152 9 9 4 2 4 1 9 2 2 3 3 2 2 0.5 1 4 1 3 2 4 1 2 
153 9 9 4 2 2 0 9 2 2 2 3 2 2 0.5 1 3.5 2 4 2 4 2 4 
154 9 9 4 2 3 0 9 2 2 2 3 2 2 0.5 1 3 2 4 2 4 1 4 
155 9 9 4 2 2 0 9 2 2 2 2 3 2 1 2 2.5 2 4 2 4 1 4 
156 9 9 4 2 4 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
157 2 2 4 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 1 3 
158 9 1 4 2 4 0 1 2 2 2 9 9 9 na 9 na 1 2 2 4 2 4 
159 9 9 9 2 4 3 9 2 2 2 4 9 9 na 9 na 1 4 2 4 2 4 
160 9 9 9 2 2 4 9 2 2 2 4 4 4 1.5 3 6.5 2 4 2 4 2 4 
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Sl No: Pred 
Pred-
res Allo 
Allo-
res Others 
Others
-res Sup 
Sup-
res 
Respons
e DO res DO relapse 
Trt 
rela Do LFU 
Alive/Dea
d 
Drg 
LFU 
Disease 
statusLF
U 
Cause 
death 
121 2 4 2 4 2 4 2 4 2 4-1-2005 12-9-2005 21 2-22-2012 2 4 8 9 
122 2 4 2 4 2 4 2 4 4 na na 18 6-18-2004 2 1 7 9 
123 2 4 2 4 2 4 1 4 3 na na 18 1-24-2004 1 15 4 2 
124 2 4 2 4 1 2 2 4 2 9-10-2004 11-13-2004 14 11-22-2004 1 24 8 2 
125 2 4 2 4 2 4 2 4 3 na 8-5-2005 20 9-2-2005 1 20 4 9 
126 2 4 2 4 2 4 2 4 4 na na 18 7-12-2004 2 1 7 9 
127 2 4 2 4 2 4 2 4 2 5-17-2005 na 18 12-12-2012 2 1 12 2 
128 2 4 2 4 2 4 2 4 4 na na 18 3-12-2004 2 1 7 9 
129 2 4 2 4 2 4 2 4 2 4-26-2005 na 18 10-2-2012 2 15 14 9 
130 2 4 2 4 2 4 2 4 4 na na 18 4-25-2003 2 1 7 9 
131 2 4 2 4 2 4 2 4 4 na na 18 6-14-2003 2 2 7 9 
132 2 4 2 4 2 4 2 4 2 5-13-2004 na 18 5-13-2004 2 3 17 9 
133 2 4 2 4 2 4 2 4 2 1-2-2004 na 18 1-2-2004 2 1 17 9 
134 2 4 2 4 2 4 2 4 2 1-1-2011 na 18 12-10-2012 2 15 5 9 
135 1 2 2 4 2 4 2 4 2 11-20-2003 na 18 7-23-2004 2 1 15 9 
136 2 4 2 4 2 4 1 4 4 na na 18 8-24-2003 2 6 7 9 
137 2 4 2 4 2 4 2 4 4 na na 18 11-13-2003 2 3 7 9 
138 2 4 2 4 2 4 2 4 2 2-28-2004 na 18 2-28-2004 2 2 11 9 
139 2 4 2 4 2 4 2 4 4 na na 18 4-29-2003 2 1 7 9 
140 2 4 2 4 2 4 1 4 3 na na 18 3-4-2002 1 1 4 2 
141 2 4 2 4 2 4 2 4 2 11-16-2002 6-11-2007 1 7-29-2008 2 1 8 9 
142 2 4 2 4 2 4 2 4 4 na na 18 9-11-2002 2 2 7 9 
143 2 4 2 4 2 4 2 4 3 na na 18 6-19-2003 1 13 4 3 
144 2 4 2 4 2 4 2 4 2 9-10-2003 8-12-2008 19 5-19-2010 2 1 8 9 
145 1 2 2 4 2 4 2 4 2 9-1-2002 na 18 2-6-2003 2 15 14 9 
146 2 4 2 4 2 4 2 4 4 na na 18 9-25-2002 2 1 7 9 
147 2 4 2 4 2 4 2 4 3 na na 18 10-5-2002 2 2 3 9 
148 2 4 2 4 2 4 2 4 3 na 3-5-2004 6 3-5-2004 1 6 8 9 
149 2 4 2 4 2 4 2 4 2 9-7-2001 na 18 9-7-2001 2 2 12 9 
150 2 4 2 4 2 4 2 4 2 9-10-2001 na 18 9-10-2001 2 2 16 9 
151 2 4 2 4 2 4 2 4 4 na na 18 9-17-2001 2 2 7 9 
152 2 4 2 4 2 4 2 4 2 2-11-2003 10-31-2006 20 11-1-2006 1 20 8 9 
153 1 4 2 4 2 4 2 4 4 na na 18 3-29-2001 2 4 7 9 
154 1 3 2 4 2 4 2 4 3 na na 18 12-28-2001 2 2 3 9 
155 2 4 2 4 2 4 2 4 4 na na 18 7-27-2001 2 3 7 9 
156 1 4 2 4 2 4 2 4 3 na na 18 7-20-2002 1 18 4 1 
157 2 4 2 4 2 4 2 4 3 na na 18 11-1-2001 2 2 3 9 
158 2 4 2 4 2 4 2 4 2 12-15-2000 12-12-2005 21 12-18-2007 1 24 8 9 
159 1 3 2 4 2 4 2 4 3 na na 18 7-26-2000 2 1 3 9 
160 2 4 2 4 2 4 1 3 3 na na 18 5-16-2000 1 18 4 2 
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Sl 
No 
Ag
e Sex DOD 
WH
O gr 
Du 
Sy
m 
Pallo
r 
Blee
d 
InfectIo
n 
Live
r 
Splee
n 
P
C 
PR
C 
h/o 
cytopeni
a 
Trt 
res 
H
b WBC 
Blas
t % 
AN
C PLT 
Reti
c 
AR
C 
LD
H 
FERITI
N 
161 50 2 7-28-2000 3 12 1 2 1 2 2 1 na 9 9 4 4100 0 2870 4000 3.9 na 321 na 
162 30 1 11-14-2000 1 2 1 1 2 2 2 na na 4 9 9 4100 0 2829 22000 2 na 511 na 
163 24 2 5-25-1999 3 24 1 2 2 2 2 3 na 9 9 9 2900 0 899 52000 na na 390 na 
164 35 1 9-28-1999 1 2 1 1 1 2 2 0 na 9 9 8 2300 0 276 3000 2.2 na na na 
165 49 2 7-6-1999 1 9 1 1 2 2 2 6 na 9 9 11 4800 0 1920 17000 na na 605 na 
166 38 1 10-1-1999 1 4 1 1 2 2 2 12 na 9 9 10 3300 0 792 3000 1.25 na 520 na 
167 46 1 9-22-1998 1 1 1 2 1 2 2 0 na 9 9 4 2400 0 384 9000 0.5 na 512 na 
168 34 2 4-29-1998 1 2 1 2 1 2 2 4 na 9 9 9 2200 0 880 25000 0.1 na 469 na 
169 38 1 6-26-1998 1 1 1 2 2 2 2 3 na 9 9 5 2200 0 660 21000 2.2 na 1020 na 
170 56 2 7-7-1998 1 3 1 2 2 2 2 4 na 9 9 5 2300 0 598 5000 0.3 na 466 na 
171 26 2 9-22-1998 1 60 1 2 2 2 2 15 na 9 9 5 10000 0 1000 25000 1.5 na 297 na 
172 50 1 1-27-1998 1 6 1 2 1 2 2 20 na 9 9 6 1100 0 44 72000 0.8 na na na 
173 70 1 11-13-1998 1 6 1 1 2 2 2 7 na 9 9 9 3400 0 1224 1000 0.2 na 501 Na 
CODING 
SEX:  
 
1=male 
2=Female 
 
 
WHO group 
 
1=RCMD 
2=RAEB1 
3=MDS-U 
 
Pallor, Bleeding, 
Infection, Liver, Spleen: 
1=yes  
2=No 
9=NA 
 
h/o cytopenia 
1=AA 
2=Bicytopenia 
3=MDS fibrosis 
4=Nil 
9=NA 
Treatment response 
1=CR 
2=PR 
3=NR 
9=NA 
 
Hb in g% 
ANC,WBC,ARC  & Platelet:  /cumm,  
LDH - mg% 
Ferritin- ng/ml 
 
 
 
 
 
 
Sl 
No: DCT ANA BBVS 
BM 
Celllarity Dysplasia Blast% RS Megs Mye Ery Reticulin 
Cyt-
IPSS/WPSS 
Cyt 
IPSS-
R 
IPSS 
score 
WPSS 
score 
IPSS-
R 
score CSA 
CSA-
res ATG 
ATG-
res Andr 
Andr-
res 
161 9 9 4 4 1 0 9 2 2 2 4 2 2 0.5 1 3.5 2 4 2 4 2 4 
162 9 9 4 2 4 1 1 2 2 2 1 3 3 1 2 4.5 2 4 2 4 2 4 
163 9 9 9 2 1 0 9 2 2 2 4 9 9 na 9 na 2 4 2 4 2 4 
164 9 9 9 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
165 9 9 9 4 2 1 9 2 2 2 2 9 9 na 9 na 2 4 2 4 2 4 
166 9 9 9 2 4 0 9 2 2 2 2 2 2 0.5 1 3.5 2 4 2 4 2 4 
167 9 9 9 4 2 1 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
168 9 9 9 2 2 1 9 2 2 2 3 3 4 1 2 5 2 4 2 4 2 4 
169 9 9 9 2 2 1 9 2 2 2 3 9 9 na 9 na 2 4 2 4 2 4 
170 9 9 9 4 2 0 9 2 2 2 1 9 9 na 9 na 2 4 2 4 2 4 
171 9 9 9 2 2 1 9 2 2 2 3 3 3 1 2 4.5 2 4 2 4 2 4 
172 9 9 9 2 2 0 9 2 2 2 1 9 9 na 9 na 2 4 2 4 2 4 
173 9 9 9 2 2 0 9 2 2 2 3 9 9 na 9 na 2 4 2 4 1 4 
CODING 
DCT & ANA: 
1=postive  
2=Negative 
3=nil 
9=NA  
 
BBVS: 
1=HBV+ 
2=HCV+ 
3=HIV+ 
4=Negative 
9=NA 
BM cellularity: 
1=aplasticc 
2=Hypocellular 
3,4,5,6=Varyingly hypo 
 
 
Dysplsia: 
1=one lineage 
2=bilineage 
3=Trilineage 
 
 
Reticulin: 
1=Normal 
2=Mild increase 
3=mod increase 
4=marked increase 
9=NA 
Drugs: 
1= yes 
2=No 
 
 
 
Response to drug: 
1=CR 
2=Stable 
3=NR 
4=NA 
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Si No: Pred 
Pred-
res Allo 
Allo-
res Others 
Others-
res Sup 
Sup-
res Response DO res DO relapse 
Trt 
rela Do LFU Alive/Dead 
Drg 
LFU 
Disease 
statusLFU 
Cause 
death 
161 2 4 2 4 2 4 1 2 2 2-9-2001 na 18 2-9-2001 2 18 17 9 
162 1 3 1 3 2 4 2 4 3 na na 18 2-24-2001 1 8 4 2 
163 2 4 2 4 2 4 2 4 4 na na 18 10-1-1999 2 18 7 9 
164 2 4 2 4 2 4 2 4 4 na na 18 10-1-1999 2 18 7 9 
165 2 4 2 4 2 4 1 2 2 5-1-2000 1-30-2003 18 3-30-2003 1 18 8 1 
166 2 4 2 4 2 4 2 4 4 na na 18 10-1-1999 2 18 7 9 
167 2 4 2 4 2 4 2 4 4 na na 18 3-1-1999 2 18 7 9 
168 2 4 2 4 2 4 1 2 2 5-1-1999 na 18 12-10-2012 2 15 5 9 
169 2 4 2 4 2 4 2 4 4 na na 18 6-26-1998 2 18 7 9 
170 2 4 2 4 2 4 2 4 4 na na 18 8-1-1998 2 18 7 9 
171 2 4 2 4 2 4 2 4 4 na na 18 9-22-1998 2 18 7 9 
172 2 4 2 4 2 4 2 4 3 na na 18 9-1-1998 1 18 4 2 
173 2 4 2 4 2 4 2 4 4 na na 18 11-13-1998 2 2 7 9 
CODING 
Drug: 
1=yes 
2=No 
 
 
Response to drug: 
1=CR 
2=Stable 
3=NR 
4=NA 
Over all response  
1=CR 
2=Stable 
3=NR 
4=NA    
1= Dead 
2=Alive 
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paper text: 
A retrospective study of the clinical profile 21and outcome of adult patients with  
Hypoplastic Myelodysplastic syndrome  (hMDS) 21in a tertiary centre in India.  
Review of  Literature 64INTRODUCTION: Myelodysplastic syndromes (MDS) are  
a very heterogeneous group of clonal hematopoietic stem cell disorders  that 
represents a spectrum of diseases characterized by; ineffective erythropoiesis and marrow failure 
limited by acute leukemias, chronic leukemias and myeloproliferative disorders at one end of the 
spectrum, in which hypercellular marrow is typical, to aplastic anemia at the other end (1–3). 
Hypoplastic Myelodysplastic syndromes (hMDS) refers to a morphological entity in which the bone 
marrow cellularity is low for the age (<30% cellularity if age is <60 years or <20% cellularity if age is 
>60 years) (2). It represents approximately 10-15% of all MDS cases (2,4–9). Hypoplastic MDS 
however, does not represent a defined MDS category according to the WHO classification, but it 
rather denotes the morphologic status of other MDS categories (2). It is difficult to distinguish hMDS 
from acquired aplastic anemia (AA), 13because of considerable clinical, histologic, and  
cytologic similarities between the two disorders  (10). Patients with hMDS tend to be 
younger, have more profound thrombocytopenia and neutropenia, lower percentage of blasts, lower 
probability to evolve to leukemia, and they are less likely to display abnormal karyotype, compared 
to patients with normocellular or hypercellular MDS (1,2,6,11). Compared to AA, hMDS have a 
23poorer prognosis and have frequent karyotypic and FISH abnormalities and are  
prone to  conversion to acute myeloid leukemia (12). The prognosis for hMDS 23falls  
between that of severe and very severe AA patients  (12). The pathophysiology of 
hMDS is not very well known. Evidence suggests that immune mediated mechanisms may play a 
role (5). 4This subtype is most likely to respond to treatment with  
immunosuppressive agents  (13). Other than a few case reports and small case series, 
there are no published data on the clinical profile and 29response to treatment in patients  
with hypoplastic MDS  from India. DEFINITION: MYELODYSPLASTIC SYNDROMES: The 
22myelodysplastic syndromes (MDS) are a group of clonal haematopoietic stem  
cell diseases characterized by cytopenia(s), dysplasia in one or more of the  
myeloid cell lines, ineffective haematopoiesis, and increased risk of  
development of acute myeloid leukemia (AML) (14). The enhanced degree of  apoptosis 
in these disorders contribute to the cytopenia(s) (14). The thresholds for cytopenias 
3recommended in the IPSS (International Prognostic Scoring System) for risk  
stratification in MDSs are as follows (14); - Hemoglobin< 10g% - Absolute neutrophil  
count < 1800/mm3, and - Platelets <100,000/mm3. If definite morphologic and / or cytogenetic 
findings are present, 3values above the thresholds are not exclusionary for a  
diagnosis of MDS  (14). There may be increase in myeloblasts 3in the peripheral  
blood or bone marrow accompanying the dysplasia,  but the number is <20% (7,14). 
HYPOPLASTIC MYELODYSPLASTIC SYNDROMES: 4Usually, patients with MDS have  
a hypercellular bone marrow (5,14) . In a minority of the cases  (~10 - 15% of cases), the 
4cytopenia is associated with a hypoplastic bone marrow  (2,4–9,14). Hypoplastic 
Myelodysplastic syndromes (hMDS) refers to a morphological enitity in which the bone marrow 
cellularity is low for the age (<30% cellularity if age is <60 years or <20% cellularity if age is >60 
years) (2,5,14). In these cases distinguishing between hMDS and 4aplastic anemia may be  
difficult; the presence of  a hypocellular marrow with features of dysplasia in one or more 
cell lines, increase in reticulin content on bone marrow trephine, increase in number of blasts/CD 
34+ cells on bone marrow trephine, or abnormal karyotype showing malignant clonal cells, all favor 
the diagnosis of hMDS (2,3,5,6,9,14–16). EPIDEMIOLOGY: According to the WHO classification, 
hMDS does not represent a defined MDS category, but rather denotes the morphologic status of 
other MDS categories. Patients with hMDS tend to be younger (2) than those with 
normo/hypercellular MDS. The median age of patients with hMDS have been reported between 39 
and 58 years (1,12), where as in normo/hypercellular MDS the age ranges from 60 and 75 years 
(1,5,9,14). Maschek H et al reported a higher median age (72.6 years; range;33-88 years) in patients 
with hMDS (9). The non-age adjusted annual incidence of MDS (including hMDS) reported is 3-
5/100,000 persons, rising to over 15-50 /100,000 in those over 70 years of age (5,9,14) in the US 
population. The reports suggest that the sex distribution is balanced, although there are studies 
reporting a male preponderance in the hMDS group (1,5,9,14). There is no published data on the 
exact prevalence or incidence of hMDS among Indian population. In a study of 30 cases of MDS 
(April 1998 to May 2006 ) reported from India by Shah NM et al, the mean age at presentation was 
55 years (range 8-73 years) with a male preponderance (1,17). A recent initiative is the ‘Indian MDS 
registry’ aimed at analyzing the different aspects (epidemiology, clinico-pathology, diagnosis, 
therapeutic protocols and outcome) of MDSs among the Indian population. ETIOLOGY AND 
PATHOGENESIS: The exact pathophysiology of hMDS is not known; there are multiple, complex 
and poorly understood mechanisms involving abnormalities in the regulation of cellular proliferation, 
maturation, and survival (2,5,18). 63Association of hMDS with increasing age  
suggests a genetic damage caused by hazardous exposure or inherited  
susceptibility  (14,18). In hypoplastic MDS, marrow failure results not only from 
16ineffective erythropoiesis of abnormal clones, but also due to the inhibition of  
normal progenitors  (2). 16There is increasing experimental and clinical  
indication of an immune-mediated damage to the hematopoietic precursors and  
changes in the hematopoiesis-supporting microenvironment contributing to the  
development of  the disease (2). 16Immunosuppressive therapy with anti-
thymocyte globulin, cyclosporine, or alemtuzumab may alleviate cytopenias and  
induce cytogenetic remission in some instances  (2). However, all patients do not 
16respond to immunosuppression. Identification of relevant biomarkers for an  
immune mechanism  may help in identifying those patients who may benefit from 
immunosuppressive therapy (5,18). IMMUNOLOGICAL CHANGES IN hMDS (2) As observed in 
aplastic anaemia, abnormalities indicative of an active immune process mediated by a Th1-cell 
response are observed in MDS, including hMDS. These include; 1. Abnormal Cytokine Profile (2): a. 
High 67levels of tumor necrosis factor -α (TNF-α).  b. Over-expression of TNF-related 
apoptosis-inducing ligand (TRAIL) - preferentially targets abnormal clonal cells with aberrant 
chromosomes, inducing apoptosis. c. Lower levels of FLIP, a cytoplasmic inhibitor of apoptosis; this 
explains the higher sensitivity to TRAIL in cytogenetically abnormal clones. d. Over-expression of 
Interferon-γ (INF-γ) by bone marrow mononuclear cells in MDS. Both IFN-γ and TNF-α activate the 
expression of iNOS (induced nitric oxide synthase), which potentially mediate the dysregulation of 
haematopoiesis in MDS through Fas-mediated apoptosis. The cytokine expression profile may also 
have prognostic significance. In a recent study, interleukin-4 (IL-4) and C-C motif chemokine 3 
(CCL3) serum levels were consistently under- expressed in MDS and independently associated with 
survival (2) . 2. T-Cell Mediated Attack (2): There are strong laboratory evidence suggesting that the 
marrow failure is the result of an antigen-driven lymphocyte destruction of the haemopoietic tissue. 
An expansion of cytotoxic T cells expressing defined T-cell-receptor (TCR) Vβ chain, indicating the 
oligoclonality of the T-cell repertoire is observed in these patients as well as in MDS. These skewed 
T-cell populations are observed to reduce or disappear after response to immunosuppressive 
therapy. Conversely, the dominant T-cell clone persists after treatment in those who fail treatment. 
The antigens triggering the immune response in MDS are not known. Patients with trisomy 8 often 
respond to immunosuppression, indicating a strong immunological mechanism for the underlying 
marrow failure. In patients with trisomy 8, the CD8+ T cells are able to recognize WT1 peptides and 
engage INFγ expression in vitro, suggesting that this antigen may contribute to elicit an immune 
response. Whether WT1 antigenicity may be used therapeutically is still unknown (2). 3. Genetic 
factors: As observed in several auto-immune disorders, HLA-DR15 antigen is overrepresented in 
patients with acquired AA, MDS with refractory anaemia, and in patients with MDS bearing a PNH 
clone These observations taken together further suggest that some MDS cases are immune- 
mediated (2). Aplastic anaemia and hMDS also may share genetic defects. Gene mutations 
encoding the telomerase complex (responsible for maintaining the length of telomeres), resulting in 
excessive telomere shortening in hematopoietic progenitors, are found in some cases of apparently 
acquired aplastic anaemia (2,9). The observation that a small subset of patients with hMDS respond 
to androgenic steroids, support this theory. These patients also often evolve to hMDS and acute 
myeloid leukemia. Acquired aplastic anaemia patients with shorter telomeres (lowest quartile for 
telomere length) are those with higher risk to evolve to MDS, especially monosomy 7 (2). CLINICAL 
FEATURES: Majority of patients (i.e.50%), 42are asymptomatic at the time of initial  
diagnosis (5,14), with the  median age of presentation in the fourth to sixth decade (1,17). 
These patients 71present with signs and symptoms secondary to  the cytopenia(s), while 
some 71are diagnosed on a routine blood count. The  dominant findings in hMDS include 
4anemia, thrombocytopenia, and leukopenia, either alone or in any combination,  
resulting from progressive hematopoietic failure (5,14). At the time of diagnosis, 66anemia is  
an almost universal characteristic  finding, with > 4280% of patients presenting  
with a hemoglobin level <10 g/dl and a reduced reticulocyte count  (5,14). In 25-30% of 
patients, the blood leukocyte count is low, and the granulocytes may exhibit features of dysplasia 
(5,14). 4One third of the individuals have recurrent infections,  due to 
granulocytopenia as well as the 4result of defects of neutrophil function (i.e. impaired  
chemotaxis & reduced phagocytic activity)  (5,14). Thrombocytopenia and the 
concomitant platelet function defect results in bleeding manifestations which may include 
4mainly petechiae, gum bleeding, or hematoma following trivial injuries;  with <10% 
of patients presenting with serious bleeding (i.e. gastrointestinal bleed, macro hematuria, 
menorrhagia, 66or retinal or central nervous system hemorrhage)  (5,14). 
DIAGNOSTIC WORK-UP Patients with hMDS have more profound thrombocytopenia and 
neutropenia, lower blast percentage, and one less likely to display an abnormal karyotype in 
comparison to patients with normo / hypercellular MDS. Diagnosis of low grade MDS is not always 
straight forward despite the well-established diagnostic criteria and ever-expanding battery of 
molecular and cytogenetic diagnostic assays. The reasons for such difficulty are multiple, i.e. inter-
observer disparity in documenting extent of dysplasia, (especially when dysplasia is mild to 
moderate) and the frequent lack of detectable chromosomal abnormalities (19). The most difficult 
part in the diagnosis of hMDS is differentiating it from acquired aplastic anemia. The diagnostic 
work-up of hMDS includes morphologic evaluation of peripheral blood, bone marrow aspirate, and 
bone marrow biopsy specimens, interpreted in the context of an adequate clinical information and 
CBC results (18). Correlation with marrow cytogenetics is essential. A normal karyotype however 
does not exclude a diagnosis of an MDS (18). Recently multiparameter flow cytometry has proven to 
be an important diagnostic tool, especially when added to cytomorphology (CM) and cytogenetics 
(CG) in patients with suspected MDS (19,20). Blood and bone marrow morphology and 
immunohistochemistry: Although MDS can be suspected from the clinical history and the peripheral 
blood counts, the 69diagnosis is often made by morphologic inspection of the  
peripheral blood, bone marrow aspirate, and bone marrow  biopsy specimen (18). The 
current World Health Organization (WHO; 2008) system approach is a more comprehensive one, 
which stresses the importance of integrating other techniques; ie bone marrow biopsy histologic 
examination, molecular genetics, and cytogenetics in the light of relevant clinical information (18). 
Morphologic dysplasia is not necessarily synonymous with an MDS. To address the issue of “false-
positive” myelodysplasia, the current WHO classification system recommends that, to declare a 
dysplasia of a particular lineage, at least 10% of cells in the lineage has to be morphologically 
dysplastic (14,18). Specific criteria for dysplasia in the three different cell lineages are detailed in the 
table in Appendix 1 (Table: 1 in Appendix 1) below (14,21). The presence of dysgranulopoiesis and 
dysmegakaryopoiesis favor the diagnosis of hMDS over AA. Blasts: The 56percentage of  
blasts in the bone marrow is important for the diagnosis, classification and  
prognostication of  MDS. It is also an integral component of the currently used prognostic 
scoring systems; ie 49International Prognostic Scoring System (IPSS), WHO  
classification–based prognostic scoring system and the  more recent revised 
International Prognostic Scoring System (IPSS-R) (18). Immature cells to be included in the blast 
count include myeloblasts (with and without a few fine azurophilic granules), megakaryoblasts and 
monoblasts, promonocytes are considered as “blast equivalents” in the WHO classification scheme 
(14,18). It may be hard to appreciate blast in marrow biopsy specimen, particularly if there is marrow 
fibrosis (14,18). Immunohistochemical (IHC) stain for CD34 antigen may be very helpful in such a 
situation (14,18). Additional markers used to facilitate visibility of CD34– blasts include; CD117, 
lysozyme, and CD68 (14,18). The blasts seen in MDS, are often myeloperoxidase negative or only 
weak positive (18). Flow cytometry may help in confirming the immunophenotype and assessing the 
frequency of blasts. In addition, side scatter abnormalities (due to granulocyte hypogranularity) and 
aberrant antigen expression have also been shown to correlate with the severity of the MDS (18). 
Aplastic anemia can be distinguished from hMDS by the presence of a decreased number of CD34+ 
cells and reduced 13expression of proliferating cell nuclear antigen (PCNA) in bone  
marrow  (10). The presence of increased reticulin content on silver staining on trephine biopsy 
favors the diagnosis of hMDS over AA. CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES: 
To classify MDSs, a number of morphological classifications are in place; the most recent one being 
the WHO classification (2008 Revision, 4th ed) (22). The current WHO 3classification of  
MDS is principally based on the blast percentage in the peripheral blood and bone  
marrow, and the type and degree of dysplasia  (14,18). In particular, the extent of 
dysplasia, multilineage vs unilineage, 56and the presence of ring sideroblasts  
(assessed by iron staining) have important roles in the WHO sub-classification (14,18). The absence 
of monocytosis (monocytes <1,000/μL in the blood and <5% in bone marrow) is important to 
distinguish between CMML (chronic myelomonocytic leukemia), and MDS (18). 29The WHO  
Classification of Myelodysplastic Syndromes  (table below), recently published, 
distinguishes the following MDS subtypes (14,18): 25(1) Refractory cytopenia with  
unilineage dysplasia (RCUD); subcategories- Refractory anemia (RA), Refractory  
neutropenia (RN), & Refractory thrombocytopenia (RT); (2) Refractory anemia  
with ring sideroblasts (RARS); (3) Refractory cytopenia with multilineage  
dysplasia (RCMD); (4) Refractory anemia with excess blasts (RAEB), with  
subcategories RAEB-1 & 2. (5) MDS, unclassifiable (MDS-U); and (6) MDS with isolated del (5q) 
chromosomal abnormality. The WHO 2008 classification of MDS is detailed in Appendix 1 (Table:2 
in Appendix 1). Hypoplastic MDS: In about 10-15 % of patients with myelodysplastic syndromes, the 
bone marrow is hypocellular, referred to as ‘hypoplastic MDS’ (5,14,18). This group do not have 
independent prognostic significance per se (14,18). The major problem is in the differential diagnosis 
with aplastic anemia. Toxic myelopathies and auto-immune disorders should be excluded when a 
diagnosis of hypoplastic MDS is considered (5,14,18). According to the WHO classification, 
Hypoplastic MDS however, does not represent a defined MDS category, but it rather denotes the 
morphologic status of other MDS categories (2,14,18). MDS with fibrosis: In 3a small subset  
of patients (~10%) with  MDS, 3significant degrees of myelofibrosis are  
observed  (14). These are 3referred to as MDS with fibrosis. Most of these  
cases have excess blasts and an aggressive clinical course  (14). In the fibrotic 
group, due to inadequate aspirate, most often blast determination requires immunohistochemical 
studies (for CD34 on the trephine biopsy) (14). Multiparameter Flow Cytometry (MFC) in MDS: The 
5current World Health Organization classification of MDSs is based on  
morphological evaluation of bone marrow dysplasia. The reproducibility of the  
recognition of dysplasia is poor in  clinical practice, 5especially in cases where  
specific markers such as ring sideroblasts and clonal cytogenetic abnormalities  
are lacking (23,24). In patients with MDS, a recent complementary DNA microarray analyses on 
CD34+ hematopoietic progenitor cells have found that MDS, including the early-stage/low-grade 
MDS, is characterized 72by a B-cell progenitor defect  (19). Many 72genes  
involved in B-lymphocyte development  are down- regulated (19). This observation was 
validated by the flow cytometric finding that in a small number of MDS patients, the maturing B-
lineage precursors (hematogones) are reduced (19,23). 36Recently a multiparameter flow  
cytometric scoring system has been validated5for the diagnosis of  
myelodysplastic syndrome. This encompass four reproducible parameters i.e.  
CD34+ myeloblast-related and B-progenitor- related cluster size (defined by  
CD45 expression and side scatter characteristics on CD34+marrow cells),  
myeloblast CD45 expression and granulocyte side scatter value (23). A5flow  
cytometric score may help to establish the diagnosis of myelodysplastic  
syndrome, especially when morphology and cytogenetics are indeterminate  (i.e. 
early-stage/low- grade MDS). The calculations of 5flow cytometric score for the  
diagnosis of low-risk  MDS is detailed in Appendix 1 (Table: 3 in Appendix 1). Cytogenetic 
and molecular studies: Molecular and cytogenetic 3studies have a major role in the  
evaluation of patients with myelodysplastic syndrome with regard to prognosis,  
determination of clonality and recognition of morphologic, cytogenetic and clinical  
correlates (5,14). Clonal cytogenetic abnormalities are usually observed in ~ 50% of  
cases  of MDS (and upto 80% of cases with mutagen-related MDS) (5,14). A study by Vundinti 
BR et al (25) reported 54.48% 60chromosome abnormalities including novel  
chromosome aberrations in patients with and that these chromosome aberrations  
increased with advancing age.27Cytogenetic changes observed in MDS are not  
unique to the disease; both numerical and structural cytogenetic changes may occur.  
Most frequent chromosomal abnormalities observed involve, deletions of  
chromosomes 5, 7, 11, 12, and 20 and/or trisomy 8  (5,14). The chromosomal 
aberrations and its frequencies are described in detail in table in Appendix 1 (Table:4 in Appendix 1) 
Detection of certain chromosomal abnormalities, either by routine cytogenetic analysis or FISH, aids 
in the classification of MDS and determination of the prognostic risk group (5,14). With occasional 
exceptions (i.e. 5q- syndrome/MDS with isolated del(5q)), chromosomal abnormalities in MDS have 
not correlated with specific clinical or morphological subsets using the WHO classification system 
(5,14). 62Deletion of the long arm of chromosome 5 (5q) is the most common  
chromosomal abnormality seen in MDS (in  15% of cases). Cytogenetic and molecular 
analysis has led to the identification of two small commonly deleted regions; i.e. del (5q33.1) which 
is most commonly associated with the 5q minus syndrome with a relatively good prognosis, and del 
(5q31), which is more commonly seen with therapy-related MDS and is associated with more 
aggressive disease. MDS with 5q minus syndrome occur primarily in women, and is characterized 
by refractory macrocytic anemia, normal or increased platelet count, megakaryocytes with non-
lobated or hypolobated nuclei, a favorable clinical course & good response to lenalidomide treatment 
(14). Cytogenetics as a predictor of prognosis: Cytogenetic abnormalities have an impact on 
outcomes in patients with MDS. The abnormalities are risk categorized into 3 different cytogenetic 
categories 34in the international prognostic scoring system (IPSS) and WHO  
prognostic scoring system,  and into 5 groups in the recent revised IPSS (IPSS-R) (26) . 
The risk categories, their risk for progression to AML and median survival for the different groups are 
as follows; Cytogenetic subgroups in the IPSS & WPSS for adults with MDS. Prognostic subgroups 
Cytogenetic abnormality 25 % AML progression Median survival 3Good risk Normal  
karyotype, isolated del(5q), del(20q), or –Y  5.6 years 3.8 years Intermediate risk Other 
abnormalities 1.6 years 2.4 years Poor risk -7/del(7q), or complex 0.9 years karyotypes(≥3 abn) 0.8 
years The 5 cytogenetic risk categories and their median OS in the revised IPSS (IPSS-R) are as 
follows; Cytogenetic subgroups in the IPSS-R for adults with MDS Prognostic Subgroups 
Cytogenetic abnormality Median OS 19Very Good del(11q),-Y 60.8 months Good Normal,  
del(20q), del(5q) alone and double, del(12p) 48.5 months Intermediate +8, 7q-,  
i(17q), +19, +21, any other single or double, independent clones 25.0 months Poor  
der(3)q21/q26-7, double including 7q-, 15.0 months complex (3 abnormalities Very  
poor Complex (>3 abnormalities)  5.7 months GENE MUTATIONS: Abnormalities in 
certain genes have been identified in patients with MDS and acute myeloid leukemia with or without 
the presence of chromosomal abnormalities. These include mutations in TET2, ASXL1, TP53 tumor 
suppressor gene, RUNX1 transcriptional core-binding factor gene(CBF), IDH gene, FLT3 gene and 
SF3B1 genes. These gene mutations also confer prognostic significance in adult patients with MDS, 
for instance, it has been reported that patients with TET2 mutations may have higher response rates 
to azacitidine than those without the mutations (26). PROGNOSIS & RISK STRATIFICATION: 
Myelodysplastic syndromes, in view of the 50progressive impairment in the ability of the  
myelodysplastic stem cells to differentiate,  are clinically characterized by an increased 
44risk of evolution into acute myeloid leukemia (AML) (27). The natural history of  
MDS ranges from indolent conditions spanning years to rapid progression to  
leukemia.  The probability of leukemic evolution is lower in hMDS (1,6) than the normo-
/hypercellular MDS (NH-MDS) (1,2,6), but compared to AA, hMDS have poorer prognosis with 
frequent karyotypic and FISH abnormalities and a higher probability of leukemic evolution. As the 
prognosis of patients with MDS is very heterogeneous, development of a prognostic system 
1that allow risk stratification and help in the timing and choice of therapy  is 
essential (26). 1A number of prognostic scores are currently in use,  and these 
include; a. IPSS (International Prognostics Scoring System): This is the most commonly used score 
and has been in use since 1997 (26). Prognostic score includes, the number of cytopenias, 
percentage of blasts, and the type of cytogenetic abnormality (26). Based on this scoring system 
there are 4 prognostic risk categories; i.e. 45‘Low’ (score:0), ‘Intermediate-1’ (score  
:0.5-1), ‘Intermediate-2’ (score:1.5-2) and ‘High risk’ (score:≥2.5).  IPSS is highly 
reproducible 1and very simple to use, but has several limitations;  i.e. 1it is not  
a very precise predictor of prognosis in those with lower risk disease and it  
attributes relatively little weight to cytogenetics  (26). The IPSS scores, prognostic risk 
categories and their clinical outcomes (in terms of survival and risk of transformation to AML) are 
detailed in Appendix 1 (Table:5 in Appendix 1). b. Revised international score (IPSS-R) : This score 
presented at the 2011 MDS Meeting in Edinburgh, incorporates a new cytogenetic score and 
includes different cut off for cytopenias (26). Prognostic score includes, the type of cytogenetic 
abnormality, percentage of blasts, hemoglobin level, platelet count and ANC (absolute neutrophil 
count) (26). Based on this systems, there are 5 prognostic risk categories i.e. 70‘Very low’  
(score:≤ 1.5), ‘Low’ (score:.1. 5-3), ‘Intermediate’ (score:>3-4. 5), ‘High’ (score: >4.5-
6) and ‘Very high’ (score:>6) risk groups. The IPSS-R scores, prognostic risk categories along with 
their clinical outcomes (i.e. survival and risk of AML transformation) are outlined in Appendix 1 
(Table: 6 in Appendix 1). c. WPSS (WHO prognostic scoring system): This is another commonly 
used system that incorporates the transfusion dependency in addition to cytogenetics and WHO 
diagnostic category (26). The main limitations of this system is that it requires, prior information of 
transfusion needs and WHO classification (26). A recent modification of the WPSS score included 
hemoglobin levels instead of transfusion needs(26). Prognostic score includes, the WHO MDS 
category, the type of cytogenetic abnormality and the transfusion requirement (26). Based on this 
system 34patients are categorized into 5 prognostic risk groups; i.e.40‘Very low’  
(score=0), ‘Low’ (score=1), ‘Intermediate’ (score=2), ‘High’ (score=3-4) and ‘Very  
high’ (score=5-6). WHO prognostic scoring system  with its clinical outcomes is detailed 
in Appendix 1 (Table:7 in Appendix 1). d. Global MDACC (MD Anderson Cancer Center) model: A 
more recent one is the 1global MDACC model that allows evaluation of all patients  
considered to have 1MDS at any time during the course of their disease without  
needed WHO evaluation(  26). The Global MDACC and MDACC MDS lower risk Prognostic 
Models are tabulated in Appendix 1 (Tables:8a & 8b in Appendix 1). e. Recently, based on the study 
on 9a cohort of 253 patients with hypocellular MDS (diagnosed at The University  
of Texas MD Anderson Cancer Center between 1993 and 2007) and a cohort of  
1725 patients with hyper-/normocellular MDS (diagnosed during the same time  
period),  a new prognostic model 9was built that segregated patients into 3  
distinct risk categories independent of International Prognostic Scoring System  
(IPSS) score (26). This model is independent from the IPSS, and further refines  
IPSS-based prognostication. It may be used to develop of risk-adapted  
therapeutic approaches for patients with hypocellular MDS  (26,28). The details of 
the prognostic model of hypoplastic MDS is tabulated in Appendix 1 (Table: 9 in Appendix 1) 
HYPOPLASTIC MDS AND APLASTIC ANAEMIA: 13Because of considerable clinical,  
histologic and cytologic similarities between these two disorders,  it is sometimes 
difficult to distinguish Hypoplastic myelodysplasia from acquired aplastic anemia (10). The presence 
of dysmegakaryopoiesis, dysgranulopoiesis, increased percentage of blasts, increased bone marrow 
reticulin content and abnormal karyotype, favour the diagnosis of hMDS. In addition, an abnormal 
antigen expression pattern in marrow CD34+ cells indicating an aberrant clone, and the presence of 
elevated haemoglobin F-containing erythroblast production suggest the diagnosis of hMDS. 
However, findings compatible with an immune process (oligoclonal T-cell expansion, relative 
lymphocytosis in the marrow and increased cytokine levels) do not contribute to differential 
diagnosis, as these elements are present in both (2). The distinction between hMDS 7and AA  
is of great prognostic and therapeutic importance. With modern therapies; ie bone  
marrow transplantation and immunosuppressive therapy,13severe AA patients  
have long term survival7(80% at 14 years), and those with moderate AA have a  
median survival of >174 months with androgen and supportive therapy;  while 
13for patients with hMDS, the median survival is not significantly different from  
hypercellular MDS  (22 to 33 months). 7Some cases of hMDS may show a  
transient response to androgens and/or immunosuppressive therapy thus  
adding further diagnostic difficulty.  Further, 13there is a higher risk of  
progression to acute leukemia in patients with hMDS compared with AA (29). Recent  
studies have  suggested that in AA, bone marrow (BM) is characterized by a decreased 
number of CD34+ cells and reduced expression of 6proliferating cell nuclear antigen  
(PCNA), which is  not a feature associated with MDS (10). A role for tumor necrosis factor-
alpha (TNF-alpha) in the development of AA has been suggested by recent studies(29). 
7Careful examination of peripheral blood, may also provide sufficient information  
to allow for the distinction between hMDS and AA early in the course of the  
disease  (30). Certain morphologic findings i.e. 7hypochromic red cells, circulating  
blasts, left shift, hypersegmentation with long filaments, Dohle bodies  
hypogranular, ring, and pelgeroid neutrophils, circulating micromegakaryocytes  
and megakaryocytic fragments  are seen only in hMDS but not in AA (30). The table 
below summarizes the major differences between hMDS and AA. (3,6,15,16,31,32). Distinction 
between hypoplastic MDS and Aplastic anemia Characteristics Dyserythropoiesis Abnormal 
neutrophil Dysplastic megakaryocytes Fibrosis Increased blasts CD34+ cells in BM Clonality 
Splenomegaly Hypoplastic MDS Yes Yes Yes Occasional Sometimes (ALIPS) Sometimes increased 
Sometimes Occasional AA Sometimes No No No No < 1.0% Possible Absent 24It is  
fortunate that the distinction is not critical since both aplastic anaemia and  
hypoplastic MDS respond to similar forms of treatment. Indeed there is close  
similarity between the two conditions and they are sometimes called ‘overlap  
syndromes’.  DIFFERENTIAL DIAGNOSES: Acquired aplastic anemia is the most important 
and difficult differential diagnosis of hMDS (discussed above). Other conditions that can present with 
cytopenia(s) and dysplastic changes include; Vitamin B12 & folic acid deficiencies, Copper 
deficiency & arsenic poisoning, medications & drugs, liver failure or hypothyroidism causing 
macrocytic anemia with a low reticulocyte count, auto-immune and other hematopoietic neoplasms, 
e.g. lymphomas, and non-hematopoietic malignancies causing para-neoplastic myelodysplasia, Viral 
infections (e.g. HIV infection,, chronic parvovirus, Epstein-Barr virus, and cytomegalovirus infections) 
and rarely, hemophagocytosis can produce marrow changes that resemble MDS (18). TREATMENT 
OF hMDS: The treatment of hMDS is similar to aplastic anemia in view of similarity in its 
pathophysiology. The options include; A. 1Options for newly diagnosed patients: In  
newly diagnosed lower risk group patients, therapy1is based on the transfusion needs  
of the patients (26). Transfusion independent patients are  usually observed until they 
become transfusion dependent (26). A new and important concept 34in the treatment of  
lower risk MDS  is early intervention in patients with ‘‘poor prognosis’’ 18lower risk  
MDS (26). To improve on the natural history of the disease,  the identification of these 
patients is going to be fundamental (26). The upcoming new prognostic scoring systems and 
development of new molecular informations for these patients will help in early identification and 
intervention (26). The list of agents currently available for treatment of patients with hMDS is as 
follows; 1. Immune therapy: Hypoplastic MDS is characterized by dysregulation of immunity, and it 
has been observed that patients with hMDS benefit from immunosuppressive therapy (26). The 
agents studied include cyclosporine-A (CSA), corticosteroids and antithymocyte globulin (ATG) 
(26,33). Standard IST is the combination of ATG & CSA (horse or rabbit ATG) with a short course 
steroid. The dose of ATG used is 40 mg/kg over 4 hours, daily for 4 days after premedication along 
with prednisolone (1 mg/kg from day 1 for 2 weeks) for serum sickness prophylaxis, and CSA (dose: 
10 mg/kg/day from day 1 to target trough level- 200 and 400 ng/ml. Cyclosporine monotherapy 
(6mg/Kg) is an easily available, and is a safe and cheap IST. The group 36at the NHLBI  
(National Heart, Lung and Blood Institute)  has developed an algorithm 1to  
predict response to these agents, i.e. younger age,  shorter duration of transfusion 
dependency and HLA-DR15 (34). Bone marrow hypocellularity is the most important predictor for 
response (35). Recently alemtuzumab (humanized 51monoclonal antibody that  
specifically kills CD52-bearing cells via both antibody-dependent cellular  
cytotoxicity & complement-mediated lysis; dose is  10 mg Alemtuzumab s/c daily x 5 
days along with CSA (2 mg/kg Q12H) x 3 months, has also been reported to have 
1significant activity in those patients with MDS predicted to respond to immune  
suppressive therapy (26,34). The1most important predictor for response has  
been the presence of marrow hypocellularity  (26,34). In 1younger patients with  
severe hypoplastic MDS, allogeneic stem cell transplantation (Allo SCT) should be  
considered as soon as possible. For those that are not candidates, a combination  
with equine ATG is recommended.  Response to immune therapy (IST) reported in 
literature is a haematologic recovery of 75- 90% after one or two courses of IST (36). A response 
rate of 68% is reported for ATG/CSA in AA, while following alemtuzumab therapy upto 57% 
response has been reported by some studies (26,33,36,37). 2. Allogeneic Peripheral blood stem cell 
transplant: 8Allogeneic hematopoietic stem cell transplantation is the treatment of  
choice in young patients with severe aplastic anemia or hypoplastic MDS. The main  
causes of failure after this procedure are graft versus host disease, infections  
and graft failure, often exacerbated by large numbers of transfusions and  
prolonged disease duration before transplant  (38). 15A less toxic regimen  
comprising reduced cyclophosphamide (Cy), fludarabine, and anti-thymocyte  
globulin (ATG) (Cy-Flu-ATG) was used to condition high-risk patients scheduled  
for allogeneic hematopoietic cell transplantation (allo HSCT) instead of standard  
Cy-ATG in patients with severe aplastic anemia (AA)  and hMDS (39). 
15Preconditioning with Cy-Flu-ATG was superior to that afforded by Cy-ATG in  
terms of reducing RRT levels without increasing engraftment failure  (39). Recent 
study by Szczylik C. et al showed 8that transplantation of hematopoietic stem cell  
using alemtuzumab, fludarabine and melphalan as a conditioning therapy is  
safe, inexpensive and effective treatment for patients with severe aplastic  
anemia, including multi-transfused adults having their disease for a long time  
(38). Five year OS following matched related and unrelated Allogeneic PBSCT reported are 73% 
and 60% respectively (36,39). 3. Androgenic steroids: Androgenic steroids i.e. Danazol (derivative of 
synthetic steroid ethisterone-17 α ethinyl testosterone; 300mg daily), Oxymetholone, and Stanazolol 
(synthetic anabolic steroid derived from testosterone; 1mg/Kg/day) have been proved to be of 
benefit in hMDS as seen in Aplastic anemia (40). 14Androgens are enzymatically  
converted into estradiol (E2) via aromatase. E2 passively diffuses into cells and  
binds theα isoform of the estrogen receptor (ERα), which acts as a transcriptional  
activator by binding to estrogen response elements (ERE) in genomic DNA. The  
telomerase reverse transcriptase (TERT) promoter contains 2 putative EREs.  
Therefore, both androgens and estrogens increase TERT expression, ultimately  
resulting in increased telomerase activity in hematopoietic cells.  Androgens also 
inhibit both interleukin-1 and TNF-a production. In patients unresponsive to IST, a response rate of 
30-35% has been reported to androgens in some studies (41). 4. Haematopoietic growth factor 
support: Currently a number of erythroid stimulating agents (ESA) are available. Reported rates of 
response to these agents range from 30 to 60% (26,42). In a retrospective observational study by 
Jadersten M et al (26,43), it was observed that addition of G-CSF to erythropoietin increased the 
response rates, and 1early introduction of this combination in patients with minimally  
transfusion-dependent and  low risk disease may have an impact on survival. In patients with 
significant anemia and with no other cytopenias, 1a course of ESA with or without G-
CSF is not contraindicated  (26). Early incorporation of these agents has been found to be 
1more effective than in patients with heavy transfusion burdens.  Due to 
complications related to disease transformation and marrow fibrosis, the use of Romiplostin in lower 
risk MDS is questionable (26). 5. Supportive care measures: The supportive care measures in 
hMDS include; 1use of prophylactic antibiotics and iron chelation. No randomized  
data exists to make formal recommendation for any of these interventions  (26). B. 
Options for 1patients with higher risk MDS: Treatment options for patients with  
higher risk MDS have significantly evolved over the last decade. Earlier most  
patients were treated with cytarabine based  therapy as for AML. Recently the use of 
azanucleosides (Decitabine & 5-Azacytidine) has modified this practice (44,45). 1Two  
candidate biomarkers and a clinical model have been proposed recently.  mutations 
on TET2 and levels of miR29b and 1have been reported to be associated with  
response to azacitidine and decitabine respectively  (26,46). 1AML-like  
chemotherapy: In higher risk MDS, AML-like protocols have generally used classical  
anthracycline-araC combinations, similar to that used in de novo AML.1AML-like  
therapy results in lower CR rates (40–60%), and shorter CR duration  (10–12 
months) 1when used in MDS or AML post-MDS.  They 1tend to be associated  
with more prolonged periods of aplasia, and in addition, due to the advanced median  
age of  the patients, the 1feasibility of AML-like therapy is also reduced  (26). 
Allogeneic Stem cell transplant: Allogeneic SCT is 1the only curative treatment of  
higher-risk MDS. Selected studies report prolonged DFS in about 30% to 50% of  
the patients. However its use is restricted mainly to younger patients with an  
appropriate donor  (26,47). RESPONSE CRITERIA: 18Definition of IWG response  
criteria in MDS: The IWG (International working group ) criteria define 4 aspects of  
responses based on treatment goals: (1) altering the natural history of the  
disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4)  
QOL  (Quality of life) (48). The responses assessed include CR 53(complete  
remission), PR (Partial remission), Stable disease, Failure, Relapse after CR or  
PR, Cytogenetic response and disease progression.  The details of the proposed 
modified International working group response criteria are described in Appendix 1 (Tables:10a & 
10b in Appendix 1). SUMMARY: Hypoplastic MDS is a distinct clinic-pathologic 43entity  
characterized by bone marrow hypoplasia, severe leucopenia and  
thrombocytopenia, macrocytosis, low incidence of progression to acute leukemia,  
and unresponsiveness to conventional therapy  (6,8). It represents approximately 10 - 
15% of all MDS cases (2,4–9,14). It is difficult to distinguish hMDS from acquired aplastic anemia 
(AA), 13because of considerable clinical, histologic, and cytologic similarities  
between the two disorders  (1,6,10,14). However, compared to AA, hMDS have 
23poorer prognosis and frequent karyotypic and FISH abnormalities (prone to  
leukemic conversion) (12). The Pathophysiology of hMDS is not very well known; auto-reactive and 
4clonal-involved T-cells are believed to suppress the normal hematopoietic cells  
by secretion of inhibitory cytokines (5). This subtype is most likely to respond to  
treatment with immunosuppressive agents;  therapy with antithymocyte 31globulin  
(ATG), cyclosporine (CSA) or both  has been shown good response in patients with 
hMDS (13). Aims and objectives: 1. To analyze the clinical profile of adult patients with Hypoplastic 
Myelodysplastic syndrome (hMDS). 2. To assess the response to different drug therapies in patients 
with hMDS. 3. To identify the demographic, clinical, and laboratory parameters that can predict 
prognosis in hMDS. Patients and 20Methods This study protocol was approved by our  
Institutional Review Board  (IRB). 20This is a retrospective analysis of patients  
diagnosed  to have hMDS from January 1998 to June 2012. Duration of the study: October 
2012 to December 2012. Settings of the study: Department of Clinical Haematology. Diagnostic 
criteria: Hypoplastic MDS was diagnosed in patients presenting with cytopenia(s) (defined as per the 
recommendation in the IPSS for risk stratification in MDSs (i.e. Hemoglobin <10g%, Absolute 
neutrophil count <1800/mm3, and Platelets <100,000/mm3) associated with a hypoplastic bone 
marrow for the age (2,5,14), and with features of dysplasia in one or more cell lines, with or without 
increase in number of blasts/CD 34+ cells on bone marrow, or increase in reticulin content on bone 
marrow trephine, or abnormal karyotype showing malignant clonal cells (all favoring diagnosis of 
hMDS) (2,3,5,6,9,14–16). Patients: Inclusion Criteria: 1. All adult patients (age≥18yrs) diagnosed to 
have hypoplastic myelodysplastic syndrome from January 1998 to June 2012 Exclusion Criteria: 1. 
Patients with other types of Myelodysplastic syndromes. 2. Patients with hMDS whose data are not 
retrievable. 3. Patients on drugs that can cause dysplasia (e.g. post renal transplant patients) 4. 
Patients with hypoplastic cytopenia(s) and positive test for PNH, or positive stress cytogenetic test 
(clastogenic stress-induced chromosomal breakage). Methods: Collection of data: After approval by 
the IRB, the patient data base at our institution was reviewed to identify all patients diagnosed to 
have hypoplastic MDS at our institute between January 1998 to June 2012. Medical information 
regarding the clinical/laboratory details at diagnosis, post treatment response and adverse events 
were obtained from the hospital records (laboratory reports/ physician documentation in hospital 
charts/hospital discharge summaries). Attempts were made to contact all patients by post or e-mail 
to collect details on any missing data as well as the recent clinical status. Only patients who had at 
least 8 weeks follow up (including those who died within 8 weeks) after initiating therapy were 
categorized as ‘evaluable‘ for assessment of response and survival. Treatment: Various treatment 
modalities that the patients received were reviewed. This included; Cyclosporine, anti-thymocyte 
globulin + CSA, androgenic steroids, corticosteroids, supportive measures, and 30allogeneic  
peripheral blood stem cell transplant, and a  few had received haematopoietic growth 
factors or lenalidomide. Data was collected with regard to type of treatment, duration of treatment, 
side effects and overall outcome with respect to the treatment given. Data analysis: Results are 
analyzed in terms of the clinical characteristics and laboratory parameters at diagnosis, response to 
the different treatment regimens [drug(s)], the survival patterns and the prognostic effects of patient 
characteristics on overall survival. The response to treatment is assessed in terms of Complete 
Remission (CR), Stable disease, Relapse, Progression of disease, No response, and failure/death. 
17CR was defined as the absence of any clinical sign of disease  and attainment of 
the following haematological parameters i.e. pperipheral blood Hb ≥ 3811 g/dL, Platelets  
≥100 x109 /L, Neutrophils ≥1.0 x109 /L, Blasts - 0%.  Patients with 38failure to  
achieve at least CR, but with no evidence of progression for >8  weeks were 
considered to have ‘Stable disease’. Relapse after CR was defined as reduction of values by 
31≥50% from maximum remission/response levels in granulocytes or platelets,  
and or reduction in Hb concentration by ≥1.5 g/dL or transfusion dependence.  
Progression of  disease was defined as any 39one of the following i.e. (1) At least  
50% decrement from maximum remission /response in granulocytes or platelets,  
(2) Reduction in Hb by≥ 2 g/dL, (3) Transfusion dependence  (Tables:10a & 10b in 
Appendix 1). All patients started on treatment and with a minimum follow up of 8 weeks 
17were considered evaluable for response and outcome.68Overall survival (OS)  
was measured from the start of therapy until death (from any cause)17or last  
follow-up (49–51). Event-free survival (EFS) was calculated from the start of  
therapy until the first adverse event, i.e. relapse or progression, secondary  
malignancy, death from any cause, or last follow- up  (49–51). 28Progression-
free survival (PFS) for all patients was taken from the start of therapy until  
disease progression or death from  hypoplastic myelodysplastic syndrome (49–51). 
41Disease-free survival (DFS) for patients in CR was measured from the first  
recording of response (CR or Stable disease) to the date of progression  or relapse (49–
51). The closing date for analysis was December 31, 2012. Statistics: Descriptive statistics were 
calculated for all variables. Differences in proportions were assessed using the chi-square statistic or 
37Fisher exact test. Differences in means were tested using a t-test or Mann-
Whitney-U test as appropriate. Survival curves were drawn by the Kaplan-Meier  
method and compared by the  log-rank test. The relationships of clinical features to the 
outcome of the procedure 20were analyzed by univariate Cox proportional Hazard  
model.57For all tests, a 2 -sided P-value of 0.05 or less was considered  
statistically significant.  SPSS 16.0 software 6was used for the analysis.  
RESULTS: Between January 1998 and June,  30, 2012, 11a total of 54413 out  
patients were seen in the  Haematology department, of which 1225 (2.3%) were diagnosed 
to have primary MDS. Of this, 173 (14.1% of MDS; 0.32% of total patients) were diagnosed to have 
hypoplastic MDS. The year wise distribution of total MDS and hMDS is depicted in Figure:1. All 
patients (n=173) were included for the analysis of baseline characteristics. Out of the total 173 
patients, only 111 (64.2%) who had a follow up of >8 weeks after initiation of treatment 26were  
considered ‘evaluable’ for assessment of response to treatment and  for survival 
analysis. Certain data are available on all patients, while certain data are available only on a portion 
of the patients. For each result category, the numbers of patients involved are mentioned. 
DEMOGRAPHY & CLINICAL FEATURES AT DIAGNOSIS: (Table:1) The median age of the 173 
patients was 41 years (range: 18-64). Seventy two (41.6%) 10patients belonged to the  
age group  of 18-40 years, 51 (29.5%) to 41-55years and 50 (28.9%) were above 55 
21years of age. Males were predominantly represented in the  study group i.e. 112 
35(64.7%) males and 61 (35.3%) females. The male female ratio was 1.8:1.  Pallor and 
bleeding manifestations were the common presenting symptoms; i.e. in 94.2% (n=163) and 40.5% 
(n=70) respectively. Sixty six (38.2%) patients had history of infections (mainly recurrent febrile 
episodes; a few had lower respiratory tract and skin infections). 33The median duration of  
symptoms was 3 months (range: 1-  120). Clinical examination showed mild (<2cms) 
splenomegaly in 6 patients (3.5%) and mild hepatomegaly (<2cms) in 2 (1.2%) patients. Forty eight 
patients (27.7%) had received previous treatment. This included,. CSA (n=8), Azathioprine (n=2), 
Anabolic steroids (n=8), Prednisolone (n=11), EPO 30(n=2), GCSF (n=1) or Lenalidomide  
(n=1)30for a median duration of 60 days (range: 7-720). Among the 173 patients,  139 
had received transfusions (packed red cells and or platelet rich concentrates) before presenting to 
our Institution. 10The median number of transfusions per month was 2 (range;1-  20) 
units. Fourteen patients (8.1%) had past history of treatment for cytopenias; 11 patients were 
diagnosed and treated for Aplastic anemia before the diagnosis of hMDS was made. 65The  
median time from diagnosis of AA to diagnosis of hMDS was 38 months  [range:4-149]. 
Among them, 2 each had attained CR or PR and were off therapy for a mean period of 53 months 
(range: 28-91). The remaining 7 remained symptomatic and were diagnosed to have hMDS on re-
evaluation. The twelfth patient was diagnosed to have B12 deficiency with bicytopenia 6 years back 
and had been lost to follow up while on B12 & folate supplementation; a second patient (male; 
23yrs) was diagnosed to have Chloramphenicol induced pancytopenia 12 years back which had 
resolved. The last patient (female; 61yrs) was diagnosed to have MDS with fibrosis 3 years back 
(hypercellular marrow with fibrosis, normal cytogenetics), was treated with thalidomide & 
prednisolone for one year followed by danazol for 2 years before she was diagnosed to have hMDS 
(with cytogenetics- del5q & WHO group RAEB-1). She was subsequently treated with Lenalidomide 
with no response and expired within 3 months of diagnosis of hMDS. LABORATORY 
PARAMETERS AT DIAGNOSIS: (Table: 2) At presentation, majority of the patients (65.3%; n=113) 
were pancytopenic, while bicytopenia was seen in 53 (30.6%) and only 7 (4.1%) had cytopenia 
involving a single lineage. The median hemoglobin for the entire cohort was 5.8g% (range:1.2-13.2); 
most of these patients (54.4%; n=94) had hemoglobin level <6g% while in 41% (n=71) the level was 
between 6.1-10g% and only 4.6% (n=8) had hemoglobin >10g% at presentation. Neutropenia (an 
absolute neutrophil count <1800/mm3) was observed in 135 (78%) patients at presentation, while 38 
(22%) had normal neutrophil count. ANC below 200/mm3 was observed in 8.7% (n=15) while ANC 
between 201- 500/mm3, 501-1000/mm3, 1000-1500/mm3, and 1501-1800mm3 was found in 16.2% 
(n=28), 22.5% (n=39), 20.8% (n=36) and 9.8% (n=17) respectively. Thrombocytopenia (platelet <100 
x109/L) was documented in 161 (93%) patients; 61.3% (n=106) had a count < 20 x109/L, while a 
count of 21-50 and 51-100 x109/L was observed in 39 (22.5%) and 16 (9.2%) patients respectively. 
The median reticulocyte percentage at diagnosis (documented in 152 patients) was 1.8% (range: 
0.05-7.06). Out of the 99 patients in whom the absolute reticulocyte count was available, the median 
absolute reticulocyte count was 37200/mm3, with 18 (18.2%) patients having an absolute 
reticulocyte count <20 x109 /L). None of the patients had monocytosis or eosinophilia. The median 
absolute eosinophil (AEC), monocyte (AMC) and lymphocyte (ALC) counts were 0/mm3 (range: 0-
966), 36/mm3 (range: 0-690) and 1656/mm3 (range: 175-8800) respectively. Data on auto-immune 
markers i.e. direct coomb’s and antinuclear antibody tests were available only in 39 and 23 patients 
respectively, with 14 (35.9%) being coomb’s positive and 8 (34.8%) positive for ANA. Serum LDH 
was documented in 160 patients, and majority (81.9%; n=131) had level <600 mg/dl. Serum ferritin 
was available in 24 patients; the median level was 825ng/ml (range: 138-46775). Report on serum 
B12 level was available in only 10 patients and the median value was 970pg/ml (range: 248-2000). 
Out of the 137 patients in whom blood borne virus screen was done at diagnosis, 3 patients were 
positive for HBV, while 1 each positive for HIV and HCV respectively. BONE MARROW FEATURES 
& WHO CLASSIFICATION AT DIAGNOSIS: (Table:3 & Figures:2a-2h] The bone marrow was 
aplastic, uniformly hypocellular or varyingly hypocellular in 5.2% (n=9), 83.2% (n=144) and 11.6% 
(n=20) of patients respectively (Fig: 2f). The data on BM blast count was available in 171 patients, 
out of which majority (46.8%; n=80) had no blasts on the aspirate and no increase in CD 34+ cells 
on the trephine biopsy. In 77 (45%) patients, the blast percentage was 1-2%, while 10 (5.8%) had 3-
4% blasts and 4 (2.4%) had ≥ 5% blasts on the marrow (Fig: 2h). Scattered ring sideroblasts (Fig: 
2e) were documented in 47 (39.2% of the 120 cases where data was available) patients and one 
had >15% ring sideroblasts. Trilineage dysplasia (Figs: 2a-d, 2f) was observed in 57 (33%) patients, 
while 36 (20.8%) patients had unilineage and 80 (46.2%) had bilineage dysplasia respectively. Data 
on bone marrow reticulin was available in 169 patients. Out of this 135 (79.9%) patients showed 
increased reticulin content (Fig: 2g) on silver stain. Most of these patients (47.3%; n=80) showed 
mild increase in reticulin, while 49 (29%) and 6 (3.6%) patients showed moderate and marked 
increase in reticulin respectively. On categorizing the patients according to the WHO classification, 
majority (77.5%; n=134) belonged to the RCMD group, with 4 (2.3%; n=4) belonging to RAEB-1 and 
35 (20.2%) belonging to the MDS unclassified (MDS-U) group. CYTOGENETIC ABNORMALITIES 
AT DIAGNOSIS: (Table: 4) Cytogenetic data was available on 116 (67%) patients. Majority (66.4%; 
n=77) had normal karyotype. Five patients had polyploidy out of which only 2 had associated 
structural chromosomal anomalies while 3 had no anomalies. Among those with chromosomal 
aberrations, 11.2% (n=13) had a sinlge abnormality, while 8 (6.9%) patients had 2 abnormalities, 3 
(2.6%) had three abnormalities and 15 (12.9%) had more than 3abnormalities/associated monosomy 
7. Among the 39 patients with chromosomal abnormalities, 55 numerical abnormalities were 
observed. Most of the numerical anomalies were monosomies (n=37), while 18 were trisomies. 
There were 13 patients (11.2%) with monosomy 7, 7 patients (6%) with trisomy 8, and 8 patients 
(6.9%) with trisomy 21. Other abnormalities noted included translocations (n=5), deletions (n=15), 
and other rare anomalies i.e. additions (n=5), derivatives (n=4) and duplications (n=1). Deletion 5q 
was observed in 7 (6%) cases. The details of each anomaly are detailed in table 4. CYTOGNETIC & 
PROGNOSTIC RISK GROUPS AT DIAGNOSIS: (Tables: 5 & 6) Cytogenetic risk groups: (Table 5) 
One hundred and sixteen patients in whom the cytogenetic reports were available, were risk 
categorized into three cytogenetic risk groups (good, intermediate and poor) as per the ‘IPSS & 
WPSS’, and into 5 risk groups (very good, good, intermediate, poor and very poor) according to the 
revised IPSS (IPSS-R ) systems. 21Majority of the patients belonged to the ‘good’  
cytogenetic risk  group, in either systems (69% [n=80] each in both), while 16.4% (n=19) and 
14.6% (n=17) 61belonged to the intermediate and poor risk cytogenetic groups  
respectively in the ‘IPSS&  WPSS’ group. Whereas in the IPSS-R group, 3 patients (2.6%) 
each belonged to ‘very good’ &‘very poor’ risk groups, while 15 (12.9%) each belonged to the 
‘intermediate’ &‘poor risk’ groups respectively. Prognostic risk groups: (Table: 6) The 116 patients 
were categorized into different prognostic risk groups using three different prognostic scoring 
systems ie; IPSS, IPSS-R and WPSS scoring systems. Using the IPSS system, majority (82.7%; 
n=96) belonged to the ‘intermediate-1’ group, while 17 (14.7%) and 3 (2.6%) belonged to the 
‘intermediate-2’ and ‘low’ risk groups respectively. There were no patients in the high risk group. 
Using the WHO classification based prognostic scoring system (WPSS), one patient (0.9%) was 
61categorized into the‘very low’ risk group,  68.1% (n=79) into ‘low’ risk group, 16.4% 
(n=19) into ‘intermediate’ risk and 14.6% (n=17) into high risk groups respectively. In the IPSS-R 
category, 2 (1.7%) patients were 32in the ‘very low’ risk group, 22 (19%) in the ‘low’  
risk,  68 (58.6%) in the ‘intermediate’ risk, 18 (15.5%) in the ‘high’ risk and 6 (5.2%) were in 
‘very high’ risk groups respectively. TREATMENT AND RESPONSE: (Table: 7) Patients who had a 
minimum of 8 weeks follow up after starting treatment (including those who expired within 2 months 
of treatment) 26were considered evaluable for assessment of response to  
treatment.  Among the total 173 patients; 111 patients (109 with >2 months follow up + 2 who 
died within 2 months of starting treatment) were considered evaluable, and the remaining 62 
26were considered non -evaluable for assessment of response to  therapy. Out of the 
111 evaluable patients, cytogenetic data was available only in 79 patients. Of the 111 evaluable 
patients, 99 received treatment with (a) Cyclosporine (CSA) or (b) Antithymocyte globulin+CSA 
(ATG+CSA) or (c) Androgenic steroids (Danazol/stanazolol) or (d) Prednisolone, or (e) Allogeneic 
PBSCT (Allo PBSCT) and 12 patients received ‘Other’ therapies (i.e. Lenalidomide or EPO/GCSF or 
supportive measures). (a) CSA (Table:7): Overall 81 patients received treatment with CSA; out of 
these only 59 were evaluable for response. Among the 59 evaluable patients, 41 showed a response 
(6 [10.2%] achieved CR while 35 [59.3%] achieved ‘stable disease’). Six (102%) patients expired 
without attaining any response and the remaining 12 showed no response to CSA. Among the 6 
patients who expired, one had progressed to AML prior to expiry. Of the non-responders, 8 were 
started on second line treatment with Androgenic steroids and 4 patients who had matched sibling 
donors were taken up for allogeneic PBSCT (detailed in the section on Allogeneic PBSCT). Among 
the responders, the 6 patients in CR continued to be in CR at last follow up. In the 35 patients with 
‘stable disease’ 24 (68.6%) continued to be in ‘stable disease’ at last follow up (6 are stable & off 
treatment, while 16 patients are stable but remain on treatment, 6and 2 were lost to follow  
up while on treatment). Of the 35 patients  with ‘stable disease’, 11 progressed while on 
follow up. One patient progressed to PNH and was started on Danazol. Another patient was started 
on danazol followed by ALG+CSA with no response (subsequently succumbed to disease 
progression and treatment failure). Of the remaining 9 patients, one expired following disease 
progression and 8 were restarted on CSA 6(2 were lost to follow up and  6 continue to be 
on follow up). While on treatment with CSA, 5 out of the total patients developed CSA related 
nephrotoxicity elevated serum creatinine, these were non-responders and was changed to 
Androgens) and 2 had gum hyperplasia. The mortality was 13.6% (n=8) among those treated with 
CSA. .Overall the response rate to CSA was 69% (41 out of 59), with mean time to response of 
5.9months (range: 3-36months), and median 11duration of treatment of 19 months  
(range:  3-126). 11At a mean follow up duration of 103 months (range: 8-110), the  
5 year  OS of the responders (n=41) was 96.9% ± 3.1%. (b) Antithymocyte globulin+CSA 
(ATG+CSA) (Table:7): 12A total of 10 patients were treated with  ATG+CSA. Of these 7 
showed response to treatment (2 CR and 5 ‘stable disease’), one patient expired without response 
and 2 showed no response. The 2 non-responders were changed over to Androgens. Among the 
responders, 2 patients who achieved CR continued to remain in CR (on CSA) at last follow up. At 
last follow up, 3 out of the 5 patients with’ stable disease’ continued to be so (2 were off treatment 
and one was on CSA) and 2 patients progressed (out of which one expired and one was continued 
on treatment). The mortality was 20% (n=2) among those treated with ATG+ CSA. Overall the 
response rate to ATG+CSA was 70% (7 out of 10), with mean time to response of 1.8 
11months (range: 1- 3 months), and median duration of  treatment of 12 months 
(range: 8-72). 11At a mean follow up duration of 58 months (range: 16-73), the 5 year  
OS of the responders (n=7) was 75.0% ± 21.7% . (c) Androgenic steroids (Danazol/stanazolol) 
(Table:7): Out of the 74 patients who received treatment with androgenic steroids (29 received 
danazol while 45 received stanazolol), 51 were evaluable. Twenty four patients (47.1%) showed 
response (2 CR & 22 ‘stable disease’), while 25 (49%) showed no response to androgens. Two 
patients (3.9%) expired without any response (out of which one expired following progression to 
AML). Of the non-responders, 4 patients were changed over to ATG+ CSA, 17 patients to CSA and 
4 52were lost to follow up. One out of the 2 patients  who attained CR continued to be in 
CR at last follow up, while the other patient relapsed and was restarted on treatment. Out of the 
patients who had stable disease, 17 continued to be stable, while 5 patients showed evidence of 
progression of disease. Two of the patients with progression of disease were restarted on treatment 
but were subsequently lost to follow up; while 3 patients expired following progression of disease 
(one patient expired following progression to AML, second one following progression of disease 
along with metastatic adenocarcinoma and the third due to disease progression). The mortality was 
9.8% (n=5) among those treated with Androgenic steroids. Overall the response rate to Androgenic 
steroids was 47% (24 out of 51), with mean time to response of 5.3months 11(range: 1- 27  
months), and median duration of  treatment of 11 months (range: 2-92). 11At a  
mean follow up duration of 68 months (range: 20-92), the 5 year  OS of the responders 
(n=24) was 51.40% ± 23.1%. (d) Prednisolone (Table:7): Twenty four patients received treatment 
with steroids, but only 17 were evaluable. Only four (23.5%) patients showed response (‘stable 
disease’) to prednisolone. One patient (5.9%) expired, while 12 (70.6%) showed no response. 
Among the 12 non-responders, treatment was changed to CSA in 7, to androgens in 4 and one 
patient was taken up for allogeneic PBSCT. Among the 4 patients who attained response to 
prednisolone, 213 were lost to follow up10after a mean follow up of 11 (7- 13)  
months, and the  fourth patient relapsed after 44 months and was then lost to follow up. 
33The median duration of steroid treatment was 4 months (range:  2-36) and the 
mean 11time to response was 1.9 months (range: 1 .3- 2 .7).  (e) Allogeneic PBSCT (Allo 
PBSCT) (Table:7): There were a total of 5 patients who underwent allogeneic PBSCT. All were 
males; with age between 19 to 56 years. One patient was diagnosed to have Aplastic anemia and 
had received treatment for 10 months prior to diagnosing hMDS. The treatment prior to allogeneic 
PBSCT included; Cyclosporine-A (CSA) for 2 months in 3 patients, CSA for 12 months in one patient 
and Prednisolone for 2 months in one patient. All except one patient had normal cytogenetics; the 
fifth patient had trisomy21 (+21). Four patients belonged to 52‘Intermediate-1’ IPSS risk  
group, ‘Low’ WPSS risk group and‘Intermediate ‘ IPSS-R risk  group; and the one patient 
with +21 belonged to intermediate-1 (IPSS), intermediate (WPSS) and intermediate (IPSS-R) risk 
groups respectively. The donors were related for all 5 patients (brother was the donor in 4 of them 
and sister in one). The conditioning regimen was Fludarabine/Cyclophosphamide in 4 patients and 
Fludarabine/Melphalan in one patient. One patient underwent second PBSCT following relapse and 
received Fludarabine/Melphalan/TBI for the second PBSCT. Two patients died before engraftment 
by day 9 and 10 post PBSCT, due to sepsis with VOD and fungal pneumonia, and sepsis with 
actinomycosis of lung respectively. Three patients engrafted (by days 11, 12 & 13 respectively). Of 
the 3 patients who engrafted, one lost response by day 52 post Allo PBSCT, and died of grade IV 
acute liver GVHD on day 77 post PBSCT. The second patient who responded (age-19yrs) relapsed 
by day 70 post PBSCT, and underwent DLI followed by a second PBSCT (using the same donor). 
He engrafted by day 11 of second PBSCT, and continued to be in CR for next one year. After a year 
post second PBSCT, he relapsed with progression to AML, and succumbed to his illness during the 
post chemotherapy (Cytosine/Idarubicin) neutropenic period due to sepsis and massive GI bleed. 
The third patient (age: 30 years) who responded is the one who was treated for Aplastic anemia for 
10 months prior to diagnosing hMDS. Post PBSCT, he developed chronic skin GVHD which 
responded to treatment. Presently he is 7 years post PBSCT, on follow up and continues to be in CR 
off drugs (except for warfarin). (f) ‘Others’: This included 12 patients (not mentioned in table: 7), who 
had received treatment with Lenalidomide (n=3) or EPO/GCSF (n=1), or only supportive measures 
(n=4), or in whom the drug was not known due to unavailable/missing data (n=4). In this group 2 
cases attained ‘CR’, 6 attained ‘stable disease’, 4 expired without response and 2 expired following 
progression of disease after initial response. Among those who received Lenalidomide, 2 attained 
‘Stable disease’, and one expired without attaining any response. The one patient who received 
EPO/GCSF progressed and expired after a short period of response (stable disease). Two out of the 
4 patients who opted for supportive measures expired following disease progression and the other 2 
showed spontaneous recovery of blood counts (CR) within 2 months and were subsequently lost to 
follow up. There were 4 cases where data on the drug were not available. One patient expired 
without response and 3 had shown initial response to treatment (stable disease). Of the 3 who 
showed response, one was lost to follow up, one patient subsequently progressed and expired, and 
the third patient who had been diagnosed and treated in 1998 was found to be stable and off drug on 
last follow up (the information was obtained by mail, documents on previous drug treatment could 
not be retrieved). TREATMENT RELATED MORBIDITY: Sixty three (36.4%) patients developed 
morbidities during treatment. Drug induced nephropathy was observed in 6 (3.5%) of the patients. Of 
these, 5 (83.3%) patients had CSA induced and one (16.7%) had analgesic induced nephropathy. 
Two patients had Cyclosporine related gum hyperplasia. Drug related hepatitis (transaminitis) was 
documented in 7 (4.0%) patients (stanazolol induced in 5 (71%) patients and Danazol induced in 
2(29%)). Three (1.7%) patients were HBV positive at diagnosis, while an additional one patient 
(0.6%) was documented to be positive for hepatitis B virus during follow up. Three (1.7%) patients 
developed lower limb Deep vein thrombosis; one among them developed pulmonary embolism. Nine 
(5.2%) developed steroid induced diabetes mellitus, of which one had Cushing’s habitus. Two 
patients (1.2%) developed tuberculosis while on treatment for hMDS (one had pulmonary 
tuberculosis and one had lymph node tuberculosis). Fourteen (8%) patients developed infectious 
complications during treatment (i.e. febrile neutropenia with/without sepsis in 10 cases, and Gram 
negative bacilli sepsis, peri-anal abscess, cellulitis and osteomyelitis in one patient each 
respectively. On follow up, 2 patients were found to have vitamin D deficiency while evaluating for 
back ache, and one of them presented with vertebral fracture. In Allo PBSCT patients, one had 
acute grade IV liver GVHD and the other had chronic skin GVHD. MORTALITY: Table: 8 Twenty six 
(15%) patients expired on follow up. Of these, 16 (61.6%) patients died because of poor response to 
treatment, while 10 patients died following disease progression/relapse after attaining response 
(‘CR’ or ‘stable disease’). Of the former 16 patients, 2 were of post Allo PBSCT status, while 2 had 
progressed to AML without attaining any response, and the remaining 14 patients died of primary 
treatment failure. Among the 10 patients who died following disease progression after CR or ‘stable 
disease’, one patient was of post Allo PBSCT status and had progressed to AML (following relapse 
after second Allo PBSCT), while a second patient was the one who had responded to androgens 
and then progressed to AML, the third patient was an initial responder to androgens who 
subsequently progressed with associated metastatic adenocarcinoma. The remaining 7 patients died 
of progressive disease. Sepsis with multi-organ failure was the immediate cause of death in 10 
patients, while 2 patients died following massive intracranial bleed, 3 following severe pneumonia 
and one following grade IV GVHD. All the remaining 10 patients died of progressive disease related 
events (details of the exact events not available). Among those patients who died of sepsis, one had 
disseminated mucor ycosis, 4 had fungal pneumonia, one had pulmonary actinomycosis, and 
another one patient had associated massive GI bleed. SURVIVAL ANALYSIS: (Figs: 4-11; Table: 9) 
Survival analysis was done for the 111 patients who were evaluable for treatment response. Among 
these, only 79 patients had cytogenetic data. 26Overall (OS), Event free (EFS),  
progression free (PFS)  and disease free survivals (DFS) (Figs: 4-7): The 6mean  
follow up was 110 months (range: 1-  178). There were a total of 26 deaths, all deaths 
were due to progressive disease and related complications. The 5 year and 10 year overall survivals 
for the whole cohort (n=173) was 61.9% ± 7.2%, and 53.1% ± 10.3% respectively. With a mean 
follow up period of 70 months (range: 1-178), the 5 year EFS for the entire cohort was 37.9% ± 
7.8%. The 5 year progression free survival 6with a mean follow up period of 86 months  
(range:1- 78) for the  entire cohort was 49.5% ± 9.3% and the 655 year disease free  
survival with33a median follow up period of 69 months (range:1- 166) was 46 .6 ± 
9.5%. OS of the different IPSS risk groups (Table: 9 and Fig:8): Among the 79 evaluable patients 
with cytogenetic data, 10with a mean follow up period of 125 months (range: 1-178) and  
34 months (range: 1-78) respectively, the  5 year OS in the lower risk groups (Low+Int-1) 
versus higher risk groups (Int-2+high) was 65.9% ± 9.7% versus 38.1% ± 20.4% respectively (P= 
0.056). OS of different WPSS risk groups (Table: 9 and Fig: 9): In the WPSS risk groups, the mean 
follow up period was 83 months (range:2-110), 92 months (range:1-178) and 34 months (range:1-
78) for the lower risk (very low + 46low risk), intermediate risk and high risk groups  
respectively. The  5 year OS was noted to be significantly higher 55in the lower risk  
groups than the  higher risk groups (Int and high risk groups ); ie Lower versus Int (5yr OS= 
66.6% ± 12.1% versus 50.5%±15.8%; P=0.026), Lower versus High (66.6%±12.1% vs 
38.1%±20.4%; 55P=0. 017). However there was no significant survival advantage for  
the intermediate risk  group over high risk group (P=0.973). OS of different IPSS-R risk groups 
(Table: 9 and Fig: 10): The mean follow up period of the IPSS-R risk groups were as follows; 83 
months (range: 2-110) for the lower risk group (very low + low + Int) and 67 months (1-178) for the 
higher risk group (high + very high). The 5 year OS of the lower risk groups (ie very low + Low + Int) 
was again significantly better than the higher risk groups (High + very high), ie; 68.0% ± 10.8% vs 
35.0% ± 15.7% (P=0.002). OS of different WHO classification groups (Fig: 11): Using the WHO 
criteria, the out of the 111 evaluable patients, 82 belonged to RCMD, 26 to MDS unclassified and 3 
to RAEB-1. 6With a mean follow up period of 109 (range:1-  82), 61(2-78) and 8.5 
(range:3-14) months, the 5 year OS was 61.2% ± 8.4%, 74.4 % ± 11.8% and 0 % ± 0% for RCMD, 
MDS-U and RAEB-1 respectively (P=0.000). UNIVARIATE ANALYSIS OF ADVERSE EFFECTS OF 
PATIENT CHARACTERISTICS ON OVERALL SURVIVAL (Table: 10) Univariate Cox proportional 
hazard 2model was used to find out significant prognostic factors for adverse  
effects on survival among overall hMDS patients. Variables  with significant adverse 
effects on overall survival included age, gender, blood counts (Haemoglobin, ANC, 48platelet  
count), number of cytopenias, serum LDH, bone marrow cellularity, bone marrow  
blast percentage,  bone marrow dysplasia, bone marrow reticulin, WHO classification groups, 
chromosome changes and prognostic risk categories (IPSS, WPSS & IPSS-R). Parameters of 
independent significance associated with poor overall survival were; ANC < 0.2 x10 /L at diagnosis 
(RR=4.2; 1295%CI=1. 32- 9 13.5 ;P= 0.  015), Bone marrow blast at diagnosis > 5% (RR=11 
12.0; 95%CI=2. 27-53.77; P= 0.  003), WHO category RAEB-1, (RR=7 12.5; 95%CI=1.  
68-34.12; P= 0.  008), Moderate/marked increase in BM reticulin, (RR=4 12.0; 95%CI=1.  
13-14.17; P= 0.  031), >3 cytogenetic anomalies, 12(RR=3. 5; 95%CI=1. 09-11.82; P=  
0.  035), Monosomy 7, 12(RR=5. 1; 95%CI=1. 54-17.03; P= 0.  008), Trisomy 21, 
(RR=14 58.4; 95%CI=2. 88-72.7; P= 0.001), WPSS intermediate risk group,12(RR=3. 3;  
95%CI=1. 11-10.00; P= 0.  031), WPSS high risk group , (RR=3.6; 1295%CI=1. 11 -12.  
00; P= 0.033), and  IPSS-R very high risk group (RR=13.5; 95%CI=2.64-69.90; 20P=  
0.002). However on multivariate analysis, none of the above parameters  retained its 
statistical significance. RESULTS - TABLES: Table 1: DEMOGRAPHY & CLINICAL FEATURES AT 
DIAGNOSIS: n =173 Variables n (%) / Median(Range) Age at diagnosis in years 18-40 72 (41.6) 41-
55 51 (29.5) >55 50 (28.9) Gender Male 112 (64.7) Female 61 (35.3) Presenting symptoms Pallor 
163 (94.2) Bleeding 70 (40.5) Infection 66 (38.2) Duration of symptoms (months) 3 (1-120) 
Organomegaly Splenomegaly 6 (3.5) Hepatomegaly 2 (1.2) Patients who received prior treatment 48 
(27.7) Median duration of previous treatment (days) 60 (7-720) Past history treatment for cytopenia 
(s) 14 (8.1) Median transfusions per month (n=139) 2.0 (1-20) . Table 2: LABORATORY 
PARAMETERS AT DIAGNOSIS n=173 Variables n (%) / Median (Range) Hemoglobin [g%] <6 6.1-
10 >10.0 Absolute neutrophil count[x109/L] 94 71 8 (54.4) (41.0) (4.6) <0.2 0.21-0.5 0.51-1.0 1.1-1.5 
1.51-1.8 >1.8 Platelet count [x109/L] 15 28 39 36 17 38 (8.7) (16.2) (22.5) (20.8) (9.8) (22.0) <20 21-
50 51-100 >100 106 39 16 12 (61.3) (22.5) (9.2) (7.0) Reticulocyte count Median Percentage of 
reticulocytes (n=152) Median Absolute reticulocytes [x109/L] (n=99) 1.8 37200 (0.05-7.06) (6175-
133472) No. of cytopenia(s) Single cytopenia Bicytopenia Pancytopenia 7 53 113 (4.1) (30.6) (65.3) 
Direct coomb’s test (n=39) Positive Negative 14 25 (35.9) (64.1) Antinuclear antibody (n=23) 
Positive Negative 8 15 (34.8) (65.2) Serum LDH [mg/dl] (n=160) <600 >600 131 29 (81.9) (18.1) 
Serum ferritin [ng/ml] (n=24) 825 138-46775) Serum Vitamin B12 [pg/ml] (n=10) 970 (248-2000) 
Blood borne virus screen (n=137) Positive Negative 5 132 (3.6) (96.4) Table 3: BONE MARROW 
FEATURES & WHO CALSSIFICATION AT DIAGNOSIS: n = 173 Variables n (%) Bone marrow 
cellularity Aplastic 9 (5.2) Uniformly hypocellular 144 (83.2) Varyingly hypocellular 20 (11.6) BM 
blasts[%] (n=171) 0 80 (46.8) 1-2 77 (45.0) 3-4 10 (5.8) ≥5 4 (2.4) BM ring sideroblasts (n=120) 
>15% 1 (0.8) Scattered/occasional 47 (39.2) Absent 72 (60.0) BM dysplasia Unilineage 36 (20.8) 
Bilineage 80 (46.2) Trilineage 57 (33.0) BM Reticulin (n=169) Normal 34 (20.1) Mild increase 80 
(47.3) Moderate increase 49 (29.0) Marked increase 6 (3.6) WHO classification MDS-Unclassified 
35 (20.2) RCMD 134 (77.5) RAEB-1 4 (2.3) 59Abbreviations: MDS: Myelodysplastic  
syndrome, RCMD: Refractory cytopenia with multilineage dysplasia, RAEB:  
Refractory anemia with excess blast.  Table 4: CYTOGENETIC ABNORMALITIES AT 
DIAGNOSIS n =116 Variables n (%) Cytogenetic abnormalities No abnormality One abnormality 
Two abnormalities Three abnormalities >3 / chromosome 7 abn 77 (66.4) 13 (11.2) 8 (6.9) 3 (2.6) 15 
(12.9) Individual chromosomal aberrations Monosomies: -7 -5 -Y -X Other monosomies@ 13 (11.2) 
2 (1.7) 3 (2.6) 2 (1.7) 17 (14.7) Trisomies: +8 +21 Other trisomies@ 7 (6.0) 8 (6.9) 3 (2.6) 
Translocations t(18;21) t(20;21) t(11;14) t(7;13;16) t(7;?) 1 (0.9) 1 (0.9) 1 (0.9) 1 (0.9) 1 (0.9) 
Deletions: del 5q del 11q del 12p del 20q Other deletions@ Other rare anomalies@ 7 (6.0) 2 (1.7) 1 
(0.9) 1 (0.9) 4 (3.4) @ Other anomalies included; monosomies ( Additions Derivatives Duplications 5 
(4.3) 4 (3.4) 1 (0.9) -1, -2,-3,-9,-10,-13,-14,-15,-16, & -19 seen in one patient each and -11, -18, &-20 
seen in two patients each), trisomies (+1, +2,+4 seen in one patient each), deletions (del 11q in 2 
patients and 1p, del 5p, del 6q, del 9q, del 12p, & del 20q seen in one patient each), additions 
(+11p,+11q,+14q,+1p, & +7q seen in one patient each), derivatives [der(7), der(12), der(14), & 
der(16 seen in one patient each) and duplication (dup1), seen in one patient. Table 5: 
CYTOGNETIC RISK GROUPS AT DIAGNOSIS n =116 IPSS&WPSS cytogenetic risk group IPSS-R 
cytogenetic risk group n (%) n (%) Very good - - 3 (2.6) Good 80 (69.0) 80 (69.0) Intermediate 19 
(16.4) 15 (12.9) Poor 17 (14.6) 15 (12.9) Very poor - - 3 (2.6) Abbreviations: 32IPSS:  
International prognostic scoring system, WPSS: WHO prognostic scoring  
system,  IPSSS-R: Revised IPSS. Table 6: PROGNOSTIC RISK GROUPS AT DIAGNOSIS: n 
= 116 Risk group IPSS WPSS IPSS-R n (%) n (%) n (%) Very low - - 1 (0.9) 2 (1.7) Low 3 (2.6) 79 
(68.1) 22 (19.0) Intermediate-1/ 96 (82.7) - - - - Intermediate - - 19 (16.4) 68 (58.6) Intermediate-2 17 
(14.7) - - - - High 0 (0.0) 17 (14.6) 18 (15.5) Very high - - - - 6 (5.2) Table 7: TREATMENT AND 
RESPONSE: DRUG GROUPS CSA ATG +CSA Androgens Prednisolone Allo-PBSCT n (%) n (%) n 
(%) n (%) n (%) Total patients (n=173) Non-evaluable Evaluable 81 (46.8) 22 (27.0) 59 (73.0) 10 
(5.8) 0 (0.0) 10 (100.0) 74 (42.8) 23 (31.0) 51 (69.0) 24 (13.9) 7 (29.0) 17 (71.0) 5 (2.9) 0 (0.0) 5 
(100.0) Response: CR Stable disease No response (LFU/drug changed) Failure (expired with no 
response) 6 (10.2) 35 (59.3) 12 (20.3) 6 (10.2) 2 (20.0) 5 (50.0) 2 (20.0) 1 (10.0) 2 (3.9) 22 (43.2) 25 
(49.0) 2 (3.9) 0 (0.0) 4 (23.5) 12 (70.6) 1 (5.9) 2 (40.0) 1 (20.0) 0 (0.0) 2 (40.0) On follow up: CR: 
Continued in CR Relapse & alive/LFU Relapse & expired Stable disease: Continued in Stable 
Progression & alive/LFU Progression & expired 6 (100.0) 0 (0.0) 0 (0.0) 24 (68.6) 9 (25.7) 2 (5.7) 2 
(100.0) 0 (0.0) 0 (0.0) 3 (60.0) 1 (20.0) 1 (20.0) 1(50.0) 1(50.0) 0(0.0) 17(77.3) 2 (9.1) 3(13.6) 0 (0.0) 
0 (0.0) 0 (0.0) 3(75.0) 1(25.0) 0 (0.0) 1(50.0) 0 (0.0) 1(50.0) 0 (0.0) 0 (0.0) 1(100.0) Duration of 
treatment-months; median(range) 19 (3-126) 12 (8-72) 11 (2-92) 4 (2-36) -- Response rate 69% 70% 
47% 23.5% 60% Time to response - months; mean (range) 5.9 (3-36) 1.8 (1-3) 5.3 (1-27) 1.9 (1.3-
2.7) 0.5 (0.4-0.5) Follow up duration –months; mean(range) 103 (8-110) 58 (16-73) 68 (20-92) 19 (7-
44) 39 (15-81) Mortality in each drug group 8 (13.6) 2 (20.0) 5 (9.8) 1 (5.9) 4 (80.0) 5 year OS of 
responders 96.9% ± 3.1% 75.0% ± 21.7% 51.4% ± 23.1% 100%** 33.3% ± 27.2% Table 8: 
MORTALITY: Variables n (%) Total number of death 26 (15.0) Disease status at death (n=26) 
Failure without any response Progression/Relapse after CR or ‘stable disease’ 16 10 (61.6) (38.4) 
Cause of death Disease failure related events (exact event unknown) Sepsis with MODS ICH Liver 
GVHD Pneumonia 10 10 2 1 3 (38.5) (38.5) (7.7) (3.8) (11.5) Table 8: OVERALL SURVIVAL OF 
DIFFERENT PROGNOSTIC RISK GROUPS. Risk group IPSS WPSS IPSS-R n (%) 5 yr OS n (%) 5 
yr OS n (%) 5 yr OS Very low - - 1 (0.9) 0% ± 0% 2 (1.7) 0% ± 0% Low 3 (2.6) 0% ± 0% 79 (68.1) 
66.6% ±12.1% 22 (19.0) 73%±14% Intermediate-1/ 96 (82.8) 68.3%±9.7% - - - - Intermediate - - 19 
(16.4) 50.9%±15.8% 68 (58.6) 68.4%±12.2 Intermediate-2 17 (14.6) 39.3%±2% - - - - High 0 (0.0) 0 
(0) 17 (14.6) 39.3%±20.8% 18 (15.5) 48.8±19.3 Very high - - - - 6 (5.2) 0% ± 0% TABLE 9: 
UNIVARIATE ANALYSIS OF ADVERSE EFFECTS OF PATIENT CHARACTERISTICS ON 
OVERALL SURVIVAL. n =111 Variables Alive n (%) Dead n (%) RR 95% CI P-value Age at 
diagnosis in years: 18-40 41-55 >55 38(44.7) 28(32.9) 19(22.4) 9(34.6) 7(26.9) 10(38.5) 1.0 1.0 1.8 - 
0.38-2.80 0.74-4.50 - 0.933 0.189 Sex Female Male 33(38.8) 52(61.2) 5(19.2) 21(80.8) 1.0 2.3 - 
0.87-6.13 - 0.092 Hb at diagnosis >10.1 6.1 – 10 <6 ANC [x109/L] 4(4.7) 39(45.9) 42(49.4) 1(3.8) 
9(34.6) 16(61.5) 1.0 2.1 3.4 - 0.26-17.91 0.44-27.02 - 0.466 0.235 >1.5 1.0-1.5 0.5-1.0 0.2-0.5 <0.2 
Platelet [x109/L] 30(35.3) 21(24.7) 21(24.7) 11(12.9) 2(2.4) 7(26.9) 3(11.5) 8(30.8) 3(11.5) 5(19.2) 
1.0 0.5 1.7 1.7 4.2 - 0.13-2.09 0.63-4.86 0.44-6.97 1.32-13.50 - 0.372 0.282 0.418 0.015 >100 51-
100 21-50 <20 7(8.2) 9(10.6) 19(22.4) 50(58.8) 2(7.7) 4(15.4) 8(30.8) 12(46.2) 1.0 1.3 1.0 0.6 - 0.24-
7.30 0.22-5.19 0.15-3.14 - 0.742 0.922 0.637 No. of cytopenia(s) Single cytopenia Bicytopenia 
Pancytopenia 3 (3.8) 30(35.3) 52(61.2) 1(3.8) 8(30.8) 17(65.4) 1.0 0.8 0.9 - 1.00-6.48 0.12-7.30 - 
0.837 0.974 Serum LDH (n=101) <600 >600 65(83.3) 13(16.7) 18(78.3) 5(21.7) 1.0 1.5 - 0.55-4.10 - 
0.420 Bone marrow cellularity Varyingly hypocellular Uniformly hypocellular Aplastic 11(12.9) 
73(85.9) 1(1.2) 2(7.7) 23(88.5) 1(3.8) 1.0 1.8 1.2 - 0.15-20.91 0.29-5.42 - 0.631 0.745 BM blasts [%; 
n=109] 0 1-2 3-4 ≥5 42(50.0) 37(44.0) 4(4.8) 1(1.2) 9(36.0) 11(44.0) 3(12.0) 2(8.0) 1.0 1.2 2.9 11.0 - 
0.52-3.04 0.77-10.87 2.27-53.77 - 0.610 0.113 0.003 TABLE 10: UNIVARIATE ANALYSIS OF 
ADVERSE EFFECTS OF PATIENT CHARACTERISTICS ON OVERALL SURVIVAL contd… 
Variables Alive N (%) Dead N (%) RR 95% CI P- value BM dysplasia Unilineage Bilineage Trilineage 
22(25.9) 37(43.5) 26(30.5) 5(19.2) 10(38.5) 11(42.3) 1.0 1.0 1.2 - 0.36-3.18 0.44-3.69 - 0.888 0.652 
BM Reticulin (n=108) Normal Mild increase Moderate/Marked increase 20(23.8) 42(50.0) 22(26.2) 
3(12.5) 8(33.3) 13(54.2) 1.0 1.6 4.0 - 0.43-6.28 1.13-14.17 - 0.456 0.031 WHO SUB-CLASS MDS-
Unclassified RCMD RAEB1 22(25.9) 62(72.9) 1(1.2) 4(15.4) 20(76.9) 2(7.7) 1.0 0.7 7.5 - 0.24-2.15 
1.68-34.12 - 0.569 0.008 Cytogenetic anomalies (n=79) No anomaly One anomaly 2-3 anomalies >3 
anomalies or -7 47(77.0) 5(8.2) 4(6.6) 5(8.2) 9(50.0) 3(16.7) 2(11.1) 4(22.2) 1.0 2.4 2.3 3.5 - 0.65-
9.00 0.50-10.92 1.09-11.82 - 0.182 0.274 0.035 Individual chromosomal abn (n=75) Normal del 5q 
Monosomy 7 Trisomy 21 Trisomy 8 Monosomy Y 47(82.4) 4(7.0) 4(7.0) 0(0.0) 1(1.8) 1(1.8) 9(50.0) 
1(5.6) 4(22.2) 2(11.0) 1(5.6) 1(5.6) 1.0 1.0 5.1 14.4 3.4 4.2 - 0.13-8.55 1.54-17.03 2.88-72.7 0.43-
27.78 0.51-34.24 - 0.947 0.008 0.001 0.241 0.178 IPSS Risk groups: (n=79) Low Intermediate-1 
Intermediate-2 2(3.3) 54(88.5) 5(8.2) 1(5.6) 13(72.2) 4(22.2) 1.0 0.6 1.8 - 0.08-4.88 0.20-16.84 - 
0.664 0.583 50WPSS Risk groups (n=79) Very low Low Intermediate High  1(1.6) 
49(80.3) 6(9.8) 5(8.2) - 9(50.0) 5(27.8) 4(22.2) - 1.0 3.3 3.7 - - 1.11-9.95 1.13-12.24 - - 0.032 0.030 
IPSS-R Risk groups (n=79) 54Very low Low Intermediate High Very high 1(  1.6) 
16(26.2) 36(59.0) 8(13.1) 0(0.0) - 3(16.7) 8(44.4) 4(22.2) 3(16.7) - 1.0 1.1 2.9 14.1 - - 0.30-4.30 
0.65-13.66 2.75-72.19 - - 0.847 0.157 0.001 RESULTS - FIGURES: Figure 1: Year wise distribution 
of total MDS vs hMDS 140 Total MDS 126 120 Hypo MDS 120 112 113 104 100 99 104 Number of 
cases 80 81 79 69 59 60 46 48 46 39 40 24 22 20 16 17 8 4 4 9 9 10 9 9 12 11 9 0 1998 1999 2000 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Year Figure 1: Year wise 
distribution: Total MDS versus hypoplastic MDS cases from January 1998 to June 2012. Figure 2: 
Peripheral blood and Bone marrow findings: 2a 2b 2c 2d 2e 2f 2g 2h Figure 2: Peripheral blood and 
bone marrow findings. Figures 2a & 2b: PB smear showing granulocyte dysplasia - pelger heut 
anomaly and hypogranularity, 2c: BM aspirate smear showing dyserythropoiesis, 2d: BM aspirate 
smear showing micro-megakaryocytes, 2e: BM aspirate smear showing ring sideroblasts. 2f: BM 
trephine biopsy showing hypocellular marrow & dysplastic megakaryocytes. 2g: BM trephine biopsy 
silver stain showing increased rericulin and 2h: BM trephine biopsy showing CD34+ cells. Figure 3: 
Response rate to different drugs 80 70 CSA vs ATG+CSA (P= 0.974) Response rate (%) 60 50 69 
70 40 30 47 20 P= 0.017 P= 0.185 10 0 CSA (n=59) ANDROGENS (n=51) ATG+CSA (n=10) Figure 
3: On comparing the response rate to different drugs, response rate to CSA was found to be 
significantly (69% vs 47%; P=0.017) superior to Androgenic steroids. The number of patients who 
received other drugs was few to compare enough number of patients to compare. SURVIVALS: 
Figure 4: Overall survival of total evaluable patients (n=111) 5 year OS = 61.9% ± 7.2% Figure 4: 
Kaplan Meier curve for 20overall survival of the entire cohort of evaluable patients  
(n=111). With a median follow up duration of 110 months (Range: 1-178), the 5 year and 10 year OS 
were 61.9% ± 7.2% & 53.1% ±10.3% respectively. Figure 5: Event free survival of total evaluable 
patients (n=111) 5 year EFS = 37.9% ± 7.8% Figure 5: Kaplan Meier curve for Event free survival of 
the entire cohort of evaluable patients (n=111). 6With a mean follow up duration of 70  
months (Range: 1- 178), the  5 year & 10 year EFS were 37.9% ± 7.8% & 25.3% ±8.0% 
respectively. Figure 6: Progression free survival of total evaluable patients (n=111) 5 year PFS = 
49.5% ± 9.3% Figure 6: 47Kaplan Meier curve for Progression free survival of the  
entire cohort of  evaluable patients (n=111). 6With a mean follow up duration of 86  
months (Range: 1- 78), the  5 year & 10 year PFS was 49.5% ± 9.3% & 33.0% ±10.1% 
respectively. Figure 7: Disease free survival of total evaluable patients (n=111) 5 year DFS = 46.6% 
± 9.5% Figure 7: 47Kaplan Meier curve for Disease free survival of the entire cohort  
of  evaluable patients (n=111). 6With a mean follow up duration of 69 months  
(Range: 1- 166), the  5 year & 10 year DFS was 46.6% ± 9.5% & 18.1%±8.9% respectively. 
SURVIVAL BY PROGNOSTIC RISK GROUPS: Figure 8: OS of IPSS risk groups (n=79) Int-1 + Low 
Int-2 P-value = 0.062 5 year DFS = 46.6% ± 9.5% Figure 8: Kaplan Meier curve for OS IPSS risk 
groups. Among the 111 evaluable patients, cytogenetic data was available only in 79. 10With  
a mean follow up period of 125 months (range: 1-178) and 34 months (range: 1-78)  
the  5 year OS in 2the lower risk groups (Low+Int-1) versus higher risk groups (Int-
2+high) was  65.9% ± 9.7% versus 38.1% ± 20.4% respectively.. The higher survival noted in 
the lower risk group was statistically near significant (p= 0.056). Figure 9: OS of WPSS risk groups 
(n=79) Low + very low Int High P-value = 0.019 Figure 9: Kaplan Meier curve for OS of WPSS risk 
groups. With a mean follow up period was 83 (range:2-110), 92 (range:1-178) and 34 months 
(range:1-78) for the lower risk (very low + 46low risk), intermediate risk and high risk  
groups respectively, the  5 year OS were, Lower versus Int (66.6% ± 12.1% vs 50.5% ± 
15.8%; P value=0.026), Lower vs High (66.6% ±12.1% vs 38.1%±20.4%; P value=0.017). OS 
32was significantly higher in the lower risk groups than the  higher risk groups (Int and 
high risk groups), but 10there was no significant survival advantage for the intermediate  
risk group  over high risk group (P value=0.973). Figure 10: OS of IPSS-R risk groups (n=79) 
Very low+Low+Int High+Very high P-value = 0.002 Figure 10: Kaplan Meier curve for OS of IPSS-R 
risk groups. 48With a mean follow up period of 83 months (range:2- 110) for the lower  
risk  group (very low+low+Int) and 67 months (1-178) for the higher risk group (high+very 
high), the 5 year OS was noted 67to be significantly higher in lower risk group than  
higher risk groups (High + very high), ie; 68.0% ± 10.8% vs 35.0% ± 15.7% (P=0.002). Figure 11: 
OS by WHO classification for the entire evaluable patients (n=111) MDS Unclassified RCMD RAEB-
1 P-value = 0.000 Figure 11: Kaplan Meier curve for OS of WHO classification groups Using the 
WHO criteria, the out of the 111 evaluable patients, 82 belonged to RCMD, 26 to MDS unclassified 
and 3 to RAEB-1. 6With a mean follow up period of 109 (range:1-  82), 61(2- 78) and 8.5 
(range:3-14) months, the 5 year OS were 61.2% ± 8.4%, 74.4 % ± 11.8% and 0 % ± 0% for RCMD, 
MDS-U and RAEB-1 respectively. MDS-U and RCMD showed significantly better survival than 
RAEB-1 (P=0.000). Figure 12: Overall survival of responders to different drugs CSA ATG+CSA 
Androgens P-value =0.213 Figure 12: Kaplan Meier curve for OS of responders to different drugs. 
The OS of the responders to different drugs showed no significant difference. The 5 yr OS of CSA vs 
Androgens was 96.9% ±3.1 % vs 51.4% ± 23.1% (P=0.090); ATG vs Androgens was 75.0 % ±21.7 
% vs 51.4% ± 23.1% (P=0.972) and CSA vs ATG+CSA was 75.0 % ±21.7 % vs 96.9% ±3.1 % 
(P=0.180). DISCUSSION: Between January 1998 and June 2012, there were a total of 173 adult 
patients (age ≥18 years) diagnosed to have hypoplastic myelodysplastic syndrome from January 
1998 to June, 30, 2012. The total number of patients seen in the outpatient department of Clinical 
Haematology during this period was 54413, out of which 1225 (2.3%) adult patients were diagnosed 
to have primary MDS. In this study, hMDS constituted 14.1% of MDS cases diagnosed during this 
period. This is similar to that reported in literature ; i.e. 10-15% of all MDS cases (2,4,7–9,14) [Fig 
6:1]. In the present study the  majority (41.6%; n=72) of the 10patients belonged  
to the age group  18-40 years, 11with a median age of 41 years (range: 18-64).  
In a  study by Koh Y and colleagues, 23based on a medical record review at Seoul  
National University Hospital,  51 patients were diagnosed to have hMDS, 20and the  
median age reported was 39 years (12), similar to the  observation in the present study. 
This is much lower than the median age of patients with normo/hypercellular MDS ie; 60–75 years 
(5). However in a comparative study 2of hypoplastic myelodysplastic syndrome (MDS)  
with normo-/hypercellular MDS by  Huang et al, the median age reported was similar in 
both groups ie; 58 years (range: 26–86) in hMDS and 55 years in normo-/hypercellular MDS (1). In 
the present study, 112 were males (64.7%) and 61 females 35(35.3%), with a male: female  
ration of 1.8:1. A similar observation of male preponderance was reported  by Huang et al ( 
29:8) (1). The median duration of symptoms before diagnosing hMDS was 3 months. The duration of 
symptoms before diagnosis is made ranges from 6-12 months as per reports by Hoffman and 
Koeffler (5). Majority of the patients in the present study (94.2%; n=163) were diagnosed following 
evaluation for pallor. Diagnosis was made following a routine medical check-up in 5.8% (n=10) of the 
patients. In MDS as a whole, it is reported that 50% of the patients are asymptomatic and are 
diagnosed following routine check-up (5). The presence of occasional splenomegaly has been 
reported by some authors (3,16); in the present study 3.5% (n=6) of patients had mild splenomegaly 
[Table:1]. Haemogram showed that 95.4% (n=165) had a hemoglobin level below 10g%, with a 
median hemoglobin of 5.8g% (range: 1.2- 13.2). In the study by Huang et al (1) the median 
hemoglobin reported was 7.8g% (range: 4.0–14.0), a little higher than that observed in the present 
study. The median WBC count and ANC at diagnosis were 3.3x109/L (range: 0.2-13.8) and 1.05 
x109/L (0.0-5.32) respectively. This is slightly higher than that reported by Huang et al (1) i.e. 2.37 
x109/L (range:1.00–15.70) of WBC count and 0.98 x109/L (range: 0.196–10.360) of ANC. 58In  
the present study, majority of the patients had  a severe thrombocytopenia with 61.3% 
(n=106) of patients presenting with platelet count <20 x109/L. The 10median platelet count  
was 14 x 109/L (range:1-  307), much lower than that observed in the study by Huang et al ie; 
54 x109/L (range: 3–433) (1). However, only 70 patients presented with bleeding manifestations 
[Table:2]. 36The diagnosis of hMDS was based on the presence of  a hypocellular 
marrow with features of dysplasia in one or more cell lines, increase in reticulin content, 
30increase in the number of blasts/CD34+ cells on the  bone marrow trephine, or 
abnormal karyotype, all favoring the diagnosis of hMDS (3,6,15,16). Out of the 169 cases where 
data on reticulin content was available, increase in reticulin content was seen in 79.9% (n=135) 
[Table3]. The median bone marrow blast percentage was 1 (range: 0-5), as compared to 2.6% (0–
26.0) in the Huang et al study (1). All cases with bone marrow blasts greater than 5%, and/or those 
with a diagnosis of RAEB-2 or acute leukemia at presentation, irrespective of the presence of 
hypocellular marrow were excluded from the study. This may be the reason for the lower range of 
BM blasts observed in this study. Ring sideroblasts were observed in 48 cases (27.8%), of which 
only one (0.6%) had >15% ring sideroblasts (RCMD-RS). This is similar to the study published by 
Huang et al (1), where only 2 (5.4%) cases were diagnosed to have RARS. WHO classification of 
the cases in the present study showed that 77.5% (n=134) befitted the RCMD (Refractory cytopenia 
with multilineage dysplasia) group, while 20.2% (n=35) were MDS-U (MDS unclassified) and 4 
(2.3%) were 54RAEB-1 (Refractory anemia with excess blasts-1)  [Table:3]. In the 
studies by Nand S et al (8) and Huang et al (1), the FAB classification was followed. In these studies 
the FAB subgroups included RA (n=7), RARS (n=1) and RAEB (n=3) in the former and 29RA  
(n= 21), RARS (n=2), RAEB (n= 9) and RAEB-T (n=  5) in the latter study respectively. 
Cytogenetic data was available in 116 (67%) patients. A normal karyotype was found in 77 (66.4%). 
Earlier reports by Toyoma K et al have shown that patients with hMD frequently had complex 
aberrations (chromosome changes at three or more regions) (53). In the present study among the 39 
(33.6%) patients with abnormal karyotype, 2.6% (n=3) had three aberrations and 12.9% (n=15) had 
more than 3 aberrations / monosomy 7. Among the numerical abnormalities observed in 55 (47.4%), 
majority had monosomies (n= 37). Monosomy 5 (-5)/del 5q (5q-) was observed in 9 (7.8%) cases, 
and monosomy 7 (-7) was found in 13 (11.2%) patients [Table: 4]. The reports on 
2chromosomal aberrations in hypoplastic MDS are limited  (1,8,9). In the report by 
Nand and Gonwinz (1,8), 2none of the nine h-MDS patients  harboured monosomy 
27/7q-, while only one out of 23 hMDS patients reported by Tuzuner et al (1,54)  
showed this abnormality. On the contrary, Maschek et al (1,9) demonstrated  
monosomy 7 in two out of the six h-MDS patients.  The karyotype profile in the Huang et 
al (1) study showed that 57.6% (n=19) had normal karyotype, and among those with abnormal 
karyotype, 3% (n=1) had -5/5q-, none had chromosome7 abnormalities, 12.1% (n=4) had trisomy 8, 
24.2% (n=8) had single aberration, 9.1% (n=3) had double aberrations and 9.1% (n=3) had complex 
aberrations. This observation is similar to the observation in the present study except that 
chromosome7 abnormalities were observed in 11.2% of patients in this study. 2Further  
studies on more patients may be needed to clarify whether the variations in the  
frequency of  cytogenetic abnormalities, especially involving chromosome7, in 2h-MDS  
observed among these reports may represent the difference of the pathogenesis  
of h-MDS in different geographical areas.  As per the IPSS/WPSS and IPSS-R 
cytogenetic risk categorization, in the present study, majority belonged to the Intermediate 
cytogenetic risk group (69% each in either category) [Table:5]. While applying various MDS 
prognostic scoring systems, majority fell into the intermediate -1 (82.8%; n=96) by IPSS, 
intermediate category (58.6%; n= 68) by IPSS-R, and low risk (68.1% (n= 79) by WPSS [Table: 6]. A 
similar observation was noted in the comparative study by Huang et al (1), where 57.6% (n=19) of 
patients were scored into the intermediate -1 risk category of IPSS. In our study none of the cases 
belonged to the IPSS high risk group, while 9.1% (n=3) cases 21belonged to high risk  
group in the  study by Huang et al (1). This may be due to the fact that patients with RAEB-2 
and Acute leukemia were excluded in the present study. One hundred and eleven (64.2%) patients 
who had atleast 8 weeks follow up after initiation of therapy were evaluated for response. Eighty 
seven (78.4%) showed response, either ‘Complete remission‘[CR] (12.6%; n=14) or ‘Stable disease” 
(65.8%; n=73) [Table:7]. On comparing the response rate to different drugs, the response rate to 
cyclosporine was found to be significantly higher than Androgens (69.5% vs 47.1%; P=0.017) . 
Although a 70% response rate was seen to ATG+CSA, this was not found to be significantly superior 
over other drugs [Fig:3]. The 5 year overall survival among the responders to the different drugs 
however showed no statistically significant difference [Fig;12]. The mean time to response were 5.9 
months (range: 3-36) in CSA group, 1.8 months (range: 1-3) in ATG+CSA group and 5.3 months (1-
27) in androgen group [Table:7]. In 49a prospective randomized multicenter phase III  
trial  (where 9 out of total 45 cases were hMDS) comparing Antithymocyte globulin + 
cyclosporine with best supportive care by Passweg JR et al (33), 29% of the total 45 patients 
showed response to ATG+CSA by 6 months. In a study on Cyclosporine therapy in hMDS by 
Jonasova A et al (55), out of the 9 patients of hMDS (of total 17 MDS cases), 8 showed response, 
and the time to response was observed to be between 3 to 9 months, similar to the observation in 
our study. However in another study by Catalano Let al (56), out of 9 patients with hypoplastic 
refractory anemia who were treated with cyclosporine, 3 showed response in a mean duration of 22 
months (median 14.5 months); longer than that observed in this study. Literature review shows 
reports suggesting better response to immunosuppressive therapies (CSA, ATG) in patients with 
hMDS by several authors (2,13,33,57,58). However data comparing the response to different drug 
groups in hMDS could not be found. In our study, the number of patients in other drug groups are 
very few (eg; ATG+CSA [n=10], Lenalidomide [n=3], Allogeneic PBSCT [n=5], Haematopoietic 
growth factors [n=1], and supportive treatment [n=4]), limiting significant correlative study between 
these groups. For the entire cohort, with 28a median follow up duration of 110 months,  
the 5 year OS, EFS, PFS and DFS are  61.9%+7.2%, 37.9%+7.8%, 49.5%+9.3% and 
46.6% ± 9.5% respectively [Figs: 4-7]. Bartl and colleagues, in a retrospective and prospective 
10follow-up study of 495 patients with  MDS between 1975 to 1991, reported 10a  
median survival of 29 months (n=95) in patients with  hMDS (7). In the study by Huang 
et al (1), the OS was less than the present study (5b year OS: <60%; median survival = 58 months). 
2To identify different survival groups in h-MDS patients, we took advantage of  
the different risk  scoring systems (IPSS, WPSS & IPSS-R). Obviously, in this study, h-MDS 
patients of lower risk groups 12had a significantly higher 5 year OS than  those of higher 
risks groups in the WPSS 12(P=0.018) and IPSS-R (P=0.  002) systems [Figs:9,10]. Risk 
categorization by the IPSS showed only near significant survival benefit in the lower over the higher 
groups [Fig:8]. Our study demonstrate that in hypoplastic MDS, WPSS and IPSS-R prognostic 
scoring systems are better than the IPSS systems in predicting survival advantage. However in the 
comparative study by Huang et al (1), 2a significant survival difference was observed  
between these two groups in h-MDS patients (median survival 112 vs 16 months,  
P=0.002).  The OS of IPSS lower risk groups reported by Huang et al (1), however is much 
lower than that observed in our study (5 year OS: <40%) versus 66.0% ± 9.7%) . The overall 
mortality was 26 patients (15% of the total 173 cases and 23.4% of the 111 evaluable patients). Of 
these 4 had shown progression to Acute myeloid leukemia, whereas one patient developed 
metastatic adenocarcinoma along with progression of disease. 2With a mean follow up  
duration of 110 months in 111 evaluable patients, the cumulated incidence of  
transformation to acute leukemia at 5 years was  3.6 % (n=4) [Table:8]. In the study by 
Huang et al (1), 2with a median follow-up duration of 98 months in 187 evaluable  
patients, the cumulated incidence of acute leukemic transformation at 7 years  
was 8.1% for h-MDS.  This is higher than the observation in our study. This may be due to 
the fact that hypocellular RAEB 2 was excluded from our study. Univariate Cox proportional hazard 
2model was used to find out significant prognostic factors for survival among  
overall hMDS patients  [Tables:10-12]. 2Parameters of independent 9  
significance for adverse effects on overall survival were  ANC < 0.2 x10 /L at diagnosis, 
bone marrow blast at diagnosis >5%, WHO category RAEB-1, moderate/marked increase in BM 
reticulin, >3 cytogenetic anomalies, monosomy7, trisomy 21, WPSS intermediate risk group, WPSS 
high 29risk group , and IPSS- R very high risk group. However on multivariate  
analysis  none of the parameters were In the multivariate model by Huang et al (1), 
2parameters of independent significance for overall survival were age, marrow  
hypocellularity, RA with excess of blast, RA with excess of blast-T, monosomy 5  
or 5q deletion and monosomy 7 or 7q deletion.  However on multivariate analysis, none 
of the above parameters retained its statistical significance. LIMITATIONS OF THE STUDY: 1. 
Retrospective study: limited available data due to non-retrievable records, intractability of patients 
due to wrongly recorded/changed/non-availability of address. 2. Not all hypocellular MDS were 
recruited in this study; RAEB-2 and AML with hypocellular marrow were excluded. In the reported 
studies on hMDS; all categories of hypocellular MDS are included into the group hypoplastic MDS. 
This limits the comparison with these studies. 3. Karyotyping is not available for all patients- limited 
by the nature of the study. 4. Lesser number of patients in drug groups limiting comparison between 
drug groups. CONCLUSION: 2Hypoplastic MDS is a distinct subgroup of MDS  of 
unknown etiology which needs to be distinguished from aplastic anemia. It is a disease associated 
with a relatively good prognosis, with significant response to immunosuppressive therapy and 
reasonable response to treatment with androgens, and a lower probability for leukemic 
transformation. Cytogenetic analysis at diagnosis is crucial in prognostic risk categorization of the 
patient. WHO classification based prognostic scoring system and revised IPSS appear to be better 
than IPSS in predicting survival.  
 
